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Summary
Oral liquid formulations are ideal dosage forms for paediatric, geriatric and patient with
dysphagia. Dysphagia is prominent among patients suffering from stroke, motor neurone
disease, advanced Alzheimer’s and Parkinson’s disease. However oral liquid preparations
are particularly difficult to formulate for hydrophobic and unstable drugs. Therefore current
methods employed in solving this issue include the use of ‘specials’ or extemporaneous
preparations. In order to challenge this, the government has encouraged research into the
field of oral liquid formulations, with the EMEA and MHRA publishing list of drugs of interest.
The current work investigates strategic formulation development and characterisation of
select API’s (captopril, gliclazide, melatonin, L-arginine and lansoprazole), each with unique
obstacles to overcome during solubilisation, stabilisation and when developing a palatable
dosage from. By preparing a validated calibration protocol for each of the drug candidates,
the oral liquid formulations were assessed for stability, according to the ICH guidelines along
with thorough physiochemical characterisation.
The results showed that pH and polarity of the solvent had the greatest influence on the
extent of drug solubilisation, with inclusion of antioxidants and molecular steric hindrance
influencing the extent of drug stability.
Captopril, a hydrophilic ACE inhibitor (160 mg.mL-1), undergoes dimerisation with another
captopril molecule. It was found that with the addition of EDTA and HP-β-CD, the drug
molecule was stabilised and prevented from initiating a thiol induced first order free radical
oxidation. The cyclodextrin provided further steric hindrance (1:1 molar ratio) resulting in
complete reduction of the intensity of sulphur like smell associated with captopril.
Palatability is a crucial factor in patient compliance, particularly when developing a dosage
form targeted towards paediatrics. L-arginine is extremely bitter in solution (148.7 g.L-1). The
addition of tartaric acid into the 100 mg.mL-1 formulation was sufficient to mask the bitterness
associated with its guanidium ions.
The hydrophobicity of gliclazide (55 mg.L-1) was strategically challenged using a binary
system of a co-solvent and surfactant to reduce the polarity of the medium and ultimately
increase the solubility of the drug. A second simpler method was developed using pH
modification with L-arginine.
Melatonin has two major obstacles in formulation: solubility (100 μg.mL-1) and
photosensitivity, which were both overcome by lowering the dielectric constant of the medium
and by reversibly binding the drug within the cyclodextrin cup (1:1 ratio). The cyclodextrin
acts by preventing UV rays from reaching the drug molecule and initiated the degradation
pathway.
Lansoprazole is an acid labile drug that could only be delivered orally via a delivery vehicle.
In oral liquid preparations this involved nanoparticulate vesicles. The extent of drug loading
was found to be influenced by the type of polymer, concentration of polymer, and the
molecular weight.
All of the formulations achieved relatively long shelf-lives with good preservative efficacy.
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CHAPTER 1
Introduction
1.1. Project scope and significance
The United States identified the problem of poor availability of paediatric medication in the
1990’s and since 1998 there has been a regulation in place (Federal Register 66632, 1998)
requiring all medicines produced to be assessed for safety and efficacy in paediatrics. As
such, since 4th January 2002 under the ‘best pharmaceuticals for children’ act (FDA/Pub L
No. 107-109, 2002) the Food and Drug Administration (FDA) require evidence that the
medication is both safe and effective. In 2007 the European Medical Agency (EMEA)
followed suit in the recognition of the problem and has since devised a priority list of off-
patent paediatric medications with the goal of directing the research and development in the
direction of the medications deemed the most important and the most in need of
reformulation and investigation. The most recent list was released in 2010
(EMA/480197/2010).
Only a small percentage of all of the medications currently available are developed and
tested with the paediatric patient segment as the primary target. Current methods employed
in managing this problem include the use of; extemporaneous preparation, off-label drugs,
unlicensed drugs and via the production of ‘specials’ (Giam and McLachlan, 2008). Giam and
McLachlan (2008) carried out a review to provide an insight into the incidence of
extemporaneous preparation. In the United Kingdom the prevalence of extemporaneous
preparation was indicated to be around 10% for paediatric administration, with a similar trend
being observed across Europe.
Many problems have been related to these ‘alternative formulations” for paediatric treatment,
mainly associated with unlicensed and off-label drug use. For example the extemporaneous
preparation of medications to be administered to children usually involves the use of drugs
intended for adult use in which the dose is adjusted for each individual case (Nahata, 1999).
In the case of very small children (newborn) the dose may need to be extremely small,
causing issues with dosing accuracy and errors, which could result in irritation and toxic
effects in paediatric patients. Children are more susceptible to side effects associated with
medications and are less well able to cope with accidental overdose when compared to an
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adult. Extemporaneous preparation carries with it further problems including: published
standards relating to the production of extemporaneous preparations are not available, there
is a lack of information regarding the reproducibility of the medication via extemporaneous
preparation, and procedures such as crushing tablets which have been designed for the
controlled release of the drug can result in large overdoses.
1.2. Reformulation of medicines
Reformulation of existing medicinal products is performed for a variety of reasons.
Pharmaceutical companies ‘alter’ their own products so as to allow for re-patenting and in
doing so maintain their market exclusivity in that area, to expanding the scope of an existing
drug to better target other patient segments (Yoshitani and Cooper, 2007). Also there are
many factors of existing formulations which can be improved in an effort to maximise their
potential for targeting specific patient groups. Where paediatric reformulations are concerned
some of the most common areas for improvement include; increasing the understanding of
pharmacokinetics of the drug, improving the drug’s safety and developing an age appropriate
formulation.
Reformulation of off-patent medications in an attempt to improve the availability of
medication to children is a much more attractive proposition when compared to developing a
completely new chemical entity (NCE). Further developing an existing active pharmaceutical
ingredient (API) recognised by the FDA, means that all of the data collected via clinical trials
associated with the production of a NCE will already have been carried out in order for the
FDA advisory committee to approve the product (Bhattaram et al, 2005). This will remove
much of the cost associated with the formulation of a new drug. Reformulation is generally
categorised into three sub classes: (1) the reformulation of a molecular entity, (2) new
deliveries and (3) new indications (Yoshitani and Cooper, 2007).
The reformulation of molecular entities involves the modification of an existing API just
enough so as that the changed molecule can be patented without compromising its in vivo
performance. In this way the FDA views the modified API as the same drug under the
guidelines regarding bioequivalency. In the area of molecular entity reformulation there are
three further subsections which involve: (1) metabolites, (2) polymorphs and (3) chiral
switching.
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Metabolites are the molecules produced following a chemical reaction in the body, the
modification implemented with regards to metabolites is the creation of prodrugs which enter
the body in an inactive form and following metabolism the active form of the drug is produced
(Yoshitani and Cooper 2007).
Polymorphs which exist with different crystalline structures, waters of hydration, solvents and
amorphous forms come into play where reformulation is concerned, as the FDA recognise a
modified API so long as there is no change in its physical form and that it is also
bioequivalent to the original drug (Yoshitani and Cooper 2007). It is often difficult to produce
reformulations which display characteristics that are bioequivalent to the original product as
changes in the polymorphism often bring about changes in the solubility of the drug, which in
turn can result in changes in the dissolution properties (Wiliams et al 2008).
Chiral switching is implemented in reformulation as the ratio of each chiral version can be
changed resulting in a more pure S- enantiomer or a purer R- enantiomer, with each chiral
version bring about very different responses in the body (Fleming and Ma 2002). A more
pure mix would produce a more effective response in favour of one or the other enantiomer
depending on which was present in the highest concentration. In this way the efficacy of a
drug is improved without altering the molecule itself (Yoshitani and Cooper 2007).
Reformulation to produce new delivery methods is fairly self explanatory with factors such as
the alteration of the dosage form (from an oral liquid such as a suspension to an oral solid
such as a tablet or a capsule). Another approach is alternative route of delivery (a nasal
spray to an oral tablet or a capsule). In both cases it is essential that the behaviour of the
drug once inside the body is identical to the original formulation (Yoshitani and Cooper
2007).
New indications involve the use of medication to treat a disease or condition not covered in
an existing drug patent (Ashburn and Thor 2004). If this is achieved then there are no
changes to the existing API but can be used to treat different disease condition. This is a
relatively uncommon occurrence as drug companies go to great lengths to protect their
products in order to maintain market exclusivity (Yoshitani and Cooper 2007).
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1.3. Gastrointestinal physiology and its impact on
bioavailability
The oral route remains as the preferred route of drug administration for patients, due to its
ease of convenience, good patient compliance, and low medicinal cost (Wong et al, 2006).
However the human body is a complex system that has a multitude of functions which
include: secretion, digestion, absorption and excretion. All medicinal products ingested must
pass a range of physiological barriers before the systemic delivery of the drug, particularly
the extreme pH conditions encountered through the gastrointestinal tract (GIT) (Figure 1.1).
The acidic environment of the stomach is attributed to the presence of gastric fluids, and the
secretion of hydrochloric acid from the parietal cells of the stomach. Under fasted conditions
the pH of the stomach is ~1.7, with the stomach contents becoming neutralised in the
duodenum by the bicarbonate ions through the pancreatic duct, raising the pH steeply to
pH 5.0 (pH-
1.4-2.1)
pH 4.7 (pH 6-7)
pH 6.5
pH 8
pH 5-8
pH 2.4-6.8
pH 4.5-5.5
(pH 5.8-6.2)
Figure 1.1. Schematic of the GIT and its relative pH. Under fed conditions the pH of the stomach is
pH 5, however under faster conditions the pH of the stomach significantly decreases to pH 1.4-2.1.
The pH of the duodenum is in the range of pH 2.4-6.8, with the small intestines displaying a
relatively alkaline environment (pH 6.5).
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~4.6. Between the proximal jejunum and the distal ileum, the pH rises further ~6 to 8. This
alkaline environment is due to the secretion of bicarbonate. The ingestion of food has a
dramatic affect on the acidity of the stomach, by raising its pH profile briefly to 7, after 6
minutes the pH drops to 5, which reduces further to pH 3 after 1 hour, and returns to the
fasted level (pH ~1.7) after 3 hours. As the movement of food transgresses through the
proximal jejunum, the pH reduces to 4.5; however the distal portions of the small intestine
are not dramatically changed by the presence of food (Avdeef, 2003). As well as pH, other
obstacles exerted by the GIT include: degradative enzymes, first pass metabolism and
hydrophilic and lipophillic barriers. The physiology of the GIT has a major influence on drug
bioavailability and drug absorption. There are a number of physiological factors which can
influence drug bioavailability and drug absorption from the GIT.
The surface area of the gastrointestinal (GI) absorption sites vary significantly along the GIT.
The small intestine (i.e. duodenum, jejenum and ileum) possesses the largest surface area
for absorption in the GI for the majority of active drug candidates and therefore is the site
where maximum absorption of API occurs. The large difference in surface area across the
GIT results in variation in the rate and extent of absorption of active drug across the GIT.
pH influences both the ionisation and chemical stability of active drug, as the ionisation and
stability of active drug ingredients, varies according to the acidity or basicity of the
surrounding environment in the GIT. For example, a weakly acidic drug will exist in its
unionised form at low pH (such as the stomach), however as the pH of the environment
increases the drug will become ionised, and ultimately affect its solubility.
Gastric emptying rate also has a significant effect on drug absorption. Gastric emptying rate
is defined as the rate at which a drug in solution leaves the stomach and enters the
duodenum. As most active drug ingredients are efficiently absorbed from the small intestine,
a reduction in gastric emptying rate is likely to reduce absorption and subsequently delay the
onset of the therapeutic/medicinal response. Gastric emptying rate may be influenced by the
type of dosage form in which the active drug ingredient is contained, as solid dosage forms
show pronounced differences when compared to liquid dosage forms.
The consumption of food can also lead to a reduction in active drug ingredient absorption
and bioavailability due to complexation, in which active drug ingredients form a permanent
complex/interaction with components in the diet. The formed complex is not able to be
absorbed across the GI membrane, therefore a reduction in bioavailability is observed. For
example, tetracycline forms a non-absorbable complex with calcium (found in milk and other
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dairy products), therefore patients are advised not to consume dairy products at the same
time of day as they administer tetracycline.
1.4. Drug formulation strategies
The mainstay for drug delivery research has always been to identify strategies for efficient
delivery of drugs in order to improve their therapeutic performance. Since the best option for
paediatric administration is the production of an oral liquid formulation, the aqueous solubility
of a drug can be a determinate in the dosage form selection with soluble drugs lending
themselves easily to the production of solutions. For insoluble drugs however the options are
to produce a suspension where the drug remains undissolved, or alternatively to utilise
techniques to solubilise the insoluble drug (such as complexation, co-solvency or micelles).
In addition, a variety of successful techniques have been developed over the years, which
are specific to the drug candidate. These techniques include: liposomes (Dupont, 2002),
emulsions (Nakano, 2000), microemulsions (Lawrence and Rees, 2000) and solid
dispersions (Leuner and Dressman, 2000).
1.4.1. Solubility Enhancement
Oral solutions can either be complex formulations or simple preparations, involving various
types of excipients which include: water, water-soluble organic solvents, water-insoluble
organic solvents, organic solvents, surfactants, buffers, sugars, flavours, sweeteners,
aromatics and dyes (Strickley, 2004). This simple approach aims to increase the
bioavailability of hydrophilic and lipophillic drugs without compromising their chemical
stability. Common methods of solubilisation include: pH adjustment, co-solvent/binary system
and polarity adjustment.
1.4.1.1. pH adjustment
A common and simple method of drug solubilisation involves the adjustment of the pH of the
medium. However this method can only be possible with hydrophobic drugs whose molecular
structure enables them to be protonated (base) or deprotonated (acid) (Vemula et al, 2010).
This is the simplest and most commonly used method to increase water solubility of ionisable
compounds, by forming a salt form, which then converts into its respective acid and base
forms in the GIT. This method of solubilisation is not suitable for unionisable compounds. A
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drug with a basic functional group can be solubilised in acidic solutions at pH values below
the pKa of the drug (Strickley, 2004).
1.4.1.2. Solvent and Co-solvents
The main concern in pharmaceutical development is the inability to dissolve relatively
hydrophobic (non-polar) drugs in aqueous (polar and mixed polar) solvents. Oral solutions
can be simple or complex formulations, involving many types of excipients including water-
soluble organic solvents (forming a co-solvent system). Co-solvents are mixtures of miscible
solvents, such as ethanol and water, forming a binary system, used to solubilise poorly
water-soluble drugs to the required concentration in oral solutions (Strickley, 2004). Other
common pharmaceutical solvents include propylene glycol, glycerine and polyethylene glycol
(PEG), due to their relatively low toxicity (Vemula et al, 2010). The advantage of using a co-
solvent system to solubilise hydrophobic drugs is mainly associated with the simplicity and
ease of preparation of the formulation. This method of solubilisation has been commonly
applied for drug molecules that cannot be solubilised by pH adjustment, as their chemical
structures lack ionisable groups. The co-solvent binary system causes a change in the polar
condition of the solution, which becomes the governing factor on the extent of solubilisation
of a given compound.
The key to co-solvent solubilisation of hydrophobic compounds rests on the polarity of the
hydrophobic compound matching the polarity of the solvent mixture (Rubino, 2002; Miyako et
al, 2010). Polarity can be defined as the ability of a molecular structure to delocalise its
electronic charges (Miyako et al, 2010). Hence the term polarity refers to the hydrophilicity of
the compound; greater the polarity of a compound, greater its hydrophilicity. With regard to
solvation of a compound in solution, the polarity of the solvent mixture greatly influences the
extent of drug solubilised.
1.4.1.2.1. Mechanism of solvent action on drug solubility
Polar solvents (such as water) can solubilise polar compounds in one of two ways: (1)
dissolve ionic salts by separating the cations and the anions of the salt, and (2) its ability to
break a covalent bond in solution and produce an ionised form of the compound. The latter
method can be observed clearly when dissolving hydrogen chloride (HCl) in water (Figure
1.2). Water is a unique solvent that has a high boiling point, a high dielectric constant (78.36
ε), and is polar. The dielectric constant dictates the affect a medium has on the ease with
which two oppositely charged species may be separated. Thus the ability of water to
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solubilise salts can be explained by their high dielectric constants, with an increase in solvent
polarity increasing the dielectric constant of the solution (Gupta, 2005) and resulting in the
solubilisation of highly polar compounds (hydrophilic drugs).
Ethanol, a partly polar solvent with a reduced dielectric constant (24.3 ε), and low molecular
weight, forms a water-alcohol complex (Figure 1.3). Alcohols with larger molecular weights
are less polar (due to the increase in carbon backbone), and are less able to compete with
water molecules for a place in the water-lattice arrangement formed through hydrogen
bonding (Gupta, 2005). From figure 1.3, it can be observed that the hydrogen bond between
the hydroxyl group and the water molecule plays a major role in the extent of solubilisation.
Individually the water molecules have a higher dielectric constant than ethanol. However,
when arranged in a lattice form through hydrogen bonding the dielectric constant of the
overall solution is reduced, thereby enabling less polar molecules to be dissolved within this
lattice matrix. The non-polar hydrocarbon region of the co-solvent (ethanol portion) can lower
the ability of the aqueous system to squeeze out non-polar compounds by weakening the
intermolecular hydrogen bonding network of water. The solubilisation efficiency of the co-
solvent system therefore depends upon the extent by which the structure of water is
weakened (seedher and Kanojia, 2009). Alternatively, by increasing the hydroxyl groups in
the alcohol (such as sugars and glycosides), the solubility of non-polar compounds in water
can be increased further.
ClH OH2 OH3
+ Cl
-
+ +
Figure 1.2. Chemical reaction of hydrogen chloride (HCl) in water. The water molecule breaks the
convalent bond of H-Cl, forming an ionised chloride ion (Cl-) and a protonated water molecule.
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1.4.2. Cyclodextrins
Cyclodextrins are cyclic oligosaccharides consisting of six, seven or eight glucose ring
molecules forming α-, β- and γ-cyclodextrins respectively (Figure 1.4.) (Kayser et al, 2003).
Their main advantage is the spontaneous formation of hydrophobic cores with inner
diameters ranging from 4.70-11.20 Å (Table 1.1). The cyclodextrins are arranged with their
hydrophilic hydroxyl groups on the outside with a lipophillic inner cavity. This cavity allows for
Figure 1.3. Schematic representation of the lattice structure of water with ethanol. The incorporation
of ethanol within the lattice matrix reduces the polarity of the aqueous system, thereby enabling less
polar molecules to be dissolved within the solution.
Figure 1.4. Structure of (A) β-CD and (B) its derivative HP-β-CD.
(A) (B)
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dipolar interactions to be formed between the lipophillic compounds (guest molecule) and the
cavity of the cyclodextrin (Forgo et al, 2003). The advantages of using cyclodextrins for
complexation include; increased uniformity and absorption of poorly soluble drugs that are
known for their erratic absorption behaviour and increased drug activity upon oral
administration.
1.4.2.1. Pharmaceutical applications
Cyclodextrins have been used in pharmaceuticals to overcome various obstacles exhibited
by hydrophilic and hydrophobic drugs, such as solubilisation, taste masking, drug
stabilisation, and photostability.
1.4.2.1.1. Solubilisation
Cyclodextrins are naturally water soluble (Table 1.1), with modified cyclodextrins (HP-β-CD)
having a greater solubility profile. HP-β-CD owes this solubility to its degree of substitution,
which plays a major role in balancing cyclodextrin water solubility and its complexing ability.
By increasing the degree of substitution the solubility of the cyclodextrin increases
exponentially until a plateau effect is seen at which point the steric hindrances of the host
molecule impairs the cyclodextrin solubility efficiency.
Table 1.1. Cyclodextrin characteristics (taken from Brewster and Loftsson, 2007).
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1.4.2.1.2. Taste masking
In order for medicinal products to be acceptable by the patient, the preparation must have
good organoleptic properties (particularly for oral drug formulations). These include; taste,
smell, colour and consistency (gritty/smooth). Taste has been a particular issue when
administering drugs to paediatrics therefore taste masking is essential to ensure patient
compliance. Taste is associated by four major taste receptors on the tongue; sour, bitter,
salty and sweet (Figure 1.5). In order to elicit a taste sensation, a molecule must dissolve or
come into contact with the saliva; the molecules then react with the taste receptors on the
tongue to give a particular taste sensation. Every molecule is specific to a taste response
depending on its sapophore groups (groups of atoms in a molecule of a compound that gives
the substance its characteristic taste).
In order to mask unpleasant tastes (such as bitter tasting drugs), the molecule can be bound
to a second molecule preventing its sapophores from reaching the taste receptors. Previous
research has highlighted the application of cyclodextrins in masking the bitter taste of
midazolam (a preoperative anaesthetic commonly prescribed to children) (Marçon et al,
2009). Current applications of cyclodextrins in the food industry has seen Japan approving
the use of cyclodextrins as ‘modified starch’ in food applications (Prasad et al, 1999; Singh et
al, 2002, Kant et al, 2004; Astray et al, 2010)
Figure 1.5. Schematic representation of the tongue and the four zones of taste receptors: Sour,
bitter, salty and sweet.
Bitter
Sour
Salty
Sweet
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1.4.2.1.3. Drug stabilisation
The chemical structure of cyclodextrins allows for molecules to be partly or completely
complexed within their hydrophobic core, thereby bringing about enhancement of the stability
of the formulation. The strength of this affect depends entirely upon three factors; (1) Van der
Waals forces between the guest and the host molecules, (2) the way in which the guest
molecule fits into the cavity of the cyclodextrin, and (3) size of the host cavity. Previous
studies have looked at the impact of cyclodextrin on the stabilisation of adrimycin
(doxorubicin) and daunomycin (daunorubicin), in which it was found that the cavity size of the
cyclodextrin greatly impacted the strength of the inclusion complex (Emara et al, 2000).
As well as the strength of inclusion complexes, the characteristic nature (ionic and non-ionic)
of the cyclodextrins also plays a part in chemical stability, with possible drug degradation
occurring between the guest and the hydroxyl groups of the cyclodextrin (Loftsson, 1995). It
was found that ionic cyclodextrins formed stronger complexes with non-ionic molecules, and
weaker complexes with molecules carrying the same charge as the cyclodextrins (Másson et
al, 1998). This was a direct result of the changes in the location of the molecules within the
cyclodextrin cavity. This was particularly important with modified cyclodextrins (such as HP-
β-CD), which have a different structural conformation to its parent cyclodextrin, in order to
accommodate for the additional methyl groups, and thus ultimately changing the shape of the
cyclodextrin cavity (Másson et al, 1998).
1.4.2.1.4. Photostability
The rate of photodegradation depends upon light intensity and the spectrum of light used
(Backensfeld et al, 1991), thus degradation bi-products can occur in one of two ways: the
first being sunlight and the second being exposed to light spectrum from an artificial source,
such as a light bulb, which becomes particularly important during product manufacturing. For
example, nifedipine undergoes 5-times faster degradation on exposure to sunlight than under
fluorescent lamp. Therefore in order to fully test the photostability of a drug, it first becomes
necessary to understand the kinetics of photodegradation, and then to confirm and
characterise the drug-cyclodextrin inclusion complex formed, and assess whether the part of
the drug molecule involved in the first step of drug photodegradation has formed an inclusion
with the cyclodextrin cavity. Various studies have been carried out looking at photo-
stabilising affects of cyclodextrins (Backensfeld et al, 1991; Mielcarek and Daczkowska,
1999; Sortino et al, 1999; Bayomi et al, 2002), in which it was concluded that modified
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cyclodextrins provided better photo-stabilising affects than their parent counterparts. These
findings were attributed to the screening effects of cyclodextrins on light reaching the guest
molecule (Figure 1.6).
1.4.3. Suspensions
Suspensions are dispersions of an insoluble drug (or other substance) in an aqueous or non-
aqueous continuous phase. A number of dosage form formulation factors are associated with
suspensions which can influence the bioavailability of an active drug ingredient. These
include particle size and effective surface area of the suspended drug particles, the crystal
form of the drug, drug-excipient complexation, (for example formation of a non-absorbable
complex between the drug and suspending agent) and the viscosity exhibited by the
suspension in the GI fluids (Tezlaff et al., 1978, Werling et al., 2008, Arias et al., 2009).
Suspensions are more complicated formulations than solutions to produce as they are
inherently unstable formulations. If the particles in a suspension sediment in a very compact
manner then caking can result where homogenous redistribution of the particles into the
suspension is impossible. Controlling the interaction between the particles so that any
aggregation is reversible or preventing any interaction between particles makes it possible to
prevent caking. In order to do this the inclusion of excipients such as; electrolytes, surface
active agents and hydrophilic polymers are often added in suspension formulations.
Figure 1.6. Schematic representation of photo-stabilising affects of cyclodextrin. (A) In the absence
of cyclodextrin, the drug molecule is fully exposed to UV rays. (B) However, once complexed within
the cyclodextrin core, the complex structure of the cyclodextrin glucose units act as a screen
protecting its contents within.
(A) (B)
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Electrolytes and surface active agents on the whole improve the stability of a suspension by
modifying the Zeta potential of the suspended particles (Li et al., 2009, Xu et al., 2004).
1.4.3.1. Particle-Particle Interactions
1.4.3.1.1. Electrical Properties of Particles in Suspension
When insoluble particles are added in an aqueous solution it is likely that the particles may
become charged. Ionisation of the particles is one way the particles can become charged,
the extent of which is dependent upon the pH of the liquid and the pKa of the particles. The
second way in which the particles can become charged involves the adsorption of ions onto
the surface of the particles when there are electrolytes present in the aqueous vehicle. It is
this adsorption of ions onto the surface of the particles which results in an ‘electrical double
layer’ being formed which can be modified by using electrolytes and surface active agents in
a suspension to improve the stability of the formulation (Kayes, 1977).
Figure 1.7 displays the formation of the electrical double layer after the adsorption of cations
onto the surface of the particle in the suspension. This leads to a positive charge on the
particle which is referred to as the Nearnst Potential (Willmott et al 2010). This positive
Figure 1.7. Diagrammatic Representation of the electrical double layer formed around particles in
suspension.
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charge electrostatically attracts the negatively charged anions which are present in the
vehicle. This combination of particle, cations and anions make up the first part of the double
layer with the presence of the anions acting to repel the approach of any further anions. The
charge at the outer edge of this first layer is known as the Stern potential which falls at the
Stern plane which runs through the centre of the anion layer. In most cases the charge at the
Stern plane is lower than the Nearnst potential although there are exceptions to this rule. The
second layer of the electrical double layer is the Shear plane which is formed from hydrated
counterions that are loosely attracted to the particle and the charge at this level is referred to
as the Zeta potential (Lyklema and Duval 2005). As the distance from the particle increases,
the charge decreases to a point where electrical neutrality is attained.
1.4.3.1.2. Effect of particle Separation on Particle Interaction
The distance between particles in a suspension has a dramatic impact on the interaction
between the particles. This is described by the ‘DVLO’ theory put forward by Derjaguin,
Landau, Verwey and Overbeek (Derjaguin and Landau 1941; Verwey and Overbeek 1948),
wherein they suggested a formula for the energy of interaction;
Vt = Va + Vr
Vt = The total energy of interaction
Va = The energy of attraction
Vr = The energy of repulsion
The attractive forces are London dispersion forces (LDF) and van de Waals forces. The
magnitude of these forces decreases inversely upon increasing the distance between the
particles. The repulsive forces are a result of the previously described electrical double layer
with the distance at which the forces of repulsion acts being equal to the distance between
the Shear Plane and the particle surface. These forces of repulsion are active at much closer
distances than are observed for the LDF/van de Waals forces.
There are three levels of interaction which can be observed depending upon the separation
of the particles. These are termed the primary minimum, the primary maximum and the
secondary minimum (Figure 1.8).
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In suspensions where sedimentation is observed, it is common to manipulate the particles so
that they interact in the secondary minimum. This is so that the floccules that are formed can
be easily re-dispersed into the suspension as the interaction between the particles is weak
and easily broken upon shaking. The use of electrolytes and surface active agents induces
and controls flocculation in pharmaceutical suspensions by modifying the zeta potential and
in doing so achieving a balance between the attractive and repulsive forces acting on the
particles (Strand et al., 2003).
1.4.3.1.3. Electrolytes
In an effort to stabilise suspensions the rate at which the particles or floccules sediment can
be controlled by the careful control of the electrolyte concentration. The concentration of
electrolytes present in a formulation can be modified to control the zeta potential. Their
addition reduces the zeta potential at the shear plane which leads to a reduction in the
repulsive forces between particles. Careful manipulation of this allows for the closer
interaction of the particles in the suspension. Reducing the zeta potential to a point at which
the particles can interact at the secondary minimum allows for reversible aggregation which
prevents caking upon sedimentation and allows for the redistribution of the particles in the
suspension. It is necessary to produce a range of formulations containing varying
Primary Minimum – Strong Attraction
between particles
(Vt = Highly Negative)
Primary Maximum – Repulsion between
particles
(Vt = Highly Positive)
Secondary Minimum
– Weak Attraction
between particles
(Vt = Slightly
Negative)
(A)
(B)
(C)
Figure 1.8. Schematic representation of the three possible levels of particle interaction when in
suspension. (A) Particles interacting at the primary minimum will experience strong attractive forces
and will coagulate irreversibly. (B) Particles existing at the primary maximum will experience forces
of repulsion. (C) Particles at the secondary minimum will experience weak forces of interaction much
lower than the attractive forces seen at the primary minimum and the particles will interact reversibly
forming floccules in the process of flocculation resulting in a more stable suspension.
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concentrations and assess the amount of sedimentation and the degree of flocculation at
each concentration. The formulation which displays the largest degree of flocculation will be
the most stable system. Highly flocculated systems are more stable than formulations where
flocculation is low as the floccules sediment out into a larger volume than the individual
particles which pack closer together. This reduces the compression of the sediment and
thereby prevents caking (Figure 1.9) (Midmore and Hunter, 1988; Lippincot et al, 2005).
1.4.3.1.4 Surface Active Agents
Surface active agents can be included for use in suspensions for two main reasons; they can
effect flocculation and they can also affect the wettability of the drug particles. Surface active
agents affect the degree of flocculation observed in suspensions in a similar way as
described for electrolytes. Both ionic and non-ionic surfactants can be used. However, non-
ionic surfactants are routinely used in liquid oral suspensions as ionic surfactants have
higher toxicity. Surfactants are normally used in low concentrations which vary depending
upon the surfactants and the particles present (Schwartz and Perry, 1949).
Surface active agents are also employed to improve the wettability of drug particles in
suspension which reduce the contact angle of the insoluble drug particles with the aqueous
vehicle in which they are suspended. Due to the hydrophobic nature of insoluble drugs an
aqueous vehicle in which they are suspended may resist the formation of a layer around the
Electrolyte
Concentration
Zeta Potential
(C)(A) (B)
Figure 1.9. Diagrammatic representation of the effect of changing electrolyte concentration. (A) The
electrolyte concentration is low allowing for a high zeta potential resulting in caking of the particles.
(B) Sample illustrates a balance between electrolyte concentration and zeta potential which results
in flocculation and a larger sedimentation volume. (C) Sample displays caking which results from the
electrolyte concentration being too great and the zeta potential falling too low.
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particles which results in poor wetting. In order to achieve maximum wettability the angle at
which the liquid meets the solid particles surface needs to be low. The contact angle (θ) is
defined in terms of the tensions between three phases, these being: (1) Solid/Vapour (γs/v),
(2) Liquid/Vapour (γl/v), and (3) Solid/Liquid (γs/l).
Young’s equation is used to describe Wettability;
γl/v COS θ = γs/v – γs/l
Decreasing the interfacial tensions in the Liquid/Vapour and the Solid/Liquid will lead to a
reduction in the contact angle. This is attained by the addition of surfactants into the
formulation which adsorb at the Liquid/Vapour and the Solid/Liquid interfaces reducing the
tension (Guo et al, 2005, Stamkulov et al, 2009).
Poorly wetted drug particles have a tendency to clump together in an attempt to stabilise the
suspension by lowering the Gibb’s free energy. Sufficiently wetted particles aid the
production of homogenous suspensions and this is essential for ensuring uniformity in
dosage.
1.4.3.1.5. Hydrophilic Polymers
Hydrophilic polymers improve the stability of a suspension via steric repulsion. This occurs
as the hydrophilic polymers adsorb to the surface of the particles in the suspension. However
as the hydrophilic polymers are large molecules they often have long sections not absorbed
to the particle surface and these sections extend into the vehicle which results in controlling
flocculation and enhancing the stability of the system (Kellaway and Najib, 1981).
The second function of hydrophilic polymers is to modify the flow properties of the
suspension, achieved by increasing the vehicle viscosity with increasing hydrophilic polymer
concentration. This is useful for prolonging the suspension of particles but can at times in the
same way make it more difficult to re-suspend any particles which do sediment. To get the
best results from the addition of hydrophilic polymers, the ideal properties for a suspensions
flow profile are pseudoplastic or shear thinning. These are non-Newtonian liquids for which
the rate of shear is not proportional to the shear stress exerted (Figure 1.10) (Jones 2008).
This is particularly useful as the relatively high viscosity under low shear conditions (such as
during storage) slows the sedimentation process, and the relatively low viscosity under high
shear conditions (such as shaking or pouring) allows for the easy re-dispersion of any
sediment and also the easy dispensation of the medication (Figure 1.11) (Cross 1965).
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Figure 1.10. Comparison of the response in shear rate with increasing shear stress for Newtonian
flow and pseudoplastic flow.
Figure 1.11. Typical plot of viscosity against shear rate for a pseudoplastic liquid. Increasing the
shear rate causes a decrease in viscosity.
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1.4.3.1.6. Nanoparticles
Nanoparticles are defined as submicron (<1μm) colloidal particles, of which there are
monolithic nanoparticles (nanospheres) and nanocapsules. With regards to the former, the
drug is able to be absorbed, dissolved, or dispersed throughout the matrix. With regards to
the latter, the drug is confined to an aqueous space or oily core surrounded by the polymeric
shell-like wall. This polymeric coating provides a dual action of API protection and regulated
release, with the latter being mainly influenced by polymer-to-drug ratio, and molecular
weight and composition of the polymer (Prabha and Labhasetwar, 2004)
This drug delivery system is particularly important for sensitive API’s that are to be delivered
orally, such as hydrophobic or acid labile drug molecules. Significant advancement has been
made in using polymeric nanoparticles for gene therapy towards breast cancer cells,
resulting in anti-proliferative effects (Prabha and Labhasetwar, 2004b).
1.5. Excipients for Inclusion in all Oral Liquid Formulations
The formulation of solutions and even more so for suspensions requires the use of several
excipients. It is important that all ingredients in the formulations are chemically compatible to
ensure the stability of a formulation. In addition to the previously mentioned solubilising
agents, there is a need for inclusion of preservatives to protect against microbial
contamination and in the majority of cases antioxidants are included to protect the API from
oxidising agents.
1.5.1. Preservatives
The preservatives for inclusion in oral liquid formulations should be effective over a broad
spectrum in order to prevent contamination as a result of bacterial (gram negative and gram
positive) and fungal infection. They must also however be harmless to the patients and
remain active and stable for the life of the product. There are a multitude of preservatives
available for use with some of the most commonly used including benzoic acid, ascorbic acid
and the paraben group of preservatives (Bean, 1972).
There are many factors in liquid formulations which can have an effect on the efficacy of the
preservatives included in the formulation. The first determinant is the concentration of
preservative included in the formulation. Below the minimum inhibitory concentration (MIC)
the preservative will not be sufficiently effective to fully protect the formulation from
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contamination. Other factors which can be of incidence on the efficacy of the preservatives
include: pH of the system, presence of micelles, and the presence of hydrophilic polymers
(Gallardo et al, 1991).
The pH of a system determines whether a compound will be present in its ionised or
unionised form. In some cases only the unionised form of a preservative displays
antimicrobial activity. As a result increased antimicrobial activity will be seen in acidic
formulations, an example of such a preservative is benzoic acid. There are other
preservatives which are less pH dependent such as parabens (pH range of around 4-8).
Micelles can impact preservative activity if the preservative displays hydrophobic properties,
where this is the case the preservative can pass into the oil phase of the micelle leaving
concentrations of preservative remaining dissolved in solution which may fall below the MIC.
When micelles and hydrophobic preservatives are used in conjunction, it is important for the
concentration of the preservative to be greater than intended for use, thus ensuring the
concentration of the preservative present in the solution remains above the MIC (Jones
2008).
Hydrophilic polymers have been shown to interact with the preservative dissolved in solution
via chemical reactions which reduces the availability of preservative. Electrostatic
interactions between the hydrophilic polymers and the preservatives may also render the two
incompatible (Kurrup et al, 1995).
1.5.2. Chemical stabilisers
Chemical stabilisers are substances which inhibit the reaction between two or more
molecules of interest. Some of the common stabilisers used in the pharmaceutical industry
include: antioxidants, sequestrants (inactivate traces of metal that would otherwise act as
catalysts), emulsifiers and surfactants, and ultraviolet stabilisers.
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Antioxidants are included in pharmaceutical preparations to protect the API when there is the
possibility of oxidative degradation. Antioxidants are typically either compounds that inhibit
free radical induced decomposition or they are redox systems, which exhibit higher oxidative
potential than the drug they are protecting. They work to protect the drug by being oxidised in
preference of the drug itself. Antioxidant concentration decreases markedly between
production and the end of the shelf life of a formulation as the antioxidant is used up over
time. Antioxidants are used in low concentrations and can be combined with chelating agents
which provide added protection (Shah et al, 2010).
Oxidation can be defined as a chemical reaction involving the transfer of electrons/hydrogen
from one substance to an oxidising agent, usually resulting in the formation of free radicals. It
is these free radicals that are the most damaging to biological cells. Table 1.2 highlights the
classification of antioxidants into three distinct groups: (1) true antioxidants, (2) reducing
agents, and (3) antioxidant synergists. The latter group normally have limited antioxidant
properties themselves, but enhance the actions of the true antioxidants by reacting with
metal ions that catalyse oxidation.
Class Description Example
True antioxidants Block chain reactions byreacting with free radicals
Butylated hydroxyanisole,
butylated hydroxytoluene, tert-
butyl-hydroquinone, 4-
hydroxymethyl-2,6-di-tert-
butylphenol, gallin acid, propyl
gallate
Reducing agent
Reducing agents have a lower
redox potential than the drug
or excipient they are
protecting
Ascorbic acid, thioglycolic
acid, ascorbyl palmitate,
sulphites, thioglycerol
Synergistic Enhance the affects ofantioxidants EDTA, Lecithin,
Table 1.2. Classification of antioxidants.
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1.6. Development of a Palatable Formulation
As children are less likely to be willing to take unpleasant tasting medications that an adult
may deem acceptable, and as such the production of palatable formulation is also a
necessity. This is particularly important when formulating solutions than suspensions, as the
bitter taste of many API’s is fully prevalent once the API is solubilised, where as in a
suspension the bitter taste can be somewhat masked by the suspending agent. There are
many methods of taste masking.
The inclusion of taste enhancers such as concentrates, fruit juices and sweetening agents
are widely used but are limited in their capacity in taste masking very bitter drugs. Another
approach is to coat the drug particles with agents which are not pharmaceutically active for
example Eudragit, PEG and ethyl cellulose. These coatings prevent the interaction of the
bitter tasting drug particles with the taste receptors in the mouth and thereby mask the bitter
taste. It is important that the coating of the drug particles does not limit the bioavailability of
the drug. Complexation of the drug molecule with a host molecule is another method by
which the bitter taste of a drug can be masked, in this way the whole drug molecule or part of
the molecule is contained within a host molecule (for example cyclodextrin), and in a similar
way to the coating procedure prevents the interaction of the drug with the taste receptors.
Yet another widely used approach involves the production of solid insoluble poly-electrolytes
which have a high molecular weight known as ion exchange resins. The inclusion of a bitter
tasting drug into a solid dispersion, liposomes or emulsions or alternatively the combination
of the drug with amino acids are four further methods for taste masking, with the formation of
pro-drugs or salts of the drug being two methods of improving palatability via chemical
modification (Ayenew et al 2009).
1.6.1. Sweeteners
The most commonly used sweetening agents included in pharmaceutical preparations are
sucrose, liquid glucose, glycerol, sorbitol, saccharin sodium and aspartame. Increasingly
artificial sweeteners are being used in formulations and in paediatric formulation the use of
sugar is to be avoided. This is also the case for formulations intended for use in patients
suffering from diabetes mellitus.
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1.6.2. Flavourings
In the same manner that sweeteners are included to mask the taste of unpleasant tasting
formulations, purpose made flavourings can be added. The flavour selected for use must be
effective at masking the taste and in order to do this the flavours to choose from depend on
the initial taste of the formulation. For example, when a formulation is unpleasant as the
result of a salty taste then some of the best flavours to mask this include; butterscotch,
apricot, peach, vanilla and mint. In the same way, a bitter taste is best masked with flavours
such as; cherry, mint and anise. Formulations which are overly sweet are best improved by
including vanilla or fruit and berry flavours while sour tasting formulations are best masked
using the citrus flavours and raspberry.
In most cases a combination of more than one flavouring agent coupled with a sweetening
agent will produce the most palatable formulation and excipients with the roll of enhancing
the flavours present are often included. Flavour adjuncts (such as menthol) are at times also
included and these have the effect of reducing the sensitivity of the taste buds at the same
time as adding to the flavour of the formulation.
1.7. Rational and aim of the project
Among the existing dosage preparations available on the pharmaceutical market, the oral
route remains the preferred choice with better patient compliance. However the lipophillic
nature of most API’s enables them to effectively cross the lipophillic mucosal barrier to the
site of action. Thus the current and mainstay for oral delivery remains to be solid dosage
forms, as they can be applied to the vast number of hydrophobic API’s on the market.
However, these formulations have their disadvantages as they are relatively large and bulky,
thus are difficult to administer to children and those patients who have suffered a stroke,
motor neurone disease and advance Alzheimer’s (resulting in dysphagia). Accordingly, the
current research aims to investigate the role of formulation excipients in the development of
oral liquid preparations (longer shelf life) with various API’s, and use this knowledge to
achieve further advances in the formulation field, particularly as drugs come to the end of
their patent life.
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The research strategy had been rationalised as follows:
 To develop a stable solution of captopril at 1 mg.mL-1 and 5 mg.mL-1 dosages by
preventing the degradation product captopril disulphide, and to investigate the
implications of the stabilising affects of HP-β-CD.
 To investigate the influence of salts and generally recognised as safe (GRAS) listed
solubilising excipients on the solubilisation of gliclazide, in order to prepare an 8
mg.mL-1 and 16 mg.mL-1 formulation.
 To investigate the solubilising and stabilising properties of cyclodextrin (HP-β-CD) in
the development a 1 mg.mL-1 melatonin formulation.
 To overcome the extreme bitterness of L-arginine and prepare an acceptable
palatable 100 mg.mL-1 formulation with an optimised calibration validation protocol.
 To investigate the preservative efficacy of the oral liquid formulations prepared in
chapters 2-5.
 To investigate the applications of nanoparticulate delivery for the acid labile drug
lansoprazole, and the influence of polymer composition and ratio of the efficiency of
drug loading.
The preparation of oral liquid formulations has three major advantages; firstly liquid
preparations provide a practical solution for patients who have difficulty swallowing
(dysphagia). This target group includes; geriatrics, paediatrics, and those hospitalised who
suffer from a variety of disorders limiting their motor movements (such as stroke, parkinson’s
disease etc.). Secondly, as pharmaceutical drugs reach the end of their patents, the
reformulation of the drug into a new dosage form enables the pharmaceutical companies to
extend the patent life and ultimately their market exclusivity. Thirdly, oral delivery systems do
not require strict sterile conditions and are thus less expensive to manufacture.
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CHAPTER 2
Formulation development of an oral solution of captopril
2.1. Introduction
2.1.1. Angiotensin Converting Enzyme (ACE)
Angiotensin I-converting enzyme (ACE), a dipeptidyl carboxypeptidase is a transmembrane
zinc metalliopeptidase, which not only plays a vital role in cardiovascular homeostasis but
also displays a physiological role in blood-pressure and metabolism of salt and water, via its
actions on angiotensin I and brandykinin (Mayer and Meyer, 2000; Hattori et al, 2000). The
metalloprotease acts by using a zinc atom for catalysation of the inactive decapeptide
angiotensin I to the potent vasopressor octapeptide angiotensin II. This action is carried out
by the cleavage of the carboxy-terminal dipeptide.
As seen from figure 2.1, in order to reduce high blood pressure the angiotensin-converting
enzyme can be inhibited at 2 distinctive points: the first is to inhibit the conversion of
angiotensin I to angiotensin II in the endothelial tissues via ACE inhibitors. The second point
of inhibition is by preventing further conversion of angiotensin II to angiotensin III in the
adrenal gland by angiotensin receptor blockers (ARBs).
2.1.2. ACE Inhibitors
ACE inhibitors are competitive inhibitors of ACE, mimicking the structure of its substrate.
There are a range of ACE inhibitors: sulphydryl-containing agents such as captopril,
dicarboxylate-containing agents including enalapril, ramipril, quinapril, perindopril, lysinopril
(a lysine derivative of enalapril) and phosphonate-containing agents such as fosinopril.
Captopril and lisinopril are active molecules. Others listed above are prodrugs that need to
be converted to active metabolites (di-acids) to illicit a therapeutic response. The chemical
structures of these ACE inhibitors are represented in figure 2.2. ACE inhibitors act by
blocking the formation of angiotensin II and at the same time increasing the bradykinin level.
This results in the reduction of vasoconstriction, sodium and water retention, resulting in
increased vasodilation.
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Figure 2.1. Angiotensin conveting enzyme mechanism. (Source: Katzung et al, 2009,
http://www.accessmedicine.com)
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Figure 2.2. Chemical structures of ACE inhibitors currently on the pharmaceutical market.
(Structures taken from www.Drugbank.ca)
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2.1.3. Captopril
Captopril is one of the potent hypotensive agents commonly prescribed to lower blood
pressure. It is a white crystalline powder with a molecular weight of 217.3, freely soluble in
water (160 mg.mL-1 at 25 oC) and has a distinctive sulphide like odour. As a solid dosage
form, captopril is marketed as Acepril®, Capoten®, and Ecopace®, which are available as
12.5, 25, and 50 mg tablets. Captopril is currently used for hypertension, heart failure and
after care, as well as circulation problems associated with diabetes. One of the common
physiological conditions prevalent in patients who have suffered from heart failure is
dysphagia. Dysphagia is a medical condition where the patient experiences swallowing
difficulties. To meet the patient needs, captopril is regularly prescribed as a liquid “special”
with a shelf life of one month. The short shelf life of the liquid preparation is due to chemical
instability of captopril via oxygen-facilitated first order free radical oxidation at its thiol group,
yielding a major degradation product captopril disulphide (Figure 2.3). The mechanism is
initiated by the hydrogen on the carboxylic group reacting with the free oxygen in solution
creating an ionised carboxylic acid group (–COO-). This in turn causes the thiol group (-SH)
to donate its hydrogen atom to reform a carboxylic end group, resulting in an ionised sulphur
atom (–S-), which further reacts with another molecule of captopril undergoing the same
chain reaction. The two captopril molecules dimerise to form the degradation product
captopril disulphide (Kristensen et al, 2008). The rate of oxidation can however be reduced
by a number of factors. Oxidation is pH-dependent and thus by reducing the pH of the
system the stability of the system increases, with pH<4 achieving the greatest stability
(Hillaert and Van den Bossche, 1999). Oxidation is also influenced by the presence of metal
ions such as copper and iron. Research has also shown that captopril degradation may be
inversely proportional to drug concentration, which is primarily due to the stoichoimetry of the
oxidation, as two moles of captopril is known to be lost for every half a mole of oxygen
consumed (Connors et al, 1986).
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Figure 2.3. Schematic representation of the formulation issues associated with captopril degradation. (A) Degradation pathway of captopril: oxygen-facilitated, first order, free
radical oxidation is initiated by the ionisation of the carboxylic group, which in turn ionises the thiol group, yielding the major degradation product captopril disulphide (B)
captopril formulation issues required to be overcome in the study: prevention of the oxidation reaction and masking of the sulphide like odour of captopril.
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2.1.3.1. “Specials” – current state of oral liquid captopril
Many drugs have been widely used as unlicensed oral liquid medicines that have been
extemporaneously prepared in dispensaries in order to meet the needs of specific patient
groups, such as paediatrics and geriatrics or those with swallowing difficulties.
Extemporaneous preparations are defined as formulations made to meet specific needs for
the consumer without a license requirement. However the biggest disadvantage of
extemporaneous preparations is the greater risk of adverse drug reactions as compared with
the licensed medicines. These unlicensed medicines were commonly given to the most
vulnerable patients in the community and in the hospitals and as such were unable to alert
the medical staff to any adverse drug reactions they may have been experiencing. Research
by Mulla and co-workers (2007) has shown that extemporaneous preparations of captopril
had variable shelf life ranging from 7 -28 days, dosing inconsistencies and poor formulation
harmonisation leading to potential toxicities. The research concluded that the
inconsistencies in formulation raised serious issues over optimal dosing and its influence in
paediatric cardiac surgical and interventional outcomes. Current formulations include simple
solubilisation in water, syrups, and suspending agents. However the use of syrup as a
vehicle for captopril was not recommended due to vulnerability to microbial contamination
when diluted with other excipients. In addition, dilution results in an increased risk of the
introduction of unwanted metal ions and thus catalysing drug degradation (Mulla et al, 2007)
2.1.4. Aims and objectives
The aim of the study was to formulate and stabilise captopril (max. 5 mg.mL-1) in solution for
oral delivery. This was to be achieved by overcoming two major obstacles; (1) preventing the
initiation of the oxidation process and (2) overcoming sulphur-like smell (organoleptic
properties) of captopril in solution (Figure 2.3B).
The various parameters tested to address these issues systematically included:
1. Influence of addition of antioxidant/chelating agent (EDTA-Na)
2. Influence of incorporation of antioxidant with preservative activity
3. Complex formation and stabilisation using HP-β-CD
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2.2. Methods and materials
2.2.1. Materials
Captopril, glycerol, sodium metabisulphite, ethylenediaminetetraacetic acid disodium salt
dihydrate (EDTA), hydroxpropy-β-cyclodextrin (HP-β-CD), Pluronic F127 and potassium
bromide were all purchased from Sigma. Deuterated dimethyl sulfoxide (DMSO-D6)
purchased from Goss Scientific Instrument Ltd (Cheshire, UK). Phosphoric acid and
methanol were purchased from Fisher Scientific (UK).
2.2.2. Calibration validation
Calibration was carried out using a Dionex HPLC system comprising of a GP50 gradient
pump, AS50 autosampler and a UVD170U detector (Dionex Corporation, USA). Samples
were passed though a 5 μm C18 Gemini column (150 x 4.6 mm) (Phenomenex, USA). 25 mg
of captopril was dissolved in 50 mL of water to obtain a stock concentration of 500 μg.mL-1.
Serial dilutions were then carried out to obtain concentrations of 400, 300, 200, 100, 50, and
25 μg.mL-1. Using a mobile phase consisting of 0.1 % (v/v) phosphoric acid and methanol
(72.5:27.5), 20 μL of each captopril concentration was injected into the Dionex HPLC and
analysed at a wavelength of 220 nm. The retention time for captopril was 15 minutes. (Khan
et al, 2000).
2.2.3. Formulation strategies
2.2.3.1. Captopril solubilisation
20 mg of captopril was solubilised in 20 mL water to produce a 1 mg.mL-1 formulation. The
samples were stored in polyethylene terephthalate (PeT) (Neville and More Ltd, Southwater,
England) bottles at 25 oC and 40 oC under 40 and 75 % humidity conditions respectively.
2.2.3.2. Addition of an antioxidant
20 mg of EDTA was added to 10 mL water under continuous stirring. Once fully dissolved
20 mg of captopril was added and stirred. The volume was then made up to 20 mL to
produce a concentration of 1 mg.mL-1. The samples were stored in PeT bottles at 5 oC, 25 oC
(40 % humidity) and 40 oC (75 % humidity).
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2.2.3.2.1. Addition of 0.1 % (w/v) sodium-metabisulphite
20 mg of EDTA and 20 mg of sodium-metabisulphite was added to 10 mL water under
continuous stirring. Once fully dissolved, 20 mg of captopril was added and stirred
magnetically. The volume was then made up to 20 mL to produce a concentration of
1 mg.mL-1. The samples were stored in PeT bottles at 5 oC, 25 oC (40 % humidity) and 40 oC
(75 % humidity).
2.2.3.2.2. Addition of 30 % (w/v) glycerol
20 mg of EDTA was added to 10 mL water under continuous stirring. Once fully dissolved 6 g
of glycerol was added under continuous stirring to form a final concentration of 30 % (w/v).
20 mg of captopril was then added under continuous stirring until the drug had fully
solubilised. The volume was then made up to 20 mL to produce a concentration of
1 mg.mL-1. The samples were stored in PeT bottles at 5 oC, 25 oC (40 % humidity) and 40 oC
(75 % humidity).
2.2.3.2.3. Addition of HP-β-CD
In 10 mL of water, 120 mg of HP-β-CD was dissolved under continuous stirring, to which
20 mg of captopril was then added. Once fully dissolved, 20 mg of EDTA was added under
continuous stirring and the volume was then made up to 20 mL to produce a concentration of
1 mg.mL-1. The samples were stored in PET bottles at 5 oC, 25 oC (40 % humidity) and 40 oC
(75 % humidity).
2.2.3.3. 5mg.mL-1 formulation of captopril
2.2.3.3.1. Addition of EDTA
20 mg of EDTA was added to 10 mL water under continuous stirring. Once fully dissolved
100 mg of captopril was added and stirred magnetically until fully solubilised. The volume
was then made up to 20 mL to produce a 5 mg.mL-1 concentration. The samples were stored
in PeT bottles at 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity).
2.2.3.3.2. Addition of HP-β-CD with EDTA
In 10 mL of water, 602 mg of HP-β-CD was dissolved under continuous stirring, to which
100 mg of captopril was then added. Once fully dissolved, 20 mg of EDTA was added under
continuous stirring and the volume was made up to 20 mL to produce a 5 mg.mL-1
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concentration. The samples were stored in PeT bottles at 5 oC, 25 oC and 40 oC under 40 oC
and 75 % humidity conditions respectively.
2.2.4. Microviscosity of glycerol
Viscosity of glycerol samples was measured using the automated micro viscometer (Anton
Paar, Hertford, UK). Viscosity of a sample is based upon the falling ball principle in which the
time taken for the ball to roll through transparent and opaque liquids is a measurement of the
dynamic viscosity of the sample.
Various concentrations of glycerol ranging from 10 to 50 % (v/v) were prepared in distilled
water, and transferred into the glass capillary tube to measure the dynamic viscosity using
the rolling ball. The temperature was set at 25 oC for all of the samples and the density of
water was calibrated to be 0.99700 g.cm-3.
2.2.5. Conductivity measurements
Conductometry was calculated using a conductivity meter 4310 (Jenway, Staffordshire, UK)
(K=1.08 at 25 oC). In 50 mL of distilled water 250 mg of captopril was added and the
conductivity was measured. To this increasing amounts of HP-β-CD was added and the
reading for conductivity and potentiometry were recorded.
2.2.5.1. Calculation of association constant
For a 1:1 complex to form CD + D CD - D
The stability of the inclusion complex can be described by the association constant K:
CCD,F = Concentration of non-complexed cyclodextrin
CD,F = Concentration of non-complexed drug
CCD-D = Concentration of the 1:1 complex
Thus using the above equation the association constant for this system can be calculated as
follows:
K
K = CCD-D
(CCD,FCD,F)
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Concentration of non-complexed Cyclodextrin = 4198 mg in 50 mL = 83.96 mg.mL-1
Concentration of non-complexed drug = 5 mg.mL-1
Concentration of 1:1 complex = 88.96 mg.mL-1
Therefore using K = CCD-D / (CCD,FCD,F)
= 88.96 / (83.96 x 5)
K =1.79
2.2.5.2. Calculation of Molar conductivities
Definition of a molar conductivity is as follows:
ΛD,F = Molar conductivity of non-complexed drug
ΛCD-D = Molar conductivity of the 1:1 complex
CCD,F = Concentration of non-complexed cyclodextrin
K = 1.79
Thus by using the above equation the molar conductivity of a set added amount of
cyclodextrin can be calculated:
Example:
Molar conductivity of non-complexed captopril (ΛD,F) :
ΛD,P + ΛCD-D KCCD,F
Λ =
1 + KCCD,F
Conductivity reading of captopril 1457
Moles of captopril
=
0.023
= 63347
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Molar conductivity of complexed drug with cyclodextrin (ΛCD-D):
K = 1.79
The concentration of non-complexed cyclodextrin (CCD,F) = 0.25, 0.50, 0.75 M etc.
Therefore for a 0.25 M HPβCD, which displayed a conductivity reading of 1431:
ΛD,P + ΛCD-D KCCD,F
Λ =
1 + KCCD,F
63347 + 5724 x (1.79 x 0.25)
Λ =
1 + (1.79 x 0.25)
Molar conductivity = 45533 S.m2 .mol-1
Analysis is conducted from the graph produced of molar conductivity versus concentration of
HP-β-CD. A decrease in conductometry is due to complexation between the drug and the
cyclodextrin and a plateau effect was seen when the drug was fully complexed with the
cyclodextrin.
2.2.6. Freeze-drying protocol
5 mg.mL-1 formulations of captopril with HP-β-CD were prepared (protocol 2.2.3.3.2.). The
samples were placed into flat-bottom glass vials and frozen at -60 oC for 2 hours. The
samples were then placed into an advantage 2.0 bench top freeze-dryer (VirTis, Suffolk, UK)
in order to extract the water. The freeze-drying process involved primary drying for 48 hours
at a shelf temperature of -40 ºC followed by secondary drying for 10 hours at a shelf
temperature of 20 ºC at a vacuum of 50 mTorr.
Molar conductivity reading of complex 1431
Moles of cyclodextrin
=
0.25
= 5724
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2.2.7. Proton Nuclear Magnetic resonance Spectroscopy (H1-NMR)
The freeze-dried samples and individual ingredients of each formulation were dissolved in
DMSO-D6 at room temperature in 5 mm glass tubes. Approximately 2 mg of the sample was
dissolved in 600 μL of DMSO-D6. All NMR measurements were done with standard Bruker
pulse sequences.
2.2.8. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) (Perkin-Elmer, Wellesley, USA) was used to study
glass transition temperatures (Tg) and melting points. Approximately 5 mg of sample was
placed in a Perkin-Elmer aluminium pan, cooled to 10 oC using intra-cooler (2P Perkin-Elmer,
Wellesley, USA) followed by heating to 240 oC at a rate of 200 oC.min-1 with a nitrogen purge
of 20 mL.min-1. An empty aluminium pan was used as a reference.
The Tg and melting temperature (Tm) were then analysed using the Pyris Manager software.
All of the measurements were carried out in triplicate with fresh samples being prepared for
each DSC run. The DSC was calibrated for temperature and heat flow, prior to the samples
being tested, using standard samples of indium (Tm 156.6 oC) and zinc.
2.2.9. Thermogravimetric analysis (TGA)
Thermal degradation of captopril was analysed using a TGA, which determines the
dependence of the weight loss of a sample as a function of temperature. The system
consisted of a Pyris 1 Thermogravimetric Analyzer (Perkin Elmer). The sample mass ranged
from 2-5 mg and were heated from 20-300 oC at a rate of 10 oC.min-1. The instrument self
regulates the heating rate automatically in order to maintain a constant temperature during a
given thermal event. All the studies were performed in triplicate.
2.2.10. Fourier Transform Infrared Spectroscopy (FTIR)
Characterisation of freeze-dried formulations was carried out with FTIR in order to investigate
the interaction of the excipients and the drug. Freeze-dried samples of the formulations were
prepared according to protocol 2.2.6. FTIR disks were prepared by adding the samples to
potassium bromide at a ratio of 1:5 respectively. The mixed sample was then compacted by
a mechanical press (Specac, Kent, UK) for 10 minutes at 8 tons to form a translucent pellet,
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which was analysed using an IR200 spectrometer (Thermo Electron Corporation, UK) to
determine the transmittance of each excipient.
2.2.11. pH
The pH of each sample was analysed using a Hydrus 500 (Fisherbrand, UK), calibrated at
pH 4, 7 and 10.
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2.3. Results and Discussion
2.3.1. Validation of Calibration Curve
HPLC method was developed and validated for the determination of captopril. At a
wavelength of 220 nm, distilled water was used to solubilise captopril and analysed to
generate a calibration curve. Results are presented in table 2.1.
2.3.1.1. Linearity
The linearity was evaluated by preparing the standard curve for captopril on three
consecutive days. The peak area was plotted against captopril concentration and calibration
response was assessed for variances. The resultant calibration curve was linear with a
regression equation of y=0.1905x (R2=0.9997) (Figure 2.4).
2.3.1.2. Precision
In order to access the reproducibility of the calibration protocol, the method was carried out in
triplicate over a period of 3 days for inter-day precision and in triplicate on the same day for
intraday precision. The results showed that the method was reproducible with inter-day
Table 2.1. Summary of Calibration Validation of captopril.
Criteria Validation
Y= 0.1905
R2 0.9997
Intra-day Precision 110.3 %
Inter-day Presicion 109.1 %
Accuracy (+SD) 20 μg.mL-1 97.2 (7.29)
Accuracy (+SD) 40 μg.mL-1 94.68 (5.24)
Accuracy (+SD) 60 μg.mL-1 97.73 (4.69)
LOD μg.mL-1 4.33
LOQ μg.mL-1 13.12
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precision of 110.3 % and intra-day precision being 109.1 % (Table 2.1). The standard
deviation of the regression equation was 0.002. Statistical data was compared using ANOVA
with the resulting inter-day and intra-day precision being calculated to have a variance of
P>0.05, suggesting no difference was seen between the calibration curves on the three days.
2.3.1.3. Accuracy
The accuracy of the developed method was determined from three concentrations of
captopril in distilled water representing low, medium and high portions of the standard curve
(20, 40 and 60 μg.mL-1). Accuracy of the three concentrations was in the range of 95-97 %.
2.3.1.4 Limit of detection (LOD) and limit of quantification (LOQ)
The limit of detection of an individual analytical procedure is the lowest amount of analyte in
a sample which can be detected but not necessarily quantifiable as an exact value (EMEA,
1995). From the calibration range the LOD was calculated to be 30 μg.mL-1.
The limit of quantification of an individual analytical procedure is the lowest amount of
analyte in a sample which can be quantitatively determined with accuracy and precision
(EMEA, 1995). From the calibration range the LOQ was calculated to be 100 μg.mL-1.
Figure 2.4. Graph of captopril calibration highlighting the linearity of the validation protocol (n=3).
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2.3.2. Formulation development strategy
As outlined in figure 2.3, there were two main challenges in the development of oral liquid
formulation of captopril: (1) prevention of oxidation and (2) the development of an odour free
formulation (captopril has a distinct sulphur smell) (Mulla et al, 2010). To address these, the
developmental work was divided into two phases. The first phase involved investigation of
inclusion of antioxidants and chelating agents to minimise the process of degradation via
oxidation. EDTA alone (chelating agent), EDTA along with glycerol (chelating action and
preservative activity) and sodium metabisulphite (antioxidant and preservative) were
investigated for their influence on captopril stability. This stage of the work was critical as
reduction/prevention of oxidation also has a positive effect on reducing dimerisation of
captopril (Figure 2.3). The second phase of developmental work was centred on
enhancement of organoleptic properties of the formulation including taste, smell and
appearance.
2.3.3. Approaches to reduce oxidation
2.3.3.1. Influence of addition of antioxidant on the stability of captopril in
solution
EDTA is a chelating agent with a structural formula of C10H14N2Na2O8 (Figure 2.5) and used
as an antioxidant in concentrations between 0.005 to 0.1 % (w/v). In a study carried out by
Berger-Gryllaki and co-workers (2007) a 1 mg.mL-1 formulation of captopril containing EDTA-
sodium at 0.1 % (w/v) produced a stable formulation at 5 oC and room temperature with a
shelf life of 2 years. EDTA acts by binding to metal ions by forming six bonds; two bonds are
formed with nitrogen atoms in the amino groups and a further four bonds are formed at
oxygen atoms in the carboxyl groups (Figure 2.5). These sites are able to initiate an
oxidation reaction with free oxygen ions in water resulting in ionised sites for interaction of
EDTA with the thiol group of captopril (Jurca and Vicas, 2010) thereby preventing the
initiation of free radical oxidation of captopril.
Initial studies were focused on determining the influence of addition of EDTA on the stability
of captopril. The formulation protocol comprised of inclusion of EDTA (0.1 % w/v) along with
captopril (1 mg.mL-1) in water and assessed for drug stability. All the formulations were
stored at 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity).
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The influence of addition of EDTA on the stability of captopril in solution is presented in
figures 2.6 and 2.7. In the absence of EDTA, captopril stability was compromised within 30
days. The recovery of captopril decreased to 92.22 + 0.16 % at 25 oC and 35.19 + 1.77 % at
40 oC (Figure 2.6). The degradation of captopril was possibly a direct result of dimerisation
initiated by partial deprotonation (17 %) of its carboxylic group (pKa 3.7) at pH 3.2, thereby
acting as the driving force of proton donation from the thiol group to the deprotonated
carboxylic group (Hillaert and Van den Bossche, 1999; Kristensen et al, 2008). In contrast,
the addition of EDTA resulted in stable formulations with around 100 % drug recovery over a
12 month period at three temperatures including: 5 oC, 25 oC and 40 oC (Figure 2.7). During
the 12 month stability period, no change in pH was observed, with samples remaining stable
at a pH range of 3.2-3.4 (Figure 2.8).
The improvement in captopril stability upon inclusion of EDTA can possibly be attributed to
the influence of pH and the binding capabilities (chelating activity) of EDTA. The final pH of
the formulation was around 3.2. Research by Kristensen and co-workers (2008) has shown
that EDTA exists in its ionised state at low pH and exhibits improved chelation due to the
presence of six charged groups in its structure (pKa1=0.0, pKa2=1.5, pKa3=2.0 and
pKa4=2.66 all apply to the carboxyl protons; and pKa5=6.16 and pKa6=10.24 apply to the
nitrogen protons) (Permyakov and Kretsinger, 2011). At pH 3.2, the deprotonated carboxyl
groups of EDTA potentially bond with the ionised thiol groups of captopril preventing
dimerisation (Figure 2.9).
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Figure 2.5. Structure of EDTA. Binding sites include: -O-Na, -COOH, and –NH.
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Figure 2.6. Stability of captopril in distilled water (1 mg.mL-1) stored under 25 oC (40 % humidity) and
40 oC (75 % humidity) conditions. After 30 days storage, captopril retention was reduced to 92.99 +
0.07 % under 25 oC conditions, with greater destabilisation of captopril occurring under 40 oC conditions
(35.19 + 0.75 %). (n=3)
Figure 2.7. Stability of captopril with 0.1 % EDTA (1 mg.mL-1) stored under 5 oC, 25 oC (40 % humidity)
and 40 oC (75 % humidity) conditions. After 12 months storage under 25 oC and 40 oC conditions,
captopril retention remained stable at 100.49 + 1.61 % and 116.30 + 2.15 % respectively. (n=3)
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Figure 2.9. The chelation mechanism of EDTA with captopril. The protonated carboxyl group of EDTA
binds to the ionised thiol group of captopril, thereby preventing captopril dimerisation.
Figure 2.8. pH stability of captopril with 0.1 % EDTA (1 mg.mL-1) stored under 5 oC, 25 oC (40 %
humidity) and 40 oC (75 % humidity) conditions. After 12 months storage, the captopril formulation
remained stable in the pH range 3.2-3.4. Storage conditions had no effect on the pH stability. (n=3)
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To further assess the process of chelation and the binding ratios of captopril and EDTA,
conductometry studies were performed (Figure 2.10). The conductance of a sample is
related to the mobility of the charged particles with mobility of a complex being less than that
of a free compound resulting in lowering of conductance. The experiments were performed
on free captopril and its conductance was compared upon addition of EDTA. The results
show that the addition of increasing concentration of EDTA from 0 to 0.6 M to a solution of
captopril results in a linear decrease of conductance. Increase of EDTA concentration from
0.8 to 2 M further reduces the conductance of the solution but to a lower degree. The
decrease in conductance of free captopril upon addition of increments of EDTA is possibly
due to the formation of weak electrostatic association between the oppositely charged
molecules. The molar binding ratio was determined by calculating the association complex
(K, stability constant of the inclusion complex), the molar conductivity of non-complexed
captopril (ΛD,F)  and the molar conductivity of the complexed drug with EDTA (ΛCD-D). These
calculations enabled the molar conductivity of captopril after each increment of EDTA (Λ) to 
be calculated (Section 2.2.5.1) and graphically plotted (Molar conductivity vs. number of
moles of EDTA) (Cabaleiro-Laga et al, 2006).
Figure 2.10 showed that a 1:0.75 molar ratio between captopril and EDTA existed during
complex formation. Based on the results from the assessment of stability of captopril upon
Point of convergence
Figure 2.10. Conductometry of Captopril with increasing amounts of EDTA. The point of
convergence indicated a molar ratio of 1:0.75 (captopril:EDTA). (n=3)
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inclusion of EDTA, low pH and approximately 1:1 molar association between the two
moieties, the stability offered by EDTA can be explained by the schematic presented in figure
2.9. The schematic can be further confirmed by results presented in section 2.3.4;
investigating the influence of addition of cyclodextrins to further improve the taste and
stability of the formulation.
2.3.3.2. Influence of EDTA and glycerol on the stability of captopril in
solution
Glycerol has a chemical formula of C3H8O3 and is widely used in the pharmaceutical industry
for various applications depending on the type of formulations. In topical formulations, it is
mainly used for its humectant and emollient properties, in creams and emulsions it is utilised
for its solvent and co-solvent properties. In oral solutions glycerol is used primarily for its
solvent, sweetening (0.6 times as sweet as sucrose) and viscosity-increasing and
antimicrobial preservative properties (Rowe et al, 2006). As an alcohol, the preservative
efficacy of glycerol increases with increasing concentration and would also have the added
advantage of improving the taste of the formulation due to its sweetening properties (Scheler
et al, 2010).
EDTA and glycerol were used in the formulation strategy to overcome two barriers for
captopril: the first was stabilisation of captopril in solution, and the second was to preserve
the drug from microbial activity with the added advantage of sweetening characteristics of
glycerol.
The first stage of formulation with glycerol was to establish a concentration – viscosity profile
to determine a suitable concentration that would not affect pourability significantly but at the
same time would provide sufficient preservative efficacy. This was done by carrying out
viscosity measurements of a range of concentrations of glycerol in distilled water. The results
show that by increasing the concentration of glycerol from 10 to 30 % (w/v), the viscosity of
the solution increased gradually (Figure 2.11). However further increase of glycerol
concentration to 40 % (w/v) resulted in a significant increase in the viscosity of the solution to
18.04 + 0.19 mPa.s. Above 50 % (w/v) the viscosity of the medium was too high to obtain
any reading.
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Further investigations were carried out using 30 % (w/v) glycerol. A six month stability profile
of a 1 mg.mL-1 formulation (captopril with 0.1 % (w/v) EDTA and 30 % (w/v) glycerol) stored
under 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity) conditions is presented in
figure 2.12A. The results revealed that captopril was stable for 3 months at 5, 25, and 40 oC,
with recovery values of 103.52 + 0.65, 104.26 + 0.15 and 96.19 + 0.79 % respectively. After
6 months storage, formulations stored under 25 and 40 oC remained stable and above the
95 % acceptance limits, however a significant decrease in captopril retention was observed
at 5 oC (92.42 + 0.74 %). The pH of the formulation remained stable at pH 3.2-3.4 after 6
month’s storage (Figure 2.12B).
The instability of the formulation at 5 oC can be explained by the amount of dissolved oxygen
present in the enclosed container and its ability to initiate the oxygen facilitated first-order
free radical dimerisation reaction of captopril. The law of oxygen dissociation involves the
movement of oxygen content in the air dissolving across the air-water interface and into the
medium. This is temperature dependant, with a reduction in temperature increasing the rate
of oxygen movement across the air-water interface and a rise in temperature increasing
medium resistance to the movement of oxygen across the air-water interface (Ibanez et al,
2007). In order to minimise the oxygen content within the storage containers, nitrogen-head
capping was introduce (data not shown). However, the results indicated no significant
Figure 2.11. Viscosity of glycerol in distilled water with increasing concentrations of glycerol.
Various concentrations of glycerol were transferred into glass capillary and viscosity was measure
at an angle tilt of 30 º at 25 ºC. At glycerol concentrations above 30 % (w/v), the viscosity of the
solution increased dramatically. (n=3)
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Figure 2.12. Six month stability profile of captopril with 30 % (w/v) glycerol (1 mg.mL-1) stored under
5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity) conditions. (A) Captopril was found to be stable
for 6 months at 25 and 40 oC; however formulations stored at 5 oC displayed a decrease in captopril
retention (92.42 + 0.74 %). (B) Formulation was observed to be stable over the 6 month period (pH3.2-
3.4). (n=3)
(A)
(B)
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Figure 2.13. Schematic representation of the reaction mechanism of glycerol with captopril, forming
the degradation product captopril disulphide. The hydroxyl groups of glycerol undergo a nucleophillic
attack on the thiol group of captopril, initiating captopril dimerisation (Sam and Ho, 1998).
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difference in captopril retention when compared to formulations stored in the absence of
nitrogen-head capping.
The instability of captopril upon inclusion of glycerol within the formulation demonstrates that
the presence of EDTA was insufficient as a chelating agent under 5 oC conditions for an
extended period of time. Previous research by Sam and Ho (1998) has shown that the
presence of linear sugar molecules destabilises captopril via a sugar-catalysed initiation of
the degradation mechanism. The degradation mechanism involves a nucleophillic attack of
the hydroxyl groups of glycerol on the thiol group of captopril which results in the formation of
RS- and subsequent dimerisation of captopril to captopril disulphide (Figure 2.13). Glycerol
destabilises captopril in the presence of EDTA, indicating captopril has greater affinity to
sugar molecules than to EDTA (Kristensen et al, 2008).
2.3.3.3. Influence of addition of sodium metabisulphite on captopril
stability in solution
Sodium metabisulphite, has a chemical formula of Na2S2O5 and exhibits dual functionality as
an antimicrobial preservative and an antioxidant and is used at concentrations from 0.01 to
1.0 % (w/v) in oral pharmaceutical dosage forms.
Formulations comprising of 0.1 % (w/v) of sodium metabisulphite and captopril were
prepared in water and assessed for chemical stability of the drug. The choice of sodium
metabulsphite was based on previous literature which showed that the preservative efficacy
of sodium metabisulphite rises with increase in acidity of the formulation (Rowe et al, 2006;
Winfield et al, 2009).
The results showed that the formulations did not exhibit any chemical degradation when
analysed on the day of preparation where nearly 100 % of captopril was recovered (Figure
2.14). However upon storage of the formulations at 25 oC and 40 oC for a period of 30 days,
Figure 2.14. Stability of captopril in 0.1 % (w/v) sodium metabisulphite (1 mg.mL-1) stored under
25 oC (40 % humidity) and 40 oC (75 % humidity) conditions. After 30 days, captopril retention was
reduced to 34.34 + 2.07 and 36.82 + 2.14 % under 25 and 40 oC conditions respectively. (n=3)
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the concentration of captopril was reduced to 34.34 + 2.07 % and 36.82 + 2.14 %
respectively. The formulations had a pungent sulphide like odour with no changes in the
colour or appearance (clear solution). The instability of captopril upon inclusion of sodium
metabisulphite can potentially be attributed to oxygen facilitated first order free radical
reaction. In water sodium meta-bisulphite is converted into its ionic state (Figure 2.15) which
results in the formation of ionised oxygen atoms of sodium meta-bisulphite which possibly
results in accelerating the process of dimerisation of captopril in solution (Figure 2.16).
(Kristensen et al, 2008; Abu-Shandi and Redel, 2009). The oxidative dimerisation of captopril
to a disulphide is a significant pharmaceutical obstacle to overcome.
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Figure 2.16. Schematic for the degradation pathway of captopril in the presence of sodium
metabisulphite. The thiol group of captopril donates its hydrogen atom to the ionised -S-O- groups of
sodium metabisulphite, initiating the dimerisation reaction.
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Figure 2.15. Schematic of sodium metabisulphite converted into its respective ions when placed in
water.
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2.3.4. Approaches to enhance the organoleptic properties of the
formulation
2.3.4.1. Influence of HP-β-CD on captopril in solution
Cyclodextrins are effective drug delivery vehicles which are made up of sugar molecules
bonded together in a ring. They are composed of five or more D-glucopyranoside units linked
by 1-4 glycosidic bonds. The choice of cyclodextrins for inclusion into an oral liquid
formulation is based on their binding constant and stability profile in the presence of a guest
molecule. Extensive research has been carried out characterising and assessing safety
profiles of cyclodextrins (Shabir and Mohammed, 2010). Cyclodextrins are widely used as
taste masking as well as solubility enhancing agents.
Modified β-CD have the greatest potential in oral liquid formulation due to their larger cavity
size, increased solubilising effects and reduced toxicity on the GI membrane. The
formulation strategy for captopril included investigation of inclusion of HP-β-CD to prevent
dimerisation with the eventual aim of reducing pungent like odour and improving the taste.
Preliminary investigations were focussed on determining the molar complexation of captopril
using conductometry. Every ionisable analyte displays an electrical current in solution and it
is the ability of maintaining this current in the presence of increasing concentrations of
excipient which forms the basis of measurements for conductance. The point at which the
slopes converge is an indication of the molar binding ratio in solution. The study involved
measuring the conductivity of 1 M captopril in water with increasing increments of
cyclodextrin. Using the calculations as described in section 2.2.5. (Cabaleiro-Laga et al,
2006), the mean molar conductivity was plotted (Table 2.2. and Figure 2.17). From the
results a 1:1 molar ratio of captopril with HP-β-CD was determined, which was consistent
with H1-NMR analysis of the molecular interaction of their respective proton groups (Figures
2.18-2.20). Study of the physical mixture of captopril and HP-β-CD (Figure 2.20) revealed a
reduced number of protons indicating an interaction of a 1:1 molar ratio.
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HPβCD
Moles
Molar conductivity
Captopril
Molar conductivity
complex
Association constant x
concentration of non-complexed
CD
Molar Conductivity
M ΛC,F ΛCD-C ΚCCD,F
1 +
KCDCD,F
Λ
1 2 3 1 2 3 Mean SD
0.00 41261 0 0 0 0 1 41261 41261 41261 41261 0.00
0.25 41261 3948 3944 3956 0.4475 1.4475 29725 29724 29728 29726 1.89
0.50 41261 1946 1944 1950 0.895 1.895 22693 22692 22695 22693 1.44
0.75 41261 1228 1227 1229 1.3425 2.3425 18318 18317 18319 18318 0.76
1.00 41261 909 911 910 1.79 2.79 15372 15373 15373 15373 0.64
1.25 41261 705 706 704 2.2375 3.2375 13232 13233 13231 13232 0.84
1.50 41261 573 572 575 2.685 3.685 11615 11614 11616 11615 0.97
1.75 41261 479 478 481 3.1325 4.1325 10347 10347 10349 10348 1.09
2.00 41261 408 408 409 3.58 4.58 9328 9327 9329 9328 0.60
2.50 41261 310 310 312 4.475 5.475 7790 7790 7791 7790 0.68
3.00 41261 246 245 247 5.37 6.37 6685 6684 6685 6685 0.74
3.50 41261 202 201 202 6.265 7.265 5853 5853 5854 5853 0.49
4.00 41261 168 168 169 7.16 8.16 5204 5204 5205 5204 0.44
Table 2.2. Conductiometry calculations for captopril with increasing molar concentrations of HP-β-CD.
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Figure 2.17. Investigations of the molar conductivities of captopril on the HP-β-CD molar
concentrations. The point at which the slope changes is indicative of the binding and bulking of the
molecules. Captopril and HP-β-CD achieved a 1:1 molar ratio. (n=3)
Figure 2.18. H1-NMR spectrum of captopril in DMSO-D6, displaying 14 Hydrogen atoms.
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Figure 2.19. H1-NMR spectrum of HP-β-CD in DMSO-D6, displaying 43 Hydrogen atoms.
Figure 2.20. H1-NMR spectrum of captopril and HP-β-CD in DMSO-D6, displaying 31 Hydrogen
atoms
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Figure 2.21 show the stability profile of captopril (1 mg.mL-1) with HP-β-CD (1:1 molar ratio),
in the presence of 0.1 % (w/v) EDTA. After 12 months storage at 5 oC, 25 oC (40 % humidity)
and 40 oC (75 % humidity), the formulation had greater than 95 % captopril recovery. In a
parallel study, a 1 mg.mL-1 captopril-HP-β-CD (1:1 molar ratio) formulation in the absence of
EDTA was prepared and stored at 25 and 40 oC conditions. The formulation was found to
display a high degree of degradation after just 30 days with only 56.33 + 0.96 % and
52.10 + 0.27 % of captopril recovery when stored at 25 and 40 oC respectively (data not
shown). These results can be explained by the non-convalent interaction of the cyclodextrin
with its guest molecule (captopril), which possibly enables the cyclodextrin to continually
associate and dissociate from its guest resulting in a dynamic ‘release-attach-release’
mechanism (Stella et al, 1999). In the absence of EDTA, captopril undergoes dimerisation
when it dissociates from the cyclodextrin. However in the presence of EDTA the thiol group is
protected from dimerisation as the captopril molecule associates and dissociates from the
cyclodextrin, thereby maintaining 100 % captopril retention for a prolonged period.
In order to explain these findings, the interaction of the excipients was further investigated
using analytical techniques such as FTIR and DSC.
2.3.4.2. Interaction of HP-β-CD with captopril and its influencing
properties
FTIR and hyper-DSC (were used to understand the physicochemical interactions between
EDTA, captopril and HP-β-CD.
To investigate the structural arrangement of EDTA-captopril-HP-β-CD complex, a 1 mg.mL-1
formulation was freeze-dried and analysed using FTIR. An infra-red spectrum produces
molecular absorption and transmission of each sample through a unique molecular
ﬁngerprint. These absorption peaks correspond to the vibration frequencies exhibited by 
each of the bonds present in the compound. This process of physicochemical analysis has
been widely used in the chemical industry to; identify unknown materials, determine the
quality and consistency of a sample and the components in the mixture.
Table 2.3 and figures 2.22 highlight the specific band vibrations for captopril, EDTA, HP-β-
CD. The fingerprint of captopril displayed absorption peaks for; the thiol group (-S-H) at
729 cm-1, aromatic amine (-C-N) at 1346 cm-1, aliphatic amine (-C-N) at 1123 cm-1, ester at
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Figure 2.21. 12 months stability profile of captopril (1 mg.mL-1) with 0.1 % EDTA and HP-β-CD stored
under 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity) conditions. (A) captopril was found to
have >95 % stability. (B) Formulation was observed to be stable over the 12 month period (pH 3.2-3.4).
(n=3)
(A)
(B)
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1136 cm-1, and the carboxylic group (-O-H at, 2980 cm-1, -C=O at 1747 cm-1, and –C-O at
1191 cm-1). Interestingly it was found that the fingerprint for mixture comprising of EDTA-
captopril-HP-β-CD did not reveal the absorption bands for carboxylic acid group and
aromatic amine. The remainder of captopril‘s functional groups displayed a shift in
transmittance, which was attributed to the re-arrangement of bond angles to compensate for
partial insertion within the cyclodextrin cavity. The structure of captopril is composed of two
parts: a halide and ester chain, and an aromatic side chain with a carboxylic acid side group
(Figure 2.2). The FTIR results indicate partial insertion of captopril’s aromatic side chain with
the carboxylic acid side group into the cyclodextrins cavity via electrostatic interaction (Figure
2.23).
Peak Transmittance Bond Functional group Donor
1 3274 O-H Alcohol HP-β-CD
2 2935 C-H Alkane HP-β-CD
3 1462 C-C Aromatic Mannitol
4 1351 C-H rock Alkanes Captopril
5 1261 C-N stretch Aliphatic amines EDTA
6 1087 C-O Carboxylic acid HP-β-CD
7 1022 C-N stretch Aliphatic amine Captopril
8 931 =C-H Alkene Mannitol
9 889 C-H Aromatic HP-β-CD
10 715 S-H Halide Captopril
11 624 C-S Alkyl halide Captopril
Table 2.3. Frequency of bond vibrations attributing to the captopril and HP-β-CD complex
formulation.
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DSC can be used to analyse the thermal properties of a substance. An increase in scan rate
Figure 2.22. FTIR fingerprint absorption spectrum of captopril formulation with HP-β-CD and its
excipients. In the captopril spectrum four points have been highlighted which are absent in the
formulation spectrum; (1) O-H carboxylic acid group, (2) C=O carboxylic acid group, (3) C-C aromatic
group, and (4) C-N aromatic amine.
1
2 3 4
OH
O
N
O OH
N
OO
O
O
S
Na
N
OH
O
O
CH3
Figure 2.23. Schematic representation of the molecular arrangement of EDTA and HP-β-CD with
captopril, predicted using FTIR.
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to 200 oC.min-1 allows for increased sensitivity of the thermal reactions/transitions. Thermal
analysis technique can be used to further substantiate the interactions of captopril with
HP-β-CD. The first stage of analysis was to identify the melting peaks for the individual
components and to compare these against the thermal transitions obtained from the
formulated samples. Captopril and EDTA have onset melting peaks of 103 + 0.25 oC and
98.83 + 0.54 oC respectively (Figure 2.24A). Interestingly, when captopril-EDTA complex was
formed, the melting transition shifted to the left (26.90 + 0.74 oC) (Figure 2.24B), resulting in
less energy being required to break the forces of attraction between the constituents and
causing a more disordered arrangement of constituents (Brown, 2001). Figure 2.25 showed
that inclusion of the cyclodextrin significantly strengthened the thermal properties of the
EDTA-captopril-HP-β-CD complex, as the thermal event of EDTA-captopril observed at
26.90 + 0.74 oC was now absent (Figure 2.25B). Similar observations were made with
captopril and various cycldoextrins by Ikeda and co-workers (2000). These finding further
strengthen the structural arrangement of the EDTA-captopril-HP-β-CD complex displayed in
figure 2.23.
Figure 2.24. DSC thermogram of a 5 mg.mL-1 captopril formulation with 0.1 % (w/v) EDTA. (A)
Captopril and EDTA each displaying melting temperatures of 103+0.25 oC and 98.83 + 0.54 oC
respectively, and (B) a 5 mg.mL-1 captopril formulation composed of 0.1 % EDTA with a 26.90 +
0.74 oC melting temperature.
(A)
(B)
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2.3.5. Influence of concentration of captopril and its affect on shelf
life stability
Current captopril formulations on the market are available in dose sizes ranging from 12.5 to
50 mg. In order to minimise the frequency of dosing, the concentration of the EDTA-captopril
and EDTA-captopril-HP-β-CD formulations prepared in this study were increased from
1 mg.mL-1 to 5 mg.mL-1.
The stability of 5 mg.mL-1 EDTA-captopril formulations after 12 months storage at 5 oC, 25 oC
(40 % humidity) and 40 oC (75 % humidity) is presented in figure 2.26. The results revealed
that formulations stored at 40 oC had 100 % captopril retention after 6 months. In addition,
samples stored for 12 months at 5 oC and 25 oC exhibited 94.76 + 9.03 % and
102.81 + 6.48 % captopril recovery respectively. These results were in accordance with work
(A)
(B)
Figure 2.25. TGA and DSC Thermograms of a 5 mg.mL-1 captopril formulation composed of 0.1%
(w/v) EDTA and HP-β-CD. (A) The TGA thermogram of HP-β-CD shows degradation occurring above
300 oC. (B) DSC thermogram of EDTA-captopril-HP-β-CD complex shows no endothermic reaction
occurring.
Chapter 2 – Formulation development of an oral solution of captopril
99
carried out by Florey (1982), who suggested that by increasing the captopril concentration
ultimately resulted in a reduction in its rate of degradation.
In a comparative study, figure 2.27 shows the stability of 5 mg.mL-1 EDTA-captopril-HP-β-CD
formulation after 12 months storage at 5 oC, 25 oC (40 % humidity) and 40 oC (75 %
humidity) conditions. The results showed that the formulation was stable after 6 months
storage at 40 oC (96.78 + 2.49 %) and 25 oC (95.94 + 10.04 %).
Figure 2.26. 12 month stability profile of captopril with 0.1 % (w/v) EDTA (5 mg.mL-1) stored under 5
oC, 25 oC (40 % humidity), and 40 oC (75 % humidity) conditions. The formulation achieved > 95 %
stability after 1 year storage. (n=3)
Figure 2.27. 12 month stability profile of captopril with 0.1 % (w/v) EDTA and HP-β-CD (5 mg.mL-1)
stored under 5 oC, 25 oC (40 % humidity), and 40 oC (75 % humidity) conditions. Within 6 months
storage at 40 oC, the captopril formulation achieved > 95 % retention. After 12 months storage at 5
oC and 25 oC captopril retention was analysed to be 82.99 + 9.22 % and 95.44 + 10.04 %
respectively. (n=3)
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2.4. Conclusion
The stability of captopril in solution was highly dependent upon the presence of EDTA as a
chelating agent thus preventing dimerisation of captopril. Formulations consisting of 0.1 %
(w/v) EDTA and captopril (1 mg.mL-1 and 5 mg.mL-1) were stable for up to 1 year.
However EDTA was unable to prevent captopril dimerisation when in the presence of other
excipients, such as sodium metabisulphite and 30 % (w/v) glycerol. Sodium meta-bisulphite
was able to accelerate captopril degradation due to its ionic state when dissolved in water,
whereas glycerol was able to initiate a sugar-catalysed degradation reaction of captopril.
HP-β-CD proved to be an excellent compatible stabiliser in the presence of EDTA, as well as
being an odour neutraliser. 1 mg.mL-1 and 5 mg.mL-1 dosage forms of the EDTA-captopril-
HP-β-CD complex were stable for 12 months with no change in the organoleptic properties.
Further analysis into the chemical arrangement of the moieties showed EDTA to be bound to
captopril at its thiol group, with the aromatic side chain and a carboxylic acid side group
being bound to the cyclodextrin cavity, forming a rigid structure. This rigidity resulted in steric
hindrance and thus a reduction in the sulphuric-like odour normally associated with captopril.
101
CHAPTER 3
Solubilisation and physiochemical analysis of
gliclazide
102
CHAPTER 3
Solubilisation and physicochemical analysis of gliclazide
3.1. Introduction
3.1.1. Gliclazide structure and mechanism of action
Sulphonylurea derivatives are a class of anti-diabetic drugs used in the management of Type
2 diabetes mellitus which include second generation drugs such as gliclazide and glipizide.
Gliclazide is composed of a sulphonylurea backbone, consisting of a central
S-phenylsulfonylurea structure with two unique side chain groups (Figure 3.1). However, it is
the electronegative oxygen of the sulphonyl group in the structural backbone that dictates the
acidity of the drug molecule resulting in a pKa of 5.8. The electronegative oxygen of the
sulphonyl group and the acidic carbonyl groups have a tendency to withdraw electrons
thereby creating a positive carbon atom. This results in the carbon atom attracting electrons
from the nearby nitrogen groups and thus causing the hydrogen to be held less firmly
(Alkhamis et al, 2003).
The mechanism by which gliclazide acts is by selectively binding to sulfonylurea receptors on
the surface of the β-pancreatic cells causing the potassium ion channels to close, thereby
decreasing the efflux of potassium from the pancreatic cells which leads to the depolarization
CH3
S
NH
OOO
NH
Sulphonylurea backbone Side chainSide chain
Figure 3.1. Chemical structure of gliclazide. The sulphonylurea backbone is highlighted in red, with
the unique side groups of gliclazide highlighted in blue.
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of the cell. This action results in voltage dependent calcium ion channels to open increasing
calcium influx. The calcium can then binds to and activates calmodulin, which in turn leads to
exocystosis of insulin vesicles resulting in increased secretion of insulin (Campbell et al,
1991).
3.1.1. Gliclazide and its therapeutic affects
Gliclazide is a second-generation sulphonylurea oral hypoglycaemic drug with poor water
solubility (55 mg.L-1) (Varshosaz et al, 2008). This acidic drug has the added complication of
low gastric fluid solubility and a lowered dissolution profile causing increasing inter-patient
variability on drug bioavailability (Palmer and Brogden, 1993; Arias-Blanco et al, 1998).
The therapeutic effects of gliclazide include; the stimulation of insulin secretion by the
pancreatic cells in patients diagnosed with non-insulin dependent diabetes mellitus (Davis et
al, 2000; Hiremath et al, 2008), platelet aggregation and increased fibrinolysis (Kumar et al,
2011), low incidence of hypoglycaemia and low rate of secondary failure (Biswal et al, 2009).
These therapeutic effects and good patient tolerability ensures that gliclazide remains one of
the most important drug substances for the treatment of diabetes mellitus.
3.1.2. Current dosage forms
Current formulations in the pharmaceutical market include: Diamicron®, Diamicron modified
release®, and Diaglyk® tablets. These are prescribed to adults in 40 to 80 mg dosage forms,
with a maximum recommended single dose of 180 mg (BNF 2011). In children, ranging from
12 to 18 years, the prescribed dose is 20 mg daily, with a recommended maximum single
dose of 160 mg (BNF for children 2011).
3.1.3. Aim
Previous work on the development of gliclazide formulations was focussed on increasing the
bioavailability of gliclazide in vivo via the delivery of a tablet or soft capsule system (Hong et
al, 1998; Varshosaz et al, 2008), or encapsulation with cyclodextrins (Shewale et al, 2008).
However an oral liquid solution of gliclazide using simple solubilisation techniques has not
yet been carried out.
Therefore the overall aim of the work was to establish a validated calibration protocol for the
extraction and quantification of gliclazide using HPLC and to solubilise gliclazide in an oral
liquid formulation without compromising the lipophilicity of the drug molecule.
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The objectives included:
 Phase solubility studies involving amino acids (L-arginine and L-lysine), pluronic F127
and ethanol as potential solubilising agents for gliclazide
 Preparation and stabilisation of an oral liquid formulation with 8 mg.mL-1 and
16 mg.mL-1 dosages.
 Physicochemical analysis of the chemical interactions involved in the solubilisation of
gliclazide using: DSC, FTIR and H1-NMR.
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3.2. Materials and Method
3.2.1. Materials
Acetronitrile (ACN), propan-2-ol and ethanol were purchased from Firsher Scientific (UK). L-
arginine, L-lysine, pluronic F127, potassium bromide, monosodium glutamate, xylitol, butyl
paraben, propyl paraben, HCl, sodium hydroxide, and sodium acetate were all purchased
from Sigma Aldrich (UK). Gliclazide was purchased from Discovery Fine Chemicals
(Bournemouth, UK). Deuterated water (D2O) was purchased from Goss Scientific Instrument
Ltd (Cheshire, UK).
3.2.2. Calibration Validation
Calibration was carried out using a dionex HPLC and a C18 Gemini column (150 x 4.6 mm).
15 mg of Gliclazide was dissolved in 15 mL of ACN to obtain a stock concentration of
1 mg.mL-1. Serial dilutions were then carried out to obtain further 7 gliclazide concentrations
in ACN (500, 250, 100, 50, 25, 5 and 0.5 μg.mL-1). Using a mobile phase consisting of ACN
and water (45:55), adjusted to pH 3 with phosphoric acid, 50 μL of each gliclazide
concentration was injected in turn into HPLC and analysed at a wavelength of 220 nm and
flow rate of 1 mL.min-1. The retention time for gliclazide was 9 minutes (protocol modified
from Rouini et al, 2003).
3.2.3. Phase solubility
In 10 mL of water set amounts of the solubiliser was added and fully dissolved within solution
before excess amounts of gliclazide was added to this solution. After stirring for 20 minutes,
1 mL was taken and analysed on the HPLC in order to quantify the amount of gliclazide
dissolved. Each analysis was carried out in triplicate.
3.2.3.1. Phase solubility with pH modification
In 10 mL of water, a set amount of solubiliser was added, to which sodium hydroxide or
0.1 M HCl was added to adjust the pH of the system. Excess amounts of gliclazide was then
added and left to stir for 20 minutes, after which 1 mL of sample was extracted and analysed
on the HPLC in order to quantify the amount of solubilised gliclazide. The studies were
carried out in triplicate.
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3.2.4. Oral liquid formulation of gliclazide
All excipients and their relative concentrations used within the formulations are GRAS listed
and within the recommended guidelines.
3.2.4.1. Solubilisation of gliclazide (8 mg.mL-1) with L-arginine (7 mg.mL-1)
In 10 mL of water, 140 mg of L-arginine was dissolved to which 160 mg gliclazide was then
added and magnetically stirred until the drug had fully dissolved. To this 40 mg of sodium
acetate (0.2 % w/v) was added to decrease the bitterness of the solution and to act as a
preservative, with 8 g of xylitol (40 % w/v) being added as a sweetener. Once these
excipients had fully dissolved in solution, the preservatives were added: butyl paraben and
propyl paraben, at 0.05 % and 0.02 % (w/v) respectively. 180 mg monosodium glutamate
(0.9 % w/v) was added as a final excipient to enhance the taste of the formulation. The
formulation was adjusted to 20 mL to produce a final concentration of 8 mg.mL-1 of gliclazide.
The final pH of the formulation was 8.47. The samples were prepared in triplicate and stored
in amber coloured bottles at 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity).
3.2.4.2. Solubilisation of gliclazide (16 mg.mL-1) with 5 % pluronic F127
(w/v) and 15 % ethanol (v/v).
In 10 mL of water, 1 g of pluronic F127 (5 % w/v) was dissolved, after which 3 mL of ethanol
(15 % v/v) was added. Once the solubilisers were mixed in solution, 8 g of xylitol (40 % w/v)
was added as a sweetener and stirred magnetically until fully dissolved. 320 mg of gliclazide
(16 mg.mL-1) was then added and was left to stir until it was fully solubilised in solution.
180 mg of the taste enhancer monosodium glutamate (0.9 % w/v) was added, followed by
propyl paraben and butyl paraben, at 0.02 and 0.05 % (w/v) respectively. The formulation
was adjusted to 20 mL to produce a final dosage of 16 mg.mL-1 of gliclazide, with the pH of
the formulation being adjusted to 9 using 1 M sodium hydroxide. The samples were prepared
in triplicate and stored in amber coloured bottles at 5 oC, 25 oC (40 % humidity) and 40 oC
(75 % humidity).
3.2.5. Freeze-drying protocol
5 mg.mL-1 formulations of gliclazide with L-arginine (Protocol 3.2.4.1) were prepared. The
samples were placed into flat-bottom glass vials and frozen at -60 oC for 2 hours. The
samples were then placed into an advantage 2.0 bench top freeze-dryer (VirTis, Suffolk, UK)
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in order to fully extract the water. The freeze-drying process involved primary drying for 48
hours at a shelf temperature of -40 ºC followed by secondary drying for 10 hours at a shelf
temperature of 20 ºC. Both the drying stages were carried out at a vacuum pressure of
50 mTorr. Samples were then stable enough to be stored at room temperature until further
analysis of the samples was carried out.
3.2.6. Differential Scanning Calorimetry (DSC)
DSC (Perkin-Elmer, Wellesley, USA) was used to study Tg and melting points.
Approximately 3 mg of sample was placed in a Perkin-Elmer aluminium pan, cooled to 10 oC
using an intra-cooler (2P Perkin-Elmer, Wellesley, USA). The samples were heated to 300 oC
at a scan rate of 200 oC.min-1, with a nitrogen purge of 20 mL.min-1. An empty aluminium
pan was used as a reference.
The Tg and Tm were then analysed using the Pyris Manager software. All of the
measurements were carried out in triplicate with fresh samples being prepared for each DSC
run. The DSC was calibrated for temperature and heat flow prior to the samples being tested
using standard samples of indium (Tm 156.6 oC) and zinc.
3.2.7. Thermogravimetric analysis (TGA)
Thermal degradation of glicazide was performed using TGA. The system consisted of a
Pyris 1 Thermogravimetric Analyzer (Perkin Elmer). The sample masses ranged from 2-5 mg
and were heated from 20-300 oC at a rate of 10 oC.min-1 using dry nitrogen. All the studies
were performed in triplicate.
3.2.8. Fourier Transform Infrared Spectroscopy (FTIR)
Characterisation of freeze-dried formulations was carried out with FTIR in order to investigate
the interaction of the excipients and the drug. Freeze-dried samples of the formulations were
prepared according to protocol 3.2.5. FTIR disks were prepared by adding the samples to
potassium bromide at a ratio of 1:5 respectively. The mixed sample was then compacted by
a mechanical press (Specac, Kent, UK) for 10 min at 8 tons to form a translucent pellet which
was analysed using an IR200 spectrometer (Thermo Electron Corporation, UK) to determine
the transmittance of each excipient.
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3.2.9. Proton Nuclear Magnetic Resonance Spectroscopy (H1-NMR)
Approximately 2 mg of the freeze-dried samples and individual ingredients of each
formulation were dissolved in 600 μL D2O at room temperature and placed in glass capillary
vials. The sample vials were placed into the H1-NMR machine and analysed for the presence
of hydrogen atoms using Bruker Advance DPX-250 NMR (at 250.1 MHz) and Bruker Topspin
software.
3.2.10. pH
The pH of each sample was analysed using a Hydrus 500 (Fisherbrand, UK), calibrated at
pH 4, 7 and 10.
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3.3. Results and Discussion
3.3.1. Calibration Validation
A HPLC method was developed and validated for the determination of gliclazide. At a
wavelength of 220 nm, ACN was used to solubilise gliclazide and analysed. Results are
presented in table 3.1.
3.3.1.1 Linearity
The linearity of the HPLC method was evaluated by preparing the standard curve for
gliclazide on three consecutive days. The peak area was plotted against the gliclazide
concentration and the calibration response was assessed for variances. The results show
that the Beer Lambert’s law was obeyed in the range of 0.5-1000 μg.mL-1 with the linear plot
giving the regression equation of y=0.9479x (R2=0.9996) (Figure 3.2).
3.3.1.2 Precision
In order to assess the reproducibility of the calibration protocol, the calibration method was
carried out in triplicate over a period of three days for interday precision, and in triplicate on
Criteria Validation
Y= 0.9479x
R2 0.9996
Intra-day Precision 101.36 %
Inter-day Precision 102.55 %
Accuracy (+SD) 10 μg.mL-1 92.62 (11.61) %
Accuracy (+SD) 100 μg.mL-1 103.25 (8.77) %
Accuracy (+SD) 400 μg.mL-1 104.02 (3.92) %
LOD μg.mL-1 13.02
LOQ μg.mL-1 39.46
Table 3.1. Summary of calibration validation of gliclazide
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the same day for intraday precision. The results showed that the calibration method was
reproducible with inter-day precision being calculated to be 102.55 %, and the intra-day
precision being calculated to be 101.36 %. Statistical data was compared using the ANOVA
statistical test, with the resulting inter-day and intra-day precision calculated to have a
variance of P>0.05.
3.3.1.3. Accuracy
The accuracy of the developed method was determined from three concentrations of
gliclazide in ACN representing the low, medium and high portions of the standard curve (10,
100 and 400 μg.mL-1). Accuracy of the three concentrations was in the range of 92.62-
104.02 %.
3.3.1.4 Limit of detection (LOD) and limit of quantification (LOQ)
The LOD of an individual analytical procedure is the lowest amount of analyte in a sample
which can be detected but not necessarily quantifiable as an exact value (EMEA, 1995).
From the calibration range the LOD was calculated to be 13.02 μg.mL-1.
The LOQ of an individual analytical procedure was the lowest amount of analyte in a sample
which can be quantitatively determined with accuracy and precision. The LOQ was
calculated to be 39.46 μg.mL-1.
Figure 3.2. Calibration graph of gliclazide highlighting the linearity of the validation protocol.
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3.3.2. Phase solubility
In order for the oral liquid formulation of gliclazide to be competitive with the solid dosage
forms, a minimum concentration of 8 mg.mL-1 solution/suspension had to be formulated.
However, hydrophobicity of gliclazide (0.025 + 0.001 mg.mL-1) is a major obstacle to be
overcome in the formulation stage. The hydrophobicity of gliclazide has been attributed to the
non-polar components in its structure, thereby preventing the molecule breaking into the
lattice structure of water and being solubilised (Seedher and Bhatia, 2003).
Previously, extensive research had been carried out using cyclodextrins as complexing
agents (Moyan et al, 1997; Ozkan et al, 2000) to overcome poor solubility, but did not result
in high levels of solubilisations as needed for the development of a liquid dosage form which
would be comparable to a solid dosage form in delivering a therapeutic dose. On the other
hand, limited research has been carried out investigating the use of alternative solubilisers
such as; amino acids (L-arginine and L-lysine), surfactants (pluronic F127), and ethanol.
Therefore the first phase of the developmental work was concentrated on exploring the use
of alternative solubilisers.
3.3.2.1. Solubilisation of gliclazide with amino acids.
The addition of gliclazide in water causes an acidifying affect, with the pH being reduced to
4.90 + 0.01 in a 0.02 + 0.001 mg.mL-1 gliclazide solution. Therefore basic amino acids were
chosen as solubilising agents as suggested by previous research investigating salt formation
(Tung et al, 1991). Amino acids are critical components that serve as the building blocks of
life and make up the foundation of proteins. They not only have the added advantage of
patient compliance at high concentrations, but also have no adverse affects in the presence
of gliclazide or diabetes. Table 4.1 highlights the various amino acids available, with
L-arginine and L-lysine being the most basic. Therefore L-arginine and L-lysine were studied
for their solubilising efficacy in the presence of excess gliclazide.
3.3.2.1.1. L-arginine
Figure 3.3 displays the solubilisation of excess gliclazide with increasing concentrations of
L-arginine (10-200 mg.mL-1). The results show that as the concentration of L-arginine
increased from 10 to 25 mg.mL-1, the concentration of gliclazide also increased linearly until
maximum gliclazide solubility was achieved at 15.25 + 0.09 mg.mL-1 in the presence of
25 mg.mL-1 L-arginine. The concentration of L-arginine was observed to have a direct affect
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on the pH of the resultant solution, which was found to also increase in parallel with
increasing L-arginine concentration (up to pH 8.47 + 0.05 with 25 mg.mL-1 L-arginine).
Interestingly, further increase of L-arginine (50-100 mg.mL-1) showed that there was no
increase in the solubility of gliclazide and the pH of the resultant solution was constant.
The solubilising properties of L-arginine can be attributed to the interaction of gliclazide with
L-arginine through complex formation between the electronegative nitrogen groups of the
amino acid and the acidic hydrogen of gliclazide (Grove et al, 2003). The stability of the
complex was highly dependent on the pKa of the guanidinuim group of L-arginine (pKa
12.48), which ensured a stable complex was formed. However, the decline in gliclazide
concentrations at 200 mg.mL-1 L-arginine was possibly due to the hydrophobicity of the drug
at specific pH environments. In order for a complex to be stable, pKa difference of the amino
acid and the drug needs to be greater than 3 (Stahl and Wermuth, 2002). Gliclazide has a
pKa of 5.8, attributed to the α-hydroxyl secondary amine group in its chemical structure
(Figure 3.1) (Alkhamis et al, 2003; Shewale et al, 2008), thus at pH 9 the drug existed mainly
in the unionised form (hydrophobic), thereby rendering the complex unstable.
3.3.2.1.2. L-lysine
Figure 3.4 shows the solubility of gliclazide with increasing L-lysine concentrations (10-
300 mg.mL-1). It was observed that with the inclusion of 10 mg.mL-1 of L-lysine, gliclazide
solubility increased to 5.31 + 1.88 mg.mL-1, with gliclazide concentration increasing further as
the concentration of L-lysine increased to 15 and 20 mg.mL-1 (7.47 + 0.03 and
8.82 + 0.03 mg.mL-1 respectively). Interestingly, the concentration of the drug in solution
increased dramatically with 25 mg.mL-1 of L-lysine (26.80 + 0.22 mg.mL-1) followed by a
plateau affect as the amino acid concentration was increased to 200 mg.mL-1. A further slight
increase in gliclazide solubility was observed (29.74 + 0.32 mg.mL-1) as the concentration of
L-lysine was raised to 300 mg.mL-1.
In order to observe the affect of pH against gliclazide solubility the pH of the solution was
monitored with each additional increment of amino acid. It was found that in the presence of
10 mg.mL-1 of L-lysine the pH of the medium was slightly alkaline (pH 8.32 + 0.01), which
increased in alkalinicity as the concentration of L-lysine increased to 300 mg.mL-1, exhibiting
a final pH profile of 9.37 + 0.01 (Figure 3.4). Thus as with the L-arginine phase solubility
study gliclazide concentration increased with increasing pH until solubility plateau was
observed at ~ pH 8.6.
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Figure 3.3. Phase solubility of gliclazide in L-arginine. At 25 mg.mL-1 of the basic amino acid, a
maximum of 15.25 + 0.09 mg.mL-1 gliclazide was solubilised in distilled water. The pH of the
systems remained above pH 8. As the pH increased to pH 9, the amount of gliclazide solubilised
decreased to 8.20 + 0.20 mg.mL-1. (n=3)
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Figure 3.4. Phase solubility of gliclazide with increasing concentrations of L-lysine (10-300 mg.mL-1).
At 25 mg.mL-1 of L-lysine a maximum of 26.80 + 0.22 mg.mL-1 gliclazide was solubilised in water. The
pH of the systems remained in the range of pH 8-9. However gliclazide remained unstable over time,
as the drug precipitated out. (n=3)
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Interestingly, in contrast to the L-arginine phase solubility study, L-lysine-gliclazide solution
began salting out (was seen to precipitate out) after 24 hours. This salting out process was
attributed to the pH of the medium being raised above the pH maximum of L-lysine in
solution and thereby resulting in the salt to be converted to its free base with gliclazide
returning to its solid state (Serajuddin, 2007). In order for the amino acid to act as a stable
salt the pKa difference of the amino acid and the drug had to be greater than 3 (Stahl and
Wermuth, 2002), thus the salting-out effect was attributed to the instabilities of L-lysine in the
salt form. Table 3.2 compares the pKa of gliclazide against L-arginine and L-lysine, from
which it can be concluded that the end groups in the amino acid chemical structures (pKa 3)
displayed very different ionisable strengths. L-lysine had 3 pKa values of 2.20, 8.90 and
10.28 (Figure 3.5a) with L-arginine having 3 pKa values of 2.01, 9.04, and 12.48
(Figure 3.5b). It was found that the amine group of L-lysine was shown to display lower
strength and stability than the guanidinium group of L-arginine and thus gliclazide formed a
weaker salt complex with L-lysine which quickly precipitated.
pKa1 pKa2 pKa3
L-Lysine 2.20 8.90 9.28
Difference with
Gliclazide pKa 5.8 3.60 3.10 4.40
L-arginine 2.01 9.04 12.48
Difference with
Gliclazide pKa 5.8 3.79 3.24 6.68
Table 3.2. The calculated difference of gliclazide with L-lysine and L-arginine. Greater the difference in
pKa, greater the stability of the complex.
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Figure 3.5. (A) Structure of L-lysine; containing an amine end group with a pKa3 9.28, and (B)
structure of L-arginine, containing a guanidinium end group with a pKa3 12.48.
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3.3.2.2. Solubilisation of gliclazide with Pluronic F127
Surfactants have been extensively used within the pharmaceutical field in the stabilisation of
various vehicles used in the solubilisation of hydrophobic drugs (Rachmawati et al, 2008) or
as solubilisers (Alkhamis et al, 2003). Surfactants are amphiphilic surface acting compounds
that lower surface tension of a liquid. A surfactant can effectively act when it reaches its
critical micelle concentration (CMC), which has been defined as the minimum concentration
required of the surfactant to form a micelle in a given system. In this study the effect of CMC
on the solubility of gliclazide was analysed with pluronic F127.
3.3.2.2.1. Influence of Pluronic F127 concentration
Figure 3.6 shows the affect of increasing the concentration of pluronic F127 (1-5 % w/v) in
water on the solubilisation of gliclazide. It was observed that the concentration of solubilised
gliclazide increased with increasing surfactant concentration, resulting in
0.073 + 0.000 mg.mL-1 of gliclazide with 4 % (w/v) F127. Interestingly, by increasing the
Figure 3.6. Phase solubility profile of gliclazide with increasing concentrations of surfactant F127,
and its respective pH profile. CMC was achieved with 5 % (w/v) pluronic F127 increasing the
gliclazide concentration to 0.256 + 0.001 mg.mL-1. (n=3)
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pluronic F127 concentration to 5 % (w/v), the amount of gliclazide solubilised in solution
dramatically increased, achieving a concentration of 0.256 + 0.001 mg.mL-1. This significant
rise in gliclazide concentration marked the CMC point, thereby giving a CMC value of
50 g.L-1.
The pH of the medium was closely monitored after each increment of surfactant. It was
concluded that pluronic F127 exerted minimum affects on the pH of the solution, as the pH of
the solution was seen to increase from pH 4.90 + 0.01 in the absence of surfactant, to pH
6.41 + 0.02 at the CMC (5 % w/v F127). However from the previous phase solubility study, it
was understood that the concentration of solubilised drug increased when the pH of the
medium was in the range of 6-8, hence the next stage was to analyse the influence of pH on
the surfactant and its ability to solubilise gliclazide in water.
3.3.2.2.2. Influence of pH and pluronic F127 (5 % w/v)
Figure 3.7 displays the pH modification of a 5 % (w/v) F127 solution (pH 1.5, 4.0, 7.0, and
9.1) and its influence on the solubility of gliclazide. It was observed that under acidic
conditions of pH 1.5 and 4.0, gliclazide concentration in solution increased to 0.237 + 0.001
and 0.312 + 0.001 mg.mL-1 respectively. By adjusting the pH of the system to pH 7.0, the
concentration of gliclazide was observed to increase further until a maximum of
0.531 + 0.001 mg.mL-1 was achieved. However, under more alkaline conditions (pH 9.1) the
amount of gliclazide solubilised was significantly reduced to 0.513 + 0.01 mg.mL-1 (P<0.05).
Therefore it can be concluded that the influence of pH had the following affect: acidic to
neutral conditions increased drug solubility, whereas alkaline conditions resulted in reducing
drug solubility. This pattern indicates that the degree of drug ionisation has a decisive
influence on the solubility of gliclazide at varying pH. The increase in gliclazide concentration
was attributed to the protonation of the drug molecule resulting in a slightly more hydrophilic
form, with the decline in gliclazide solubility being attributed to the pH exceeding the pKa of
gliclazide, and thereby causing the drug molecule to become de-protonated (hydrophobic)
(Shewale et al, 2008).
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3.3.2.2.3. Summary
Poloxamers (pluronic F127) are GRAS listed and FDA approved for consumption; however
they cannot be metabolised by the body, and result in gel formation and reduced fluidity with
increasing concentration (Rowe et al, 2006). Therefore a maximum of 5 % (w/v) pluronic
F127 was used in the phase solubility study. It was observed that the CMC was reached with
5 % (w/v) surfactant, however the extent of drug solubilised after pH modification was
considerably less in comparison with solubility studies carried out with L-arginine
(0.531 + 0.001 and 15.25 + 0.09 mg.mL-1 respectively). This was attributed to L-arginine
solubilising the drug through salt formation under slightly alkaline conditions (pH 8), whereas
the solubilisation of gliclazide with pluronic F127 was highly dependent upon the degree of
CMC. Thus at 5 % (w/v) pluronic F127, the concentration of micelles formed was too low for
the minimum amount of gliclazide to be solubilised (8 mg.mL-1).
Therefore in order to achieve an 8 mg.mL-1 oral liquid dosage form, the next phase of work
involved the reduction in the medium’s dielectric constant using a co-solvent system in the
presence of pluronic F127 (5 % w/v) .
Figure 3.7. Phase solubility profile of gliclazide in 5 % F127 (CMC) at varying pH. Under acidic
conditions, a maximum 0.312 + 0.001 mg.mL-1 gliclazide was solubilised. At pH 7 the concentration of
gliclazide increased to 0.531 + 0.001 mg.mL-1, which was then seen to significantly decline as the pH
was further increased to pH 9.1 (0.513 + 0.01 mg.mL-1) (P<0.01). (n=3)
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3.3.2.4. Solubilisation of gliclazide in a co-solvent system
A co-solvent, such as alcohol, is a water miscible organic solvent with two specific properties
with regards to drug solubilisation: (1) the ability to reduce the dielectric constant of the
medium (Chapter 5), resulting in a polar medium being altered into a non-polar medium, and
thus allowing for greater solubility of poorly water-soluble substances; and (2) the ability to
increase the chemical stability of the compound within this system.
Figure 3.8 demonstrates the effectiveness of using an ethanol based co-solvent system for
the solubilisation of gliclazide in water. The concentration of ethanol was increased from 10–
100 % (v/v), with the pH of the medium being closely monitored. It was observed that as the
concentration of ethanol increased from 0 to 20 % (v/v), the amount of gliclazide solubilised
remained consistent (0.046 + 0.0001 mg.mL-1). However as the concentration of ethanol was
further increased to 40 % (v/v) a significant rise in drug concentration was observed
(0.11 + 0.001 mg.mL-1, P<0.05). Interestingly, as the concentration of ethanol was doubled
(80 % v/v) the amount of drug solubilised dramatically increased to 4.18 + 0.011 mg.mL-1,
with 100 % (v/v) ethanol achieving a 5.72 + 0.069 mg.mL-1 gliclazide concentration.
The pH of the co-solvent system was not influenced by the concentration of ethanol or
gliclazide, as the ethanol-gliclazide solution remained fairly constant at pH 5.45 + 0.02 and
pH 5.94 + 0.01 (10 % and 100 % ethanol respectively, P<0.05).
The solubilising capabilities of an ethanol-water system (> 40 % v/v) was attributed to the
octanol-water partition co-efficient (Log P) of the co-solvent and the polarity of the medium.
The Log P of the co-solvent which is also referred to as the hydrophobicity of the solvent,
increases with increase in the concentration of ethanol which ultimately enhances the
solubility of gliclazide (Seedher and Bhatia, 2003). Polarity of a medium can dictate the
solubility of a compound in a given medium as solvents with reduced polarity have greater
affinity for poorly soluble drugs (non-polar molecules). In a study carried out by Seedher and
Bhatia (2003), the extent of solvent polarity was calculated as the dielectric constant. Water
and ethanol have dielectric constants of 78.36 ε and 24.3 ε respectively, thus confirming that
the polarity of water was greater than ethanol. Therefore, the dramatic increase in gliclazide
concentration with 80 % (v/v) ethanol was attributed to a significant reduction in the polarity
of the co-solvent system, enabling the solubilisation and formation of hydrogen bonds
between the co-solvent and the hetero-atoms of gliclazide (nitrogen, oxygen and sulphur
atoms).
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Figure 3.8. Phase solubility of gliclazide with increasing concentrations of ethanol as a co-solvent
(10-100 % v/v). At 15 % (v/v) ethanol 0.046 + 0.001 mg.mL-1 gliclazide was solubilised in water,
with increasing ethanol concentrations of 80 and 100 % achieving 4.18 + 0.011 and
5.72 + 0.69 mg.mL-1 gliclazide respectively. The pH of the co-solvent system remained consistent
at pH 5. (n=3)
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3.3.2.4.1. Influence of pH and ethanol (15 % v/v)
Gliclazide has been shown to have increased solubility properties when the pH of the
medium was in the range of 6-8 (Section 3.3.2.2.2.). However in the co-solvent system the
pH did not exceed pH 5.94 + 0.01, therefore the influence of pH on gliclazide solubility in a
15 % (v/v) ethanol-water system was assessed. The maximum concentration of ethanol that
is used in liquid preparations is between 15-20 %. Therefore a low concentration of ethanol
(15 % v/v) was chosen for its antimicrobial preservative actions (> 10 % v/v) as well as to
minimise the extent of a ‘burning taste’ associated with ethanol (Rowe et al, 2006).
Figure 3.9 shows that as the pH of the co-solvent became progressively alkaline the
concentration of gliclazide rapidly increased from 0.494 + 0.005 mg.mL-1 at pH 7 to
19.22 + 0.057 mg.mL-1 (pH 8). Under extreme alkaline conditions (pH 11) a maximum drug
concentration of 22.924 + 0.071 mg.mL-1 was achieved. As expected, under acidic conditions
gliclazide remained relatively insoluble (0.04 + 0.001 mg.mL-1 at pH 4). These results were
attributed to extent of ionisation (Section 3.3.2.2.2.) and the reduction of the dielectric
constant, thus allowing greater amounts of gliclazide to be solubilised and stable under
alkaline conditions.
Figure 3.9. Influence of pH on the phase solubility of gliclazide in 15 % ethanol-water (v/v). Under
acidic conditions, gliclazide remained relatively insoluble, however as the pH of the co-solvent
system increased from pH 7 to pH 8, the concentration of gliclazide increased dramatically from
0.494 + 0.005 to 19.22+0.057 mg.mL-1 respectively. (n=3)
Chapter 3 – Solubilisations and physicochemical analysis of gliclazide
122
3.3.2.5. Solubilisation of gliclazide with 5 % (w/v) F127 and 15 % (v/v)
ethanol-water
In order to effectively solubilise a hydrophobic drug, the phase solubility tests described
above concluded the role of various parameters including pH, hydrophobic environment
(CMC) and reduced polarity of the solution. Therefore a solubility study was conducted in
which all 3 factors were analysed in parallel using a solution composed of pluronic F127
(5 % w/v) and ethanol (15 % v/v). Figure 3.10 shows the influence of pH on the solubility of
gliclazide in a co-solvent-surfactant solution. As expected, under acidic conditions gliclazide
remained fairly insoluble, with neutral (pH 7) and slightly alkaline (pH 8.84) conditions
increasing the solubility of the drug considerably (1.615 + 0.007 and 28.15 + 0.1 mg.mL-1
respectively).
3.3.2.6. Phase solubility summary
The solubility of a hydrophobic drug such as gliclazide has been shown to be governed by
the following factors: pH, polarity of medium, salt formation, and CMC. Gliclazide is a weak
acid with a pKa of 5.8 (Alkhamis et al, 2003) and was only partially ionised. By adjusting the
pH of the medium to more alkaline conditions, the drug molecule is ionised to a greater
Figure 3.10. Influence of pH of the phase solubility diagram of gliclazide in 5% (w/v) F127 and 15 %
ethanol-water (v/v). Under acidic conditions, gliclazide remained relatively insoluble, however as the
pH of the co-solvent system increased from pH 7 to pH 8.84, the concentration of gliclazide
increased dramatically from 1.615 + 0.07 to 28.15 + 0.1 mg.mL-1 respectively. (n=3)
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extent. Adjusting the composition of the medium, the polarity of the system reduced,
resulting in conditions more suited to non-polar drugs.
3.3.3. Formulation and stability of an oral liquid solution of
gliclazide
From the phase solubility studies it was concluded that using L-arginine and co-solvent-
surfactant mixture as solubilisers were effective for formulating gliclazide at a dosing
concentration of 8 mg.mL-1 and 16 mg.mL-1. Formulations of gliclazide in solution were
prepared as described in section 3.2.4. The samples were stored at different stability
conditions as outlined in the ICH guidelines (5 oC, 25 oC (40 % humidity) and 40 oC (75 %
humidity)) and assessed for changes in organoleptic properties and chemical stability of the
active ingredient.
3.3.3.1. Gliclazide (8 mg.mL-1) oral liquid formulation in the presence of 7
mg.mL-1 L-arginine
Figure 3.11 highlights the stability profile of an 8 mg.mL-1 gliclazide oral liquid formulation,
prepared with 7 mg.mL-1 L-arginine at pH 8. Analysis of gliclazide showed that the chemical
stability profile of the active ingredient did not change during the entire duration of the study
with drug retention remaining above the 95 % threshold. In addition, the pH of the
formulations remained stable at pH 8 after being stored at different conditions over the 9
month period. Furthermore, the organoleptic properties of the formulation remained stable
with no discolouration or odorous smell.
3.3.3.2. Gliclazide (16 mg.mL-1) oral liquid formulation in the presence of
15 % (v/v) ethanol and 5 % (w/v) Pluronic F127
Figure 3.12 displays the stability profile of a 16 mg.mL-1 gliclazide oral liquid formulation
prepared with 5 % (w/v) pluronic F127 and 15 % (v/v) ethanol, adjusted to pH 9. The pH of
the formulations remained stable at pH 9 indicating the chemical stability of gliclazide
remained stable for the duration of the study. Furthermore, analysis of gliclazide showed that
the chemical stability profile of the active ingredient did not change during the entire duration
of the study, with drug retention remaining above the 95 % threshold under 5, 25 and 40 oC
conditions (97.45 + 1.48, 99.98 + 0.75 and 101.61 + 1.37 % respectively). The organoleptic
properties were found to remain stable with no discolouration or unpleasant smell.
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Figure 3.11. Nine month stability profile of 8 mg.mL-1 gliclazide with 7 mg.mL-1 L-arginine stored
under 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity) conditions. The formulation was
observed to have >95 % drug retention over the 9 month period. (n=3)
Figure 3.12. Nine month stability profile of 16 mg.mL-1 gliclazide with 5 % (w/v) pluronic F127 and
15 % (v/v) ethanol, stored under 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity)
conditions. The formulation was observed to have >95 % drug retention over the 9 month period.
(n=3)
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3.3.4. Physicochemical analysis of gliclazide with L-arginine
In order to understand the solubilisation properties of L-arginine, a physiochemical analysis
was carried out investigating the interactions between the active ingredient (gliclazide) and
the amino acid. This involved understanding a number of interactions occurring within the
system such as: thermodynamic interactions, which were assessed by using DSC; bond
vibrations indicating formation of complexes which were assessed by using FTIR; and the
presence/absence of hydrogen bond formation in the complexes (using H1-NMR).
3.3.4.1. DSC
DSC analysis was carried out on freeze-dried samples of formulated gliclazide-L-arginine
complex using hyper DSC. The advantage of using hyper DSC over conventional DSC was
that it allowed for the suppression of kinetic events as well as increasing the strength of the
signal allowing sensitivity towards low energy transitions. The DSC thermograms of
individual excipients and freeze-dried gliclazide-L-arginine formulation are presented in
figure 3.13. It was observed that at the beginning of each thermogram, an endothermic event
occurred at ~25 oC. These thermal events were a result of mismatching in thermal properties
between the sample and reference pan, thereby causing an unstable baseline. However
once the sample pan and reference pan were rebalanced at the same temperature, the
baseline was resumed (Brown, 2001). In order to ascertain a chemical interaction between
gliclazide and L-arginine when in the solubilised form, the individual excipient of the
formulation first had to be analysed to determine their melting points and any other distinctive
thermal events. It was noted that xylitol displayed an onset melting point of 101.75 oC, and
L-arginine had an onset melting peak at 108.41 oC, followed by a second melt at 145.65 oC,
which was immediately followed by oxidation and degradation (Brown, 2001). Gliclazide
displayed a single endothermic melt at 184.68 oC, which was followed by immediate
degradation that was further confirmed using TGA. However, the presence of xylitol in the
freeze-dried formulation potentially masked the thermal profiling of the various excipients
including gliclazide and L-arginine, hindering further thermal analysis.
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To address this, a second study was carried out looking specifically at the interaction of
gliclazide and L-arginine when in solution. A highly concentrated amount of gliclazide was
dissolved in L-arginine solution before being analysed using DSC. It was observed that
L-arginine in solution had an onset melt at 72.86 oC (Figure 3.14), and when compared
against the solubilisation of gliclazide, a Tg effect was observed occurring at 42.89 oC,
followed by a melting peak at 76.25 oC. The Tg shows an abrupt change in positioning of the
baseline, which was a direct result of the change in heat capacity of the sample as it
changed from a glassy to a rubber-like state. The significant difference between the melts of
L-arginine in solution and that of solubilised gliclazide (Table 3.3) (P<0.05), was a clear
indication of intermolecular interactions between L-arginine and gliclazide.
Figure 3.13. DSC overlay of xylitol, L-arginine, gliclazide, and gliclazide formulation with
L-arginine after being freeze-dried, at a scan rate of 100 oC.min-1.
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Table 3.3. Summary of the thermokinetic changes occurring when solubilising gliclazide with
L-arginine.
Sample loading
Excipient Scan rate /oC.min-1 mg μL
Onset of
Tm / oC
Enthalpy of
transition /
J.g-1
Powder form:
Xylitol 200 4 101.75 390.59
L-arginine 200 4 108.41 61.87
Gliclazide 200 4 184.68 137.25
In solution:
560mg L-arginine 100 40 71.80 0.4815
560mg L-arginine with
640mg gliclazide 100 40 76.25 0.6965
Figure 3.14. DSC of 40 μL L-arginine solution with dissolved gliclazide in comparison with 40 μL
L-arginine solution, at a scan rate of 100 oC.min-1.
560mg L-arginine with 640 mg Gliclazide
560 mg L-arginine
Chapter 3 – Solubilisations and physicochemical analysis of gliclazide
128
3.3.4.2. FTIR analysis
FTIR was therefore carried out in order to determine the interactions between gliclazide and
L-lysine. FTIR analysis involves the interpretation of specific bond vibrations occurring at
various wavelengths, with each compound displaying a specific fingerprint unique to its
structure and its functional group.
In order to effectively study bond vibrations, the excipients were first analysed to establish
their true bonding vibrations relevant to their structural composition. The following was
determined from their respective structures (Figure 3.15) and FTIR scans (Figure 3.16):
L-arginine was composed of the carboxylic acids group, which have set vibrations at 3079,
2312, 1332 and 3079 cm-1 for C=O, C-O and O-H functional groups respectively, as well as
an amine group (C-N) (1008 cm-1), and an imine group (C=N) (1685 cm-1); gliclazide was
composed of a double bonded aromatic (1896 cm-1) and a single bonded cyclic chain
(919 cm-1), a sulphonamide group (S=O) (1348 and 1164 cm-1), a ketone group (1710 cm-1),
and an amine functional group consisting of single bonded C-N (1087 cm-1) and a single
bonded N-H (3273 cm-1) groups; monosodium glutamate was composed of the carboxylic
acid group, which were observed to have set vibrations at 3409, 1307, 1687 cm-1 for O-H,
C-O, and C=O groups respectively, as well as an amine group (C-N) with a set bond
vibration at 1094 and 1120 cm-1; Sodium acetate was composed of a simple ethyl chain
containing ester bond vibrations at 1641 cm-1 (C-O) and 1412 cm-1 (C=O), with a methyl end
chain producing a specific bond vibration at 1020 cm-1; xylitol consisted of a five-carbon
alkane chain (2914 cm-1) with alcohol end groups (3369 cm-1 (O-H) and 1064 cm-1 (C-O);
and finally the parabens were observed to have vibrational bonds for a double bonded C=C
aromatic (1606 cm-1) with an alcohol side chain (3270 cm-1) on one side of the aromatic, and
a carbonyl (C=O) (1679 cm-1) and an ester group (C-O) (1167 cm-1) followed by a propyl or
butyl chain on the opposite end of the aromatic.
These specific bond vibrations were highlighted and extracted from the FTIR scans of the
formulation, each bond vibration being designated as a donor group (excipient), with any
alteration in bond vibration indicating possible intermolecular bonding between excipients.
The aim was to highlight the cause of the solubility of gliclazide by labelling the bond
vibrations of the formulated gliclazide-L-arginine complex and their respective donors. Once
these vibrations were compiled (Table 3.4) absence of the single bonded N-H (3273 cm-1)
functional group was studied with the major groups of the other excipients being present and
accounted for. This was indicative of hydrogen bonding between the amine group of
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Figure 3.15. Respective chemical structures of the excipients used in the formulation of an oral
liquid dosage form for gliclazide.
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Figure 3.16. FTIR scans of the respective excipients used in the formulation of an oral liquid
dosage form for gliclazide, with a comparative FTIR scan of the formulation.
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gliclazide and L-arginine. In order to fully understand the extent of the interaction H1-NMR
was carried out.
3.3.4.3. H1-NMR
Proton nuclear magnetic resonance (H1-NMR) spectroscopy can be defined as the
absorptions and emission of electromagnetic radiation by the nuclei of hydrogen atoms when
they are placed in a magnetic field (Field and Sternhell, 1989). The H1-NMR spectrum can
normally be represented as a graph of absorption intensity against the frequency of the
radiation absorbed by the nuclei in the sample, with the intensity of the signal being
proportional to the concentration of nuclei. This allows H1-NMR to be a quantitative method
of analysis, as the relative concentrations of components in the mixtures can be determined.
In the present study, L-arginine owed its hydrophilic properties to its highly polar molecular
structure. D2O was the solvent in which H1-NMR could be performed was, as L-arginine was
Table 3.4. FTIR analysis of gliclazide in solution once formulated as an oral liquid dosage form,
and its bond vibrations and their respective donors.
Peak Wavenumber
(cm-1)
Bond Functional group Donator
1 3327. O-H Alcohol Xylitol
2 1419.50 C=O Bend Sodium acetate
3 2914.62 C=O Carboxylic acid L-arginine
4 1373.34 C-O Carboxylic acid L-arginine
5 1312.52 C-O Carboxylic acid Monosodium Glutamate
6 1280.08 C-O Alkane Parabens
7 1351.77 S=O Sulfonamide Gliclzide
8 1091.12 C-N Amine Monosodium Glutamate
9 1063.97 C-O Alcohol Xylitol
10 1007.32 C-N Imine L-arginine
11 913.28 C-H Aromatic Gliclazide
12 857.13 C-H Stretch alcohol Parabens
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soluble. Gliclazide was practically insoluble in D2O, however when used in combination with
L-arginine its solubility with the solvent increased, making D2O a good candidate for H1-NMR
analysis. The choice of solvent also had an impact on the quality of H1-NMR analysis, as
each solvent gives rise to a different reference point and highlights and masks different
functional groups. D2O (heavy water) was known to be highly enriched in hydrogen isotope
deuterium, however, the use of heavy water results in protons in the –OH groups being
replaced with deuterium atoms. Deuterium has an even number of protons and neutrons in
its nucleus, and thus does not show up in a proton NMR graph.
L-arginine has 16 protons in its structure, one of which is designated to an –OH group in its
structure (Figure 3.17), this proton was therefore expected to be absent from the analytical
H1-NMR graphs, with ultimately only 15 protons emitting a signal. Gliclazide has no –OH
groups and thus is expected to emit its full 22 protons.
From the H1-NMR graphs, L-arginine was shown to display its 15 protons as expected
(Figure 3.17), with the 1:1 molar ratio of L-arginine with gliclazide emitting the presence of
only 35 protons (Figure 3.18). This reduction in protons is a quantitative conclusion of
intermolecular bonding occurring between the compounds at a 1:1 ratio, thereby aiding in the
increased polarity of the gliclazide molecular structure, and thereby enhancing its solubilising
properties.
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Figure 3.18. H1-NMR absorption graph for a 1:1 molar ratio mix of L-arginine with gliclazide using
D2O (reference at 4.77 ppm); 35 protons were detected. (n=3)
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Figure 3.17. H1-NMR absorption graph for L-arginine using D2O (reference at 4.77 ppm); 15
protons were detected. (n=3)
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3.4. Conclusion
Enhancing the solubility profile of gliclazide was successfully carried out in two ways. The
first formulation method involved the use of L-arginine, with no modification of the pH of the
solution. The advantage of using the amino acid was that, as well as all of the excipients
being GRAS listed and within the recommended guidelines, the formulation was within
regulation to be potentially administered to paediatrics. The second formulation method
involved the use of a co-solvent coupled with a surfactant; this formulation would be safe for
use for adults as all excipients used within the formulation were GRAS listed and within the
recommended dose range.
Both sets of formulations had chemical and organoleptic stability during the nine months
storage under fridge (5 oC), room temperature (25 oC) and accelerated (40 oC) conditions.
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CHAPTER 4
Optimisation of an extraction protocol and development of
an oral liquid formulation for L-arginine
4.1. Introduction and Aims
4.1.1. Amino Acids
Amino acids are one of the critical components that serve as building blocks of life and make
up the foundation of proteins. The human body consists of 20 amino acids that are sub-
divided into 7 distinct groups (Table 4.1). Amino acids are made up of an amine group,
carboxylic acid group and a side chain that varies between the different amino acids. There
are twenty two different amino acids which are incorporated to form polypeptides/proteins
and are referred to as standard amino acids. Of these, eight amino acids are classified as
“essential” as they cannot be produced by the human body and are sourced from the diet.
Group class Amino acid
Aliphatic Alanine (ala), Glycine (gly), Isoleucine (ile),
Leucine (leu), Proline (pro) and valine (val)
Aromatic Phenylalanine (phe), Tryptophan (trp), and
Tyrosine (tyr)
Acidic Aspartic acid (asp) and Glutamic acid (glu)
Basic Arginine (arg), Histadine (his) and Lysine (lys)
Hydroxylic Serine (ser) and Threonine (thr)
Sulphur-containing Cysteine (cys) and Methionine (met)
Amidic (amide group-containing) Asparagine (asn) and Glutamine (gln)
Table 4.1. Summary of amino acids based on their difference in structure and physicochemical
properties.
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4.1.2. Arginine
4.1.2.1. Therapeutic effect of Arginine
Although arginine can be synthesised by the body, it does so in insufficient quantities,
thereby requiring increased amounts to be absorbed through diet. This basic amino acid can
be found in many food sources, including dairy products, meat, poultry and fish. It has a
versatile role in the human body which includes; cell division, wound healing, immunity
towards illness, production of nitric oxide causing relaxation of blood vessels, and most
importantly removal of ammonia from the body in the urea cycle.
4.1.2.2. Structure and Metabolism
L-arginine consists of a 4-carbon aliphatic straight chain with the distal end of the chain being
capped by a guanidinium group and the other by a carboxylic acid group. The amino acid
has 3 pKa values; 2.01 (pKa1), 9.04 (pKa2) and 12.48 (pKa3) (Figure 4.2.). The pKa of the
guanidinium group ensures the cationic charge of L-arginine in most media regardless of the
pH and therefore enables L-arginine to exert its basic chemical properties.
The metabolism of L-arginine (carried out by the enzyme arginase) breaks down the amino
acid into its metabolites L-ornithine and urea.
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Figure 4.1. Chemical structures of Arginine and its stereo forms.
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Urea Cycle Disorders Definition
Hyperammonaemia in carbamylphosphate
synthetase deficiency
Autosomal recessive metabolism disorder
Ornithine carbonyl transferase deficiency Genetic disorder resulting in a mutated and
ineffective form of the enzyme ornithine
transcarbamylase
Hyperammonaemia in citrullinaemia Autosomal recessive urea cycle
Arginosuccinic aciduria Arginine succinase may be damaged or
missing within the urea cycle, preventing
the conversion of arginine succinate into
arginine.
Table 4.2. Urea Cycle disorders.
Figure 4.2. Chemical structure of L-arginine: 3-carbon aliphatic straight the distal end of which is
capped by a guanidinium group.
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4.1.3. Aim
In the human body, arginine plays a central role in the urea cycle. Although it may not be an
essential amino acid for adults, in infants the nutritional value is extremely vital, as the rate of
synthesis of L-arginine in infants may not be fast enough to cover all of the requirements of
the tissues.
Currently L-arginine is prescribed to patients who have urea cycle disorder (Table 4.2.) in
500 mg tablets or 100 mg.mL-1 dosage forms, with currently no licensed oral liquid
formulation present on the market.
In the developmental stages of drug formulation, the organoleptic properties are crucial in
determining the acceptability of the drug formulation for the patient. The organoleptic
properties include; smell, colour, appearance and taste. From the amino acids listed in table
4.1, the basic amino acids display a fairly bitter taste when in solution, particularly arginine
which is extremely bitter in taste, and can be used in D- and L- stereochemical form
(Figure 4.1).
The aim of the research presented in this chapter was to develop a stable oral liquid
formulation of L- arginine. To achieve this, the work was divided into two phases:
 Phase 1: development of a validated calibration protocol for the quantification of
L-arginine
 Phase 2: formulation of a chemically stable oral liquid preparation of L-arginine
(100 mg.mL-1) with improved shelf life
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4.2. Materials and Method
4.2.1. Materials
L-Arginine, ninhydrin, tartaric acid, sodium benzoate, sorbitol, monosodium phosphate,
disodium phosphate, phosphoric acid, and trifluoroacetic acid (TFA) were purchased from
Sigma (UK). Raspberry concentrate was purchased from Flavex International Ltd. (Hertford,
UK).
4.2.2. Method
4.2.2.1. Protocol for Ninhydrin-UV Calibration of L-arginine
4.2.2.1.1. Preparation of 1 M sodium phosphate
A 1 M stock solution of sodium phosphate was prepared by dissolving 5.723 g of
monosodium phosphate and 7.425 g of disodium phosphate in 100 mL distilled water. 2.5 mL
of this stock solution was added to 97.5 mL of distilled water under continuous stirring, to
form a final concentration of 25 mmol.L-1. The pH of this solution was then adjusted to pH 4.5
with phosphoric acid.
4.2.2.1.2. Preparation of stock solution of L-arginine
A 3 mg.mL-1 concentration of L-arginine was produced by adding 30 mg of L-arginine to
10 mL of distilled water. By carrying out serial dilution, 1 mL of the 3 mg.mL-1 stock solution
was added to 10 ml distilled water, to produce a final concentration of 300 μg.mL-1
4.2.2.1.3. Ninhydrin assay
The various stages for the development of calibration curve are outlined below:
1. Dilutions as listed in table 4.3 were prepared with samples being vortexed for 10 seconds
after the addition of 25 mmol sodium phosphate buffer and addition of ninhydrin.
2. Samples were heated for 20 minutes at 80 oC in a pre-warmed water bath.
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3. After 20 minutes, the samples were removed from the water bath and left to cool on the
bench.
4. Each sample was diluted with 25 mmol.L-1 sodium phosphate buffer at a ratio of 1:3
(sample:buffer ratio).
5. The samples were analysed using a UV spectrophotometry at a wavelength of 560 nm.
4.2.2.2. pH titrations using tartaric acid
A 100 mg.mL-1 solution of L-arginine in distilled water was prepared, to which different
concentrations of tartaric acid were added (w/v). Once the tartaric acid was fully dissolved,
the pH of the solution was measured using a calibrated Hydrus 500 pH meter. The following
tartaric concentrations (% w/v) were titrated and their pH measurements recorded: 0.1, 0.5,
1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 3.6, 3.7, 3.75, 3.8, 4.0 % (w/v).
4.2.2.3. Oral liquid formulation recipe of L-arginine
To obtain a final concentration of 100 mg.mL-1 of L-arginine, 5 g of the amino acid was
dissolved in 42 mL of distilled water and left to stir for 5 minutes until the amino acid had fully
L-arginine
concentration
μg.mL-1
L-arginine
stock
(300 μg.mL-1)
/mL
25 mmol.L-1
sodium
phosphate
buffer pH4.5
/mL
Ninhydrin
/mL
30 0.20 1.80 1.00
36 0.24 1.76 1.00
45 0.30 1.70 1.00
54 0.36 1.64 1.00
60 0.40 1.60 1.00
66 0.44 1.56 1.00
75 0.50 1.50 1.00
Blank 0.00 2.00
V
O
R
TE
X
1.00
V
O
R
TE
X
Table 4.3. Protocol for the preparation of L-arginine-ninhydrin solutions at various concentrations.
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solubilised. To reduce the pH of the solution, 2 g of tartaric acid (4 % w/v) was then added
and left to stir until the acid had fully dissolved. A 0.5 % (w/v) concentration of the
preservative, sodium benzoate (0.25 g) was then added under continuous stirring, followed
by 250 μL of raspberry concentrate (0.5 % v/v), and 5 g of sorbitol (10 % w/v). The solution
was kept under continuous stirring until all of the constituents had fully dissolved to reveal a
clear solution. The volume of the solution was then adjusted to 50 mL and stored in amber
coloured glass bottles at 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity). Samples
were prepared and stored in triplicate.
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4.3. Results and Discussion
4.3.1. Optimisation of a calibration protocol for the detection and
quantification of L-arginine in solution.
4.3.1.1. Preliminary investigations
The establishment of a validated calibration method to accurately quantify the presence of
L-arginine in solution was essential. The primary hurdle in the development of an assay was
the absence of a specific absorbance wavelength for L-arginine in the UV spectrum.
Previous published protocols in the literature required multiple and complex stages of
extraction and often relied on by product characterisation of arginine. The initial focus of our
work was to further develop and optimise published analytical protocols with the aim of
developing a simple and robust direct method.
One such method included utilising the fluorescence ability of L-arginine and its separation
from human urine samples (Markowski et al, 2007) using a reverse phase HPLC system. For
our investigation, this method was simplified on an isocratic HPLC system, with mobile phase
comprising of di-sodium hydrogen phosphate buffer (pH 6.88), methanol and acetronitrile, at
concentration ratios of 90:5:5 respectively which was pumped at a rate of 1 mL.min-1 through
a C18 column. Fluorometric detection was carried out at a maximum emission wavelength of
455 nm and at a maximum excitation wavelength of 338 nm. A 1 mmol.L-1 stock solution of
L-arginine was then prepared in methanol:water (1:1 v/v), with further diluted samples being
prepared in water (0.05-0.280 mmol.L-1). As shown in figure 4.3, 20 μL of the prepared
sample was injected and no separation of L-arginine from the diluents was observed even
after 30 minutes. This was in contrast with the work carried out by Markowski and co-workers
(2007), who detected a peak after 24 minutes. The criteria of the calibration protocol was to
produce one that was simple and quick, by having a potential retention time of no longer than
1 hour as it would lead to lengthy analytical cycles.
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Figure 4.3. HPLC spectra of (A) methanol:water mix at a 1:1 ratio and (B) 0.28 mmol.L-1
concentration of L-arginine. The spectra were very similar with no definite peak of L-arginine being
detected after 30 mins.
(A)
(B)
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In a separate study by Bi and Singh (1999), trifluoroacetic acid (TFA) was used in the
separation of arginine from Arg8-vasopressin. TFA has been widely used in liquid
chromatography as a buffering agent, allowing for the separation of organic compounds,
particularly for the separation of peptides and small proteins, as well as enhancing the
resolution of peptide separation and the presentation of the peaks (Huang et al, 2004). The
protocol was modified by changing the pH of the control sample to 4.5, instead of 5 as used
by Bi and Singh (1999). This was to ensure that the conditions of the calibration would be in
an acceptable pH range to match the proposed L-arginine formulation in solution. The
calibration protocol involved injection of 20 μL of a 25 mg.mL-1 stock solution of L-arginine
prepared in distilled water. C18 column (maintained at 35 oC) using an isocratic HPLC
system at a flow rate of 1.5 mL.min-1 was used at a wavelength of 220 nm (Bi and Singh,
1999), with the mobile phase consisting of 0.1 % TFA in water and methanol (70:30 v/v).
However L-arginine was not detected under these conditions (Figure 4.4). Due to non-
specificity of L-arginine and its wavelength detection point, a diode-array was utilised to
detect across larger ultra-violet spectrum. A protocol was adapted from Huang and co-
workers (2004) in which a photo-diode array ranging from 200-300 nm had been used to
analytically determine L-arginine and its mono- and dimethylated metabolites. Mobile phase
consisting of water and ACN (90:10 v/v) containing 0.5 % TFA (v/v), was pumped through an
isocratic HPLC setup at a flow rate of 0.2 mL.min-1, with the diode array set between
200-400 nm. 5 μL samples of L-arginine, prepared from a stock solution of 1.0 mmol.L-1
L-arginine in 0.1 mol.L-1 HCl and serial dilutions carried out in water (5 – 120 μmol.L-1), were
injected into the HPLC. The expected retention time of L-arginine according to the Huang
protocol (2004) was 3 minutes, however no clearly defined peak for L-arginine was detected
(Figure 4.5). The concentration of L-arginine was further increased to 0.5 – 0.8 mmol.L-1 but
did not yield the desired results.
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Figure 4.4. HPLC spectra for (A) Solvent front of the mobile phase consisting of 0.1 % TFA in
water and methanol (70:30 v/v) and (B) 50 μg.mL-1 sample of L-arginine. After 30 minutes, no
definite solvent front or amino acid was detected. Both HPLC spectras displayed an unsteady
baseline, which was attributed to the low sensitivity of the protocol (milli-absorbance unit did not
exceed 2 mAU).
(A)
(B)
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Figure 4.5. HPLC spectra for (A) solvent front of the mobile phase containing water and
acetronitrile (90:10 v/v) with 0.5 % (v/v) TFA, and (B) 0.08 mmol.L-1 L-arginine. The injection of
0.08 mmol.L-1 resulted in an alteration in the detection of the solvent front, with no definite peak
corresponding to L-arginine.
(A)
(B)
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4.3.1.2. Development of Ninhydrin assay
The next strategy was to use a colorimetric derivatisation approach (second compound) that
would undergo reaction with L-arginine and produce a UV detectable end product. Ninhydrin
undergoes chemical reaction with amino acids in water to produce a distinct purple colour
and has been used for the detection of peptides in a wide range of studies over a number of
years, including: non-ionic surfactant vesicles and liposomes (Brewer et al 1995), bilosomes
(Conacher et al, 2001), tissue samples (Starcher, 2001), and amino acid determination in
polymer membranes (Zhu et al, 2002).
Using a modified protocol from Kowalczuk and co-workers (2007), concentrations
(45-90 μg.mL-1) of L-arginine were prepared in phosphate buffered saline at pH 9 and
vortexed, after which 0.5 mL of ninhydrin was added to the mixture. The mixture was
vortexed thoroughly before being heated at 80 oC for 20 minutes. The solution was then left
to cool on the bench before adding 3 ml of propan-2-ol:water (1:1) to 1 ml of the ninhydrin
mixture. After ensuring the solution had thoroughly mixed, the sample was analysed using a
UV spectrophotometer at wavelength 404 nm (Figure 4.6). The blank used was a sample
that had gone through
Figure 4.6. Calibration of L-arginine (λ=404 nm) using phosphate buffered saline at pH 9. A 
linear regression was achieved (R2=0.9944), with intercept passing through the origin. (n=3)
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the ninhydrin protocol without the addition of the amino acid. A linear regression line was
obtained with intercept going through the origin (R2=0.9944). The ninhydrin assay is widely
used to study peptide hydrolysis into its constituent amino acids and can therefore be easily
adapted to quantify individual amino acids. Firstly the phosphate buffered saline at pH 9 was
omitted and replaced with a 25 mmol.L-1 sodium phosphate buffer (pH 4.5), with the pH of
the buffer being more suited to the required pH of the ultimate formulation to be prepared in
this study. Secondly, the ninhydrin volume was increased to 1 ml and was diluted with 3 ml of
the buffer (pH 4.5). L-arginine was then added to ninhydrin at various concentrations ranging
from 30-75 μg.mL-1 (Table 4.2), producing a calibration graph with a y-intercept of 0.363 nm
(Figure 4.6). Ninhydrin has two distinct lamda max absorbancies, 404 nm and 560 nm
(Meyer, 1957). As seen from figure 4.7, a higher peak area was displayed at 560 nm
suggesting a stronger absorption band for L-arginine. The ninhydrin assay described was
ultimately modified using a wavelength of 560 nm which produced a calibration curve with
the y-intercept near zero (R2=0.9852) (Figure 4.8). A calibration validation could now be
carried out using this simplified method for L-arginine quantification using UV spectroscopy.
Figure 4.7. Calibration of L-arginine (λ=404 nm) using a modified ninhydrin assay with 25 mmol.L-1
sodium phosphate buffer at pH 4.5. A linear regression line was achieved (R2=0.9916), with a
y-intercept of 0.363 nm. (n=3)
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4.3.1.3. Ninhydrin mechanism
Ninhydrin (2,2-dihydroxy-1,3-indanedione), a white crystalline powder, has a melting range of
240-245 oC, and is soluble in water and alcohols (Wu et al, 2005). The exposure to high
temperatures in solution (100 oC) causes the compound to display a distinct red colour.
Ninhydrin has been widely used for the analytical determination of free amino groups and
carboxylic groups in proteins and peptides due to its ability to change colour in the presence
of an amino acid from a distinct red to Ruhemann’s purple. Ninhydrin is composed of a
carbonyl compound with reactive ketone groups (proton accepting) and hydroxyl groups
(Figure 4.9). It is the deprotonation of these hydroxyl groups that initiates the formation of
Ruhemann’s purple, illustrated by the mechanism in figure 4.10. The reaction mechanism
takes place in three stages: (1) reduction of ninhydrin to form hydrindantin and a water
molecule; (2) the oxidative deamination, hydrolysis and decarboxylic reactions of L-arginine,
catalysed by the water molecule, finally producing its degradative products which include
aldehyde, carbon dioxide and ammonia; and (3) direct combination of hydrindantin, ninhydrin
and ammonia to form Ruhemann’s purple (MacFadyen and Fowler, 1950). The final product
is detected with UV at a maximum absorbance of 560 nm.
Figure 4.9. Chemical structure of ninhydrin (C9H6O4), displaying its main functional groups;
ketone and hydroxyl groups.
Ketone
group
Hydroxyl
groups
O
OH
OH
O
Figure 4.8. Lambda max of L-arginine solution after being treated with the modified ninhydrin
assay. Two distinctive Lambda max were determined at 404 nm and 560 nm.
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Figure 4.10. Mechanism of L-arginine and ninhydrin in the production of Ruhemann’s purple.
Ninhydrin is reduced to hydrindantin with the formation of water. This initiates the oxidative
deamination reaction of L-arginine into an imino acid, with subsequent hydrolyisis producing a keto
acid and an ammonia molecule. When exposed to heat (80 oC) the keto acid undergoes further
decarboxylation to form the degradation products of L-arginine (carbon dioxide and an aldehyde).
Simultaneously, hydrindantin condenses with ammonia and ninhydrin to produce the intense blue-
purple pigment known as Ruhemann’s purple. (Modified from MacFadyen and Fowler, 1950; Wu
et al, 2005)
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4.3.2. Calibration Validation using a modified ninhydrin assay
An in-direct, simplified UV spectroscopy method was developed and validated for the
determination of L-arginine (Table 4.3), at a wavelength of 560 nm, using ninhydrin to
quantify L-arginine. Results are presented in table 4.4.
4.3.2.1. Linearity
The linearity of the UV spectroscopy method was evaluated by preparing the standard curve
for L-arginine on three consecutive days. The peak area was plotted against the
concentration and the calibration response was assessed for variances. The results showed
that the Beer Lambert’s law was obeyed in the range of 30-75 μg.mL-1 with the linear plot
giving the regression equation of y=0.0107x (R2=0.9852), which is represented in figure 4.11.
4.3.2.2. Precision
In order to assess the reproducibility of the calibration protocol, the calibration method was
carried out in triplicate over a period of three days for interday precision, and in triplicate on
the same day for intraday precision. It was concluded that the calibration method was
Figure 4.11. Calibration of L-arginine (λ=560nm) using a modified ninhydrin assay with 25 mmol.L-1
sodium phosphate buffer at pH 4.5. A linear regression line was achieved (R2=0.9852), giving a
regression equation of y=0.0107x. (n=3)
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reproducible, with inter-day and intra-day precision being calculated to be 100 %. Data was
analysed using ANOVA statistical test, with the resulting inter-day and intra-day precision
being calculated to have a variance of P>0.05.
4.3.2.3. Accuracy
The accuracy of the developed method was determined from three concentrations of
L-arginine in the ninhydrin protocol, representing the lower section of the standard curve (21,
27 and 33 μg.mL-1). Accuracy of the three concentrations was in the range of 101-100 %.
4.3.2.4 Limit of detection (LOD) and limit of quantification (LOQ)
The LOD of an individual analytical procedure can be defined as the lowest amount of
analyte in a sample which can be detected but not necessarily quantifiable as an exact value
(EMEA, 1995). From the calibration range the LOD was calculated to be 0.112 μg.mL-1.
The LOQ of an individual analytical procedure can be defined as the lowest amount of
analyte in a sample which can be quantitatively determined with accuracy and precision.
From the calibration range the LOQ was calculated as 0.34 μg.mL-1.
Criteria Validation
Y= 0.0107
R2 0.9852
Intra-day Precision 100 %
Inter-day Presicion 100 %
Accuracy (+SD) 21 μg.mL-1 101.00 (+0.45)
Accuracy (+SD) 27 μg.mL-1 100.03 (+0.53)
Accuracy (+SD) 33 μg.mL-1 100.90 (+0.43)
LOD μg.mL-1 0.112
LOQ μg.mL-1 0.34
Table 4.4. Summary of calibration validation of L-arginine.
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4.3.3. Optimisation of an oral liquid formulation for L-arginine:
rational for taste masking
When formulating a pharmaceutical dosage form, the organoleptic properties chosen during
the developmental stages are crucial in determining patient compliance. For oral liquid
preparations these properties include; pleasant smell, smooth consistency, and most
importantly a palatable taste (not too sour or too sweet). Taste consists of the following five
basic qualities: sourness produced by hydrogen ions such as hydrochloric acid, acetic acid,
and citric acid; saltiness produced by sodium chloride; sweetness produced by sugars; and
bitterness produced by quinine, caffeine and magnesium chloride (umami) (Zheng and
Keeney, 2006).
The hydrophilic properties of L-arginine enables large quantities of the drug to be solubilised
in water (148.7 g.L-1), resulting in increased ionised guanidinium groups to be present and
subsequently increases the alkalinicity of the solution (100 mg.mL-1: L-arginine in water = pH
11). As the concentration of the guanidinium groups increases, the bitterness of the solution
also increases. In order to prepare a formulation with palatable properties (by reducing the
bitterness expressed by L-arginine), a pharmaceutical sweetener was added. Sorbitol
(C6H14O6) is a widely used excipient in liquid pharmaceutical preparations as a vehicle in
sugar-free formulations and as a stabiliser for drug suspensions. It has a pleasant cooling
sweet taste, with ~ 50-80 % sweetness as that of sucrose (Rowe et al, 2006). However, in
the presence of L-arginine, by using the maximum sorbitol concentration (40 % w/v, Rowe et
al, 2006), the addition of the sweetener was insufficient at reducing the bitterness of the
formulation. Thus the formulations presented two major challenges: (1) the high alkalinity of
the resultant solution provided a bitter taste; and (2) the absence of suitable preservatives
that can function effectively under strong alkaline conditions (most work effectively in the
more neutral and slightly acidic mediums).
4.3.3.1. Influence of Tartaric acid
Tartaric acid is used as an acidifying, flavouring and sequestering agent in pharmaceutical
products, with a molecular formula of C4H6O6 (pKa1 =2.95, pKa2 = 4.25, Mw = 150.09)
(Figure 4.12). It is a naturally occurring chemical found in plants (e.g. grapes and citrus
fruits) and is commonly used as a sour-flavour additive in beverages, food products and
pharmaceutical products. The next stage of the work was to improve the formulation of
L-arginine by lowering the pH of the solution with the addition of tartaric acid. In order to
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determine the optimal concentration of tartaric acid, a titration experiment was set up to
investigate the influence of addition of tartaric acid on pH of the solution containing
L- arginine.
Figure 4.13 displays the titration of tartaric acid with 100 mg.mL-1 L-arginine. The amino acid
has very basic properties (pH 11 in the absence of tartaric acid), thus the titration was carried
out to determine the relationship between concentration of tartaric acid and its ability to
reduce the pH of the solution. The results show that as the concentration of tartaric increased
from 0.1 to 4.0 % (w/v), a decrease in the pH of the solution was observed, reaching
4.70 + 0.02. This can be explained by the dissociation of tartaric acid in water into its
Figure 4.13. Influence of increasing concentrations of tartaric acid on the pH of L-arginine in
solution. As the concentration of the acid increased, a decrease in pH was observed, with 4 % (w/v)
tartaric acid reducing the pH of the solution to 4.7 + 0.02. (n=3)
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Figure 4.12. The mechanism of reaction of tartaric acid with water. The –OH reactive groups of
tartaric acid enables proton donation to be carried out with water, forming hydronium ions.
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corresponding anion molecule and hydronium ion (Figure 4.12). pH is a measure of
hydrogen ion concentration in a solution and as the number of hydrogen ion concentration
increases, the acidity of the formulation increases. Therefore the reduction in pH by tartaric
acid was a direct result of increased hydronium ions forming, thereby masking the basic
properties and bitterness of L-arginine.
4.3.3.1. Formulation Optimisation
The addition of 4 % (w/v) tartaric acid produced a solution with low pH and an acceptable
taste. The final formulation recipe comprising 100 mg.mL-1 L-arginine is detailed in section
4.2.2.3. The alkalinicity and bitterness of the formulation was reduced after the addition of
4% tartaric acid (w/v). The sweetness of the formulation was further increased by the
addition of 40 % (w/v) sorbitol along with 0.5 % (v/v) raspberry concentrate, providing a
pleasant odour. In order to ensure the formulation remained microbiologically stable
throughout its shelf life, sodium benzoate (0.5 % w/v) was included as preservative. Sodium
benzoate is an effective preservative and acts on the cell wall through a chemical reaction
(Rowe et al, 2006). It was also found to have good chemical and organoleptic properties
(colourless, odourless, effective in acidic mediums and readily soluble in water), thus making
it compatible with the other excipients in the formulation.
4.3.4. Stability studies
Formulations of L-arginine in solution (100 mg.mL-1) were prepared as described in section
4.2.2.3. The samples were stored at different stability conditions as outlined in the ICH
guidelines (5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity)) and assessed for
changes in organoleptic properties and chemical stability of the active ingredient.
Assessment of the organoleptic properties such as colour, smell and taste at the different
conditions of storage showed that there was no significant difference in the formulations
stored at 5 oC and at 25 oC (Table 4.5). All the formulation had pleasant raspberry fragrance
with no changes in taste. However formulations stored under accelerated conditions (40 oC)
changed colour after 30 days of storage. The intensity of colour change increased with the
duration of storage, after 6 months storage the formulations changed from peach to a dark
yellow colour and had an unacceptable taste. The change in colour can potentially be
attributed to the degradation of raspberry concentrate at higher temperature and humidity
conditions upon storage over a long duration.
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Organoleptic propertiesTemperature
oC
Number of days
Colour Smell Taste
5 0 Light Peach Raspberry Sweet
30 Light Peach Raspberry Sweet
60 Light Peach Raspberry Sweet
90 Light Peach Raspberry Sweet
180 Light Peach Raspberry Sweet
360 Light Peach Raspberry Sweet
0 Peach Raspberry Sweet
30 Peach Raspberry Sweet
60 Peach Raspberry Sweet
90 Peach Raspberry Sweet
180 Peach Raspberry Sweet
25
360 Peach Raspberry Sweet
0 Light Peach Raspberry Sweet
30 Peach Raspberry Sweet
60 Dark Peach Raspberry Sweet
90 Peach/Yellow Raspberry Sweet
180 Dark Yellow BurntRaspberry Less Sweet
40
360 Dark Yellow BurntRaspberry Less Sweet
Table 4.5. Stability study assessing organoleptic properties of the oral liquid formulation of L-arginine
(100 mg.mL-1). The formulations were stored at different storage conditions including 5 oC, 25 oC
(40% humidity) and 40 ºC (75% humidity).
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Analysis of pH of the formulations stored at the different conditions over a 1 year period
showed that there were no significant differences between pH variations (Figure 4.14)
potentially suggesting that there were no chemical changes within the formulation.
Furthermore analysis of L arginine showed that the chemical stability profile of the active
ingredient did not change over the entire duration of the study (Figure 4.15). However, data
from studies carried out at 5 and 25 oC provide a clearer indication of the stability profile as
there were physical changes to the formulations stored under accelerated conditions.
Figure 4.14. 12 months stability profile of 100 mg.mL-1 L-arginine with 4 % (w/v) tartaric acid and
0.5 % (v/v) raspberry concentrate stored under 5 oC, 25 oC (40 % humidity) and 40 oC (75 %
humidity) conditions. Formulation was observed to be stable over the 12 month period (pH 4), with no
significant difference between the time points (P>0.05). (n=3)
Figure 4.15. 12 months stability profile of 100 mg.mL-1 L-arginine with 4 % (w/v) tartaric acid and
0.5 % (v/v) raspberry concentrate stored under 5 oC, 25 oC (40 % humidity) and 40 oC (75 %
humidity) conditions. The formulation was observed to have >90 % drug retention over the 12 month
period. (n=3)
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4.4. Conclusion
Extensive investigation of the analytical method resulted in the development of ninhydrin
assay which was simple, reproducible and validated method for assessing the concentration
of L arginine. The study resulted in the production of an oral liquid flavoured formulation of
L-arginine with shelf life of one year as opposed to currently available extemporaneous
preparations which have a short shelf life of 28 days (Hey, 2007).
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CHAPTER 5
Solubilisation and formulation of melatonin as a liquid oral
dosage form
5.1. Introduction
5.1.1. Structure, biosynthesis and metabolism of melatonin
The pineal gland is a highly vascular neuroendocrine transducer located in the centre of the
brain and is predominantly made up of two types of cells; (1) pinealocytes, which produce
indolamines (melatonin) and peptides (arginine vasotocin), and (2) neuroglial cells (Amnon,
1997).
The indole structure is an aromatic heterocyclic organic compound consisting of a
6-membered benzene ring fused to a 5-membered nitrogen-containing pyrrole ring
(Figure 4.1a). Indolamines are composed of aromatic indole attached to the essential amino
acid L-tryptophan (Figure 4.1b). It is this indolamine that initiates the biosynthesis of
melatonin in the pineal gland by a four-step pathway. The process is initiated by the
conversion of the amino acid tryptophan into 5-hydroxytryptophan via the enzyme tryptophan
5-monoxygenase. Aromatic-1-amino acid decarboxylase then catalyses the hydroxynated
form of tryptophan into 5-hydroxytryptamine (serotonin), which undergoes acetylation from
NH
NH
OH
O
NH2
H
(A) (B)
Figure 5.1. Chemical structures of (A) indole and (B) an indolamine (L-tryptophan). The indole is an
aromatic heterocyclic organic compound composed of a 6-membered benzene ring fused to a
5-membered nitrogen-containing pyrrole ring. The indolamine is composed of the essential amino
acid (L-tryptophan) fused to the indole structure.
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arylalkylamine-N-acetyltransferase (AANAT) to form the precursor of melatonin:
N-acetylserotonin. This precursor is then catalysed by the enzyme hydroxyindol-O-
methyltransferase into melatonin (Figure 4.1) (Altun and Ugar-Altun, 2007).
Melatonin is metabolised in the liver, by hydroxylation to form 6-hydroxymelatonin, which is
then conjugated to either sulphuric or glucuronic acid before being excreted in the urine
(Amnon, 1997).
5.1.2. Melatonin and it therapeutic effects
Melatonin (N-acetyl-5-methoxytryptamine) is a melanophore containing indolamine hormone
with poor water solubility (100 μg.mL-1) (Hardeland, 2006). It is secreted by the pineal gland
during the dark phase of the day by simple diffusion with its lipophillic structure allowing it to
passively diffuse across the cell membranes (Reiter, 1991; Cardinali and Pévet, 1998).
The physiological functions and therapeutic uses of melatonin include sleep and circadian
entrainment (daily rhythm becomes susceptible to modulation by 24-hour environmental
cycles), blood pressure regulation, temperature regulation, oncogenesis, retinal physiology,
seasonal reproduction, ovarian physiology, immune function, inducement of osteoblast
differentiation, ageing process, as well as acting as a potent-free radical scavenger and a
broad spectrum antioxidant (Haimore et al, 1994; Pieri et al, 1995; Amnon, 1997; Altun and
Ugur-Altun, 2007; Rezzani et al, 2009).
5.1.3. Current dosage forms
The production of melatonin varies according to age, with children aged less than 3 months
secreting very little melatonin form the pineal gland. In older infants, melatonin secretion
increases and becomes circadian with the nocturnal concentration of melatonin achieving its
peak in children aged 1-3 years. As the children grow older (>3 years old) the concentration
of melatonin gradually begins to decline (Waldhauser et al, 1984; Amnon, 1997). Therefore
insufficient production of melatonin can result in the need for supplementing it from an
external source. Currently, melatonin dosage forms are supplied as modified release tablet
(Circadin®) in 2 mg doses that can only be prescribed to adults over the age of 55 as a
short-term treatment for insomnia.
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Pineal Gland
Figure 5.2. Four-step pathway synthesis of melatonin by the pineal gland. Tryptophan is converted
to 5-hydroxytrptophan by the enzyme tryptophan hydroxylase, which is then decarboxylated to
serotonin. The synthesis of melatonin from serotonin is catalysed by 2 enzymes (arylalky;amine-N-
acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase), which are mainly confined to
the pineal gland (modified from Altun and Ugar-Altun, 2007).
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5.1.4. Aim
Research into an alternative drug delivery method for melatonin has previously been carried
out including the formulation of solid lipid nanoparticles (Rezzani et al, 2009), alginate beads
(Lee and Min, 1996), lipospheres (Tursilli et al, 2006) and propylene glycol and HP-β-CD
vehicles (Lee et al, 1997). However an oral liquid solution using simple solubilisation
techniques which can be commercially translatable has not yet reached the pharmaceutical
market.
The overall aim of the study was to establish a validated calibration protocol for the extraction
and quantification of melatonin using HPLC and to solubilise melatonin in an oral liquid
formulation without compromising the lipophilicity of the molecule and thus ensuring its
diffusion across the cell layers.
The objectives included:
 Development of cyclodextrin based oral liquid formulation (1 mg.mL-1) in the absence
of conventional non-polar media, such as ethanol.
 Stabilisation of the liquid formulation from oxidation and degradation upon exposure
to light
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5.2. Materials and Method
5.2.1. Materials
Melatonin, HP-β-CD, sorbitol, tartaric acid, potassium sorbate, sodium acetate and EDTA
were purchased from Sigma (UK). Methanol and ACN was purchased from Fisher Scientific
(UK).
5.2.2. Method
5.2.2.1. Development of a calibration method for melatonin
Calibration was carried out using a dionex HPLC with a C18 Gemini column (150 x 4.6 mm)
being heated to 45 oC using a column heater. 10 mg of melatonin was dissolved in 20 mL of
methanol to obtain a stock concentration of 500 μg.mL-1. Serial dilutions were then carried
out to obtain further concentrations (250, 100, 50, 25, 10 and 5 μg.mL-1). Using a mobile
phase consisting of 75 mM sodium Acetate and ACN (84:16), 20 μL of each melatonin
concentration was injected into the dionex HPLC and analysed at a wavelength of 275 nm.
The retention time for melatonin was 20 minutes.
5.2.2.2. pH titration of tartaric acid
A 1 mg.mL-1 solution of melatonin in distilled water with HP-β-CD and 40 % (w/v) sorbitol was
prepared, to which increasing increments of tartaric acid was added. Once the tartaric acid
had fully dissolved, the pH of the solution was measured using a calibrated Hydrus 500 pH
meter. The following tartaric concentrations (% w/v) were used and their pH measurements
recorded: 0.1, 0.25, 0.5 and 1.00 % (w/v).
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5.2.2.3. Oral liquid formulation recipe of melatonin
To solubilise melatonin, 0.6286 g of HP-β-CD was dissolved in 35 mL of water, to which 20 g
sorbitol (40 % w/v) was then added and left to stir for 5 minutes until sorbitol had fully
dissolved. The solution was then heated to 40 oC and 50 mg of melatonin solution was
dissolved to achieve a 2:1 molar ratio of HP-β-CD with melatonin. To reduce the pH of the
solution, 50 mg of tartaric acid (0.1 % w/v) was then added and left to stir until the acid had
fully dissolved. A 0.2 % (w/v) concentration of the preservative, potassium sorbate (100 mg)
was then added under continuous stirring, followed by 0.1 % of EDTA as an antioxidant
(50 mg). The solution was kept under continuous stirring until all of the constituents had fully
dissolved to obtain a clear solution. The volume of the solution was then adjusted to 50 mL
and stored in amber coloured glass bottles at 5 oC, 25 oC (40 % humidity) and 40 oC (75 %
humidity). Samples were prepared and stored in triplicate.
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5.3. Results and discussion
5.3.1. Calibration Validation
A HPLC diode array calibration method initially described by Minami and co-workers (2009)
was modified to produce a validated calibration protocol for the determination of melatonin in
solution. At a detection wavelength of 275 nm, methanol was used to solubilise melatonin.
5.3.1.1. Linearity
The linearity of the HPLC method was evaluated by preparing the standard curve for
melatonin on three consecutive days. The peak area was plotted against the concentration
and the calibration response was assessed for variances. The results show that the data
complied with the Beer Lambert’s law in the concentration range investigated
(50-500 μg.mL-1) with the linear plot producing a regression equation of y=0.3045x
(R2=0.9954) (Figure 5.3).
Figure 5.3. Graph of melatonin calibration highlighting the linearity of the validation protocol.
Chapter 5 – Solubilisation and formulation of melatonin as a liquid oral dosage form
169
5.3.1.2. Precision
In order to access the reproducibility of the calibration protocol, the calibration method was
carried out in triplicate over a period of three days for interday precision, and in triplicate on
the same day for intraday precision. It was concluded that the calibration method was
reproducible with inter-day precision of 100.42 % and the intra-day precision of 103.99 %.
Statistical data was compared using ANOVA statistical test, with the resulting inter-day and
intra-day precision being calculated to have a variance of P>0.05 (Table 5.1)
5.3.1.3. Accuracy
The accuracy of the developed method was determined from three concentrations of
melatonin in distilled water representing low, medium and high concentrations of the
standard curve (20, 60 and 150 μg.mL-1). Accuracy of the three concentrations was in the
range of 92.62-104.02 % (Table 5.1).
Criteria Validation
Y= 0.3045x
R2 0.9954
Intra-day Precision 103.99 %
Inter-day Precision 100.42 %
Accuracy (+SD) 20 μg.mL-1 92.62 (11.61) %
Accuracy (+SD) 40 μg.mL-1 103.25 (8.77) %
Accuracy (+SD) 60 μg.mL-1 104.02 (3.92) %
LOD μg.ml-1 0.83
LOQ μg.ml-1 2.51
Table 5.1. Summary of calibration validation of melatonin
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5.3.1.4. Limit of detection (LOD) and limit of quantification (LOQ)
The LOD of an individual analytical procedure is the lowest amount of analyte in a sample
which can be detected but not necessarily quantifiable as an exact value (EMEA, 1995).
From the calibration range the LOD was calculated as 0.83 μg.mL-1.
The LOQ of an individual analytical procedure is the lowest amount of analyte in a sample
which can be quantitatively determined with accuracy and precision. The LOQ is particularly
determined for impurities and degradation products, and is a parameter of quantitative
assays for low levels of compounds in sample matrices (EMEA, 1995). From the calibration
range the LOQ was calculated as 2.51 μg.mL-1.
5.3.2. Influence of polarity on the solubilisation of melatonin
The aim of the study was to produce an oral liquid preparation of melatonin (1 mg.mL-1) using
a single or combination of solubilising enhancers such as saccharides, alcohols, surfactants
and pH. Previous research has shown that melatonin exhibits poor water solubility
(100 μg.mL-1) under polar conditions, due to its lipophillic nature (Hardeland, 2006). The
polarity of a molecule is dependent on the differences between the electro-negativity
between the atoms in a compound and the asymmetry of its structure. The extent of polarity
can dictate the physical properties of a medium including its aqueous solubility. For example,
polar properties exhibited by water results from the uneven sharing of its electrons between
oxygen and hydrogen atoms, with oxygen having greater electro-negativity than hydrogen. In
contrast, non-polar mediums exhibit a uniform sharing of electrons between the carbon and
hydrogen atoms in the molecular structure (e.g. methane), forming straight chains. In order
for the lipophillic melatonin molecule to be solubilised in water, investigation was carried out
in two phases: (1) development of inclusion complex of melatonin with HP-β-CD and (2)
modification of polarity of water.
Phase 1
The use of cyclodextrins as solubilising agent has been widely explored in pharmaceutical
research (Bertau and Jörg, 2004; Shabir and Mohammed, 2010). Cyclodextrins are cyclic
saccharides that are characterised by strong intramolecular proton bridges making the
overall structure of the cyclodextrin a rigid solvent cage for the inclusion molecule (Armstrong
and DeMond, 1984). This enables the lipophillic molecule to bind in a reversible manner to
the inner core of the cyclodextrin ‘cup’, solubilising and protecting the molecule from the
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external aqueous medium. The addition of HP-β-CD in solution (2:1 ratio,
cyclodextrin:melatonin respectively) temporarily enhanced the solubility of melatonin to
1 mg.mL-1 but resulted in drug precipitation upon storage after 2 hours.
Phase 2
In order to prevent precipitation of the drug, the next strategy was to reduce the rigidity of the
cyclodextrin and polarity of the medium (Bertau and Jörg, 2004). The modification of polarity
causes a shift between the undissociated and dissociated states, resulting in solubilisation in
non-polar and polar mediums respectively and thus controlling the extent of solubilisation for
hydrophobic molecules. Polarity can be measured by the dielectric constant which measures
the solvents ability to reduce the field charge of the electric field surrounding a charged
particle. Polar media such as water have a dielectric constant of greater than 50 whereas
semi-polar and non polar media exhibit lower values in the range of 20-50 and 1-20
respectively. The reduction in polarity supports the preferred media conditions for melatonin,
as a hydrophobic drug can easily solubilise in a less polar medium.
Hence an alternative co-solvency method was used to solubilise melatonin in which two
compounds of different polarities were mixed to form a system of optimum polarity (semi-
polar). The 2 components of the semi-polar system included cyclodextrin-water complex
(compound 1) and sorbitol (compound 2). Inclusion of sorbitol within the medium has a dual
effect. It enhances the organoleptic properties of the formulation as a sweetener and reduces
the polarity of the medium due to its alcohol based properties, as pure sorbitol has a
dielectric constant of 35.5 (Ramakrishnan and Prud’homme, 2000). In our study it was
observed that an increase in sorbitol concentration in the CD-water mixture resulted in an
increase in stable solubilised melatonin. Furthermore, in the study carried out by
Ramakrishnan and Prud’homme (2000) they observed that heating sorbitol above 50 oC
reduced the dielectric constant of the medium from polar to non-polar region which in turn
significantly increased the solubility of non-polar compounds. By applying this method to the
present study, melatonin at a concentration of 1 mg.mL-1 was fully dissolved and stabilised in
HP-β-CD, 40 % (w/v) sorbitol and water mixture after being heated to 50 oC. This application
of heat in the solubilisation protocol potentially caused a further reduction in the dielectric
constant of the medium resulting in an increase in the net free energy charge and resulting in
stronger attraction forces between the drug and HP-β-CD and sorbitol.
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5.3.3. Organoleptic optimisation of melatonin in solution (1 mg.mL-1)
In order to formulate a 1 mg.mL-1 melatonin in water, the following excipients were added;
HP-β-CD (2:1 ratio of cyclodextrin: melatonin), 40 % (w/v) sorbitol, potassium sorbate
(preservative) and EDTA (antioxidant and chelating agent). Although the resultant solution
was clear with no unpleasant odour, the formulation had a bitter taste despite the inclusion of
sorbitol as a sweetener. From the study carried out in Chapter 4, it was concluded that pH
can have an underlying affect on the taste of the formulation with alkaline solutions exhibiting
increased bitterness.
The pH of melatonin formulation was alkaline (pH 10.11 + 0.01) which was attributed to the
addition of potassium sorbate and EDTA. Figure 5.4 demonstrates the influence of these
excipients on the pH of the melatonin formulation. In the absence of pH modification (0 % w/v
tartaric acid) an increase in pH was observed with the addition of potassium sorbate (pH
7.18 + 0.02) which further increased with the addition of EDTA (pH 10.11 + 0.01). In order to
acidify the formulation, increments of tartaric acid (0.1-1 % w/v) were added, followed by
Figure 5.4. Influence of tartaric acid, and the subsequent addition of a preservative (potassium
sorbate) and an antioxidant (EDTA), on the pH of the melatonin formulation (1 mg.mL-1). In the
absence of tartaric acid, the addition of potassium sorbate and EDTA caused a rise in pH (pH
10.11 + 0.01). The pH of the formulation containing potassium sorbate and EDTA was reduced to
pH 4.63 + 0.01 and 2.53 + 0.01 in the presence of 0.1 and 1.0 % w/v tartaric acid respectively.
(n=3)
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potassium sorbate and EDTA. It was found that with increasing tartaric acid concentration
from 0.1 % to 1.0 % (w/v), the pH of the formulation decreased from pH 4.63 + 0.01 to pH
2.53 + 0.01 respectively. Under these acidic conditions the bitterness of the formulation had
been eliminated, resulting in a taste-free formulation. Therefore, 0.1 % (w/v) tartaric acid was
added to the melatonin formulation as it sufficiently reduced the pH of the formulation, while
remaining within the acceptable limits for the preservative efficacy of potassium sorbate
(pH<6).
5.3.4. Stability studies
Figure 5.5 demonstrates the stability of melatonin in solution (1 mg.mL-1) after the inclusion
of 0.1 % (w/v) tartaric acid. The formulation was prepared as outlined in section 5.2.2.3 and
stored at 5 oC, 25 oC (40 % humidity) and 40 oC (75 % humidity) for 12 months.
Interestingly samples stored under accelerated conditions (40 oC, 75 % humidity) showed a
reduction in melatonin retention after 3 months (91.80 + 1.73 %), with further reduction after
6 and 12 month analysis (78.08 + 10.35 % and 62.22 + 0.84 % respectively). The reduction
in melatonin concentration can potentially be attributed to three factors: (1) scavenging of
hydroxide radicals (●OH) (Bonnefont-Rousselot et al, 2011), (2) the formation of hydronium
ions from tartaric acid (Figure 4.12), and (3) Le Chatelier’s Principle.
The reaction of tartaric acid with water forms hydronium ions (H3O+) which combines with an
electron and dissociates into a hydroxyl radical and hydrogen:
OH3
+
OH + H2
Le Chatelier’s Principle states that if a dynamic equilibrium is disturbed by changing the
conditions, then the position of the equilibrium moves to counteract this change. Thus at a
storage temperature of 40 oC the equilibrium of H3O+ potentially shifted to the right in order
to lower the temperature by absorbing the extra heat. This forward reaction favoured the
production of hydrogen and hydroxyl radicals, which were rapidly oxidised by melatonin to
produce the oxidised form. Thus the oxidative degradation of melatonin was accelerated with
increase in temperature.
A similar stability profile was observed in the melatonin formulations stored at 5 and 25 oC
(40 % humidity), but to a lesser degree. After 6 months storage, melatonin retention was
reduced to 93.63 + 1.12 and 94.17 + 4.37 % respectively, with a further decrease in
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melatonin retention after 12 months (88.40 + 4.38 % and 91.52 + 0.77 % respectively). It is
possible that lower storage temperature slowed down the production of hydroxyl radicals,
thereby preventing melatonin oxidation.
The organoleptic properties of melatonin remained stable with regard to taste and smell for
formulations stored at 5 and 25 oC with formulations at 40 oC resulting in faint discolouration
which intensified over time. The stability storage conditions had no influence on the pH of
melatonin formulation, which remained stable for 12 months in the region of pH 4.5-4.65
(ANOVA, P>0.05) (Figure 5.6).
Figure 5.5. 12 months stability profile of 1 mg.mL-1 melatonin stored under 5 oC, 25 oC (40 %
humidity) and 40 oC (75 % humidity) conditions. At 5 oC the formulation was observed to have
>90 % drug retention for 6 months, with 91.52 + 0.77 % drug retention after 12 months storage at
25 oC. However, under accelerated conditions (40 oC), melatonin rapidly degraded:
91.80 + 1.73 % at 3 months to 62.22 + 0.84 % after 12 months storage. (n=3)
Figure 5.6. 12 months stability profile of 1 mg.mL-1 melatonin stored under 5 oC, 25 oC (40 %
humidity) and 40 oC (75 % humidity) conditions. Formulation was observed to be stable over the
12 month period (pH 4.5-4.65), with no significant difference between the time points (P>0.05).
(n=3)
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5.4. Conclusion
In conclusion, hydrophobic melatonin was formulated as a 1 mg.mL-1 dosage form in water,
without compromising its lipophillic properties which are essential for cellular transportation.
The drug was solubilised using a dual approach: (1) encapsulating melatonin within the inner
core of HP-β-CD and (2) reducing the polarity of water with the addition of sorbitol
(20 % w/v).
The formulation remained stable for 6 months at 5 oC and for 12 months at 25 oC (>90 %
drug retention). Under accelerated studies (40 oC), the formulation remained stable for 3
months (> 90 % melatonin retention), after which rapid degradation occurred.
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CHAPTER 6
Preservative Efficacy Test (PET)
6.1. Introduction
Investigation of microbial contamination of pharmaceutical products is vital to the
pharmaceutical industry and the World Health Organisation, as it can become a major cause
of product and economic losses, as well as deterioration in the patients’ health or related side
effects. The presence of large quantities of water in pharmaceutical drug preparation can
make them susceptible to microbial growth, with microorganisms causing organoleptic
alterations such as spoilage of product, unpleasant odour, and changes in the physical
appearance (colour, turbidity, viscosity) as well as reduced therapeutic effect (Narang et al,
2009; Chorilli et al, 2011). In order to minimise the risk of spoilage by contaminants,
preservatives are included within the formulation that kill low level of contaminants during the
manufacturing process, storage and handling during frequent dosing (Narang et al, 2009).
The chosen preservatives in a given formulation must therefore be stable for the shelf life of
the formulation (Zani et al, 1997).
Pharmaceutical preservatives that have been listed as GRAS are used to reduce the
likelihood of microbial growth in aqueous systems. Ideal preservative characteristics include
broad spectrum of activity, active within the formulation at low concentration and effective
within the pH range of the formulation.
In order to evaluate the effectiveness of the preservative within the pharmaceutical
preparation, the BP and USP guidelines recommend a preservative efficacy test (PET) to be
carried out. This challenge test involves the inoculation of microorganisms into the product,
followed by the calculation of the loss of microbial viability over a period of 28 days. In
accordance with BP and USP standards, the microbes that should be investigated include
Gram-positive (S.aureus) bacteria, Gram-negative bacteria (E.coli, P.aerginosa), mould
(A.niger), and yeast (C.albicans).
The aim of the study was to evaluate the activity of the preservatives and the formulation on
the microbes specified for the PET challenge.
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6.2. Materials and Method
6.2.1. Materials
Trypton soya agar, Sabroud dextrose agar, sodium chloride, polysorbate 80, tween 80,
sodium bisulphite, sodium thiosulphate pentahydrate, thioglycollate, L-cysteine, and Lecithin
were supplied by Sigma (UK).
6.2.2. Method
6.2.2.1. Preparation of neutraliser
In a 1 L sterile glass bottle the following ingredients were added to 500 mL distilled water, at
a pH of 7: 60 mL tween 80, 12.5 mL sodium bisulphite (40 % w/v), 7.845 g sodium
thiosulphate pentahydrate, 5 g thioglycollate, 1.5 g L-cysteine, and 2 g Lecithin. The mixture
was then autoclaved and left to stir until all components had fully dissolved. The final volume
was made up to 1 L with sterilised distilled water.
6.2.2.2. Preparation of the inocculum
All bacterial species were inoculated on Tryptone soya agar culture plates. Using the
‘streaking’ method, the surface of the agar was inoculated with E. coli ATCC 8739, and then
placed in an incubation oven for 24 hours at 35 oC. This was repeated using P. aeruginosa
ATCC 9027 and S. aureus ATCC 6538.
C. albicans ATCC 10231 was inoculated on Sabroud dextrose agar using the ‘streaking’
method and then placed in incubation cabinets for 48 hours at 25 oC.
A. niger ATCC 16404 was inoculated on Sabroud dextrose agar using the ‘streaking’ method
and then placed in incubation cabinets for 1 week at 25 oC.
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6.2.2.3. Harvesting bacteria and C. albicans
Using a sterile loop, colonies of the microbe were extracted from the surface of the culture
plate and placed into 10 mL of suspending fluid A (9 g.L-1 sodium chloride) in a sterile glass
bottle to achieve a final concentration of 108 CFU.mL-1. The sample was vortexed to produce
a suspension of microbial cells. The concentration of microbial cells present in the
suspended fluid was analysed on UV spectrophotometer using an ‘in-house’ calibration table
(Table 6.1).
6.2.2.4. Harvesting A. niger
Once sporulation was obtained, 10 mL of suspending fluid B (9 g.L-1 sodium chloride with
0.5 g.L-1 polysorbate 80) was pipette onto the surface of the colonised agar plate. A sterile
spreader was used to gently release the spores, which were then pipetted into a sterile glass
bottle and vortexed. To achieve a 108 CFU.mL-1 concentration, the spores were counted
using a haemocytometer plate and the concentration was determined using the following
equation:
CFU.mL-1 = mean number of spores x dilution factor x 104
The concentration of A. niger was then adjusted using suspending fluid B if required.
Micro-organism Absorbance Concentration(CFU.mL-1)
Absorbance at 570 nm
S. aureus 0.30 5x108
E. coli 0.45 5x108
P. aeruginosa 0.70 8x108
Absorbance at 420 nm
C. albicans 2.03 2x108
Table 6.1. ‘In-house’ calibration of known concentrations of bacteria and C. albicans.
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6.2.2.5. Inoculation of pharmaceutical preparation
10 mL of the following preparations were prepared and stored in sterile amber glass bottles;
captopril formulations with EDTA (Section 2.2.3.3.1) and EDTA-HPβCD (Section 2.2.3.3.2),
gliclazide with L-arginine (Section 3.2.4.1.) and pluronic F127-ethanol (15 % v/v) (Section
3.2.4.2.) L-arginine (Section 4.2.2.3.), and melatonin (Section 5.2.2.3.). Each of these
formulations was prepared in triplicate for the individual microbes to be tested.
For the inoculation of E. coli, 100 μL of the microbial cell suspension (108 CFU.mL-1) was
added to each of the formulation vials to achieve a final microbial concentration of
106 CFU.mL-1. The samples were vortexed and sealed, and then placed in an incubator for
28 days. Samples were taken after 7, 14, and 28 days. This procedure was repeated for the
other microorganisms.
6.2.2.6. Preservative efficacy test
All of the samples were vortexed prior to microbial analysis. 1 mL of the inoculated sample
was placed into a sterile vial containing 9 mL of neutraliser and vortexed. 1 mL of this sample
was then plated on to either Tryptone soya agar for bacteria or Sabroud dextrose agar for
fungi using the ‘pour-plate’ method, and stored accordingly (protocol 6.2.2.2.).
The preservative efficacy of the preservatives in each formulation against bacteria and
C. albicans was assessed by counting the number of colonies formed on the agar plates.
The preservative efficacy against A. niger was assessed by adding 10 mL of suspending fluid
B onto the surface of the colonised agar plate. A sterile spreader was used to gently release
the spores, which were then pipette into a sterile glass bottle and vortexed. The sample was
analysed using a haemocytometer plate.
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6.3. Results and discussion
6.3.1. Preservative activity against Bacteria
6.3.1.1. Structure of bacteria
Bacteria are composed of a large group of unicellular, prokaryotic microorganisms that are
able to produce spores in the dormant form that are potentially able to further contaminate
surfaces upon contact. There are two main classes of bacteria, Gram-positive and Gram-
negative, which can be fundamentally differentiated by their outer cell wall compositions. The
internal structure of the bacteria is similar in both types.
A structural representation of the bacteria cell is illustrated in figure 6.1, from which the
differences between the Gram-positive and Gram-negative bacterial structures can be clearly
depicted. The general structure of the bacteria consists of a cell wall, cytoplasmic membrane
and cytoplasm (Figure 6.1a). The cell wall surrounds the inner cytoplasmic membrane
providing structural support and rigidity to the cell, as well as protecting the cytoplasmic
membrane from rupture due to high osmotic pressure (Russell and Chopra, 1996). In order
for preservatives to have bacteriostatic (inhibit bacterial growth) or bactericidal (cause
bacterial death) properties, the compounds must first cross the bacterial cell wall.
The outer cell wall of Gram-negative bacteria is composed of a phospholipid layer protected
by an outer layer of lipopolysaccharides (LPS). Imbedded within this outer membrane are
transport proteins and porins which are utilised by the bacteria in the regulation of movement
of substances into and out of the cell. This outer membrane has a structural resemblance to
the cytoplasmic membrane, a structural feature unique to only Gram-negative bacteria. The
inner cell wall is composed of a thin layer of peptidoglycan, a disaccharide polymer that is
able to contribute to the mechanical stability of the cell walls. The medium between the outer
membrane and the peptidoglycan consists of periplasm (Figure 6.1b).
In Gram-positive bacteria the inner cell wall is composed of secondary wall polymers
(teichoic acids), polysacchacarides, proteins and lipocarbohydrates that are convalently
cross-linked with peptidoglycan. The composition of the outer membrane is similar to the
inner membrane and so there is no periplasm. Additional surface appendages (pili, capsules,
flagellae) are able to attach themselves to the cell wall initiating pathogenesis of bacterial
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Figure 6.1. Schematic representations of (A) Bacterial cell, (B) Gram-negative bacteria cell, and (C) Gram-positive bacteria cell. (Modified from Russel and Chopra, 1996).
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infections (Figure 6.1c). It is the structure of the outer membrane that makes Gram-positive
bacteria more susceptible to biocides than Gram-negative bacteria.
In order for preservatives to be affective as biocides they must be able to transport
themselves through the bacteria cell wall or be able to apply direct action on the components
of the cell wall, thus destabilising the cell and causing the cell to burst and release its
cytoplasmic contents. Table 6.2 highlights the 5 main factors influencing the activity of
preservatives, which include: time of exposure, temperature, concentration, pH, and the type
of micro-organism (Russell and Chopra, 1996).
Factors affecting
preservative activity Discussed
Time of exposure Increasing exposure time increases the extent of bacterial
cells death.
Temperature Increasing temperature increases the chemical activity of
most preservatives.
Concentration By increasing the preservative action the rate of bacterial
inactivation increases. The rate of inactivation varies from
preservative to preservative.
PH Changes in pH cause alterations on the bacterial cell wall.
For example an increase in pH causes the bacterial cell to
display a more anionic surface charge.
Type of micro-organism Order of bacterial sensitivity:
Spores > acid-fast bacteria > Gram-negative > Gram positive
Table 6.2. Summary of factors enhancing preservative efficacy
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6.3.1.2. Self-preserving formulations
Self-preserving is defined as having preservative actions in the absence of preservative
agents, with the conditions of the formulations being sufficient to be bactericidal and
bacteriostatic. These conditions include; low or high pH, low osmotic pressure (available
water (aw), multifunctional excipients with antimicrobial properties (alcohols, sweeteners,
chelating agents) and a combination affect of these (synergy effects).
The captopril formulations described in Chapter 2 (Section 2.2.3.3.) were hypothesised to be
a self-preserving formulation, as they contained no specific preservative. The two
formulations taken forward in this study consisted of EDTA and captopril solubilised in water
(Formula 1), and EDTA, captopril, and HPβCD solubilised in water (Formula 2), with the pH
of the final solutions being acidic (pH 3.4). In order to understand the self-preservative
actions of these formulations it was first necessary to highlight the physical and chemical
stresses that could be induced on bacterial cells such as acidic environment, low aw,
chelating agents, surface acting agents, free fatty acids and nutrient depletion (starvation).
All of these factors cause cellular injury to the microbial cell, either by altering the membrane
permeability, altering its enzyme function, degrading the ribosomes enclosed within the
cytoplasm, or by increasing the microbial cells sensitivity towards selective agents.
6.3.1.2.1. Preservation efficacy using acidic medium
Bacteria (Gram-positive and Gram-negative) require specific conditions for optimum growth;
these include ambient temperatures, good nutrient supply, but most importantly a neutral pH
environment (pH 7). By altering any one of these conditions (such as lowering of
temperature), the rate and extent of bacterial growth reduces until a dormant phase is
reached. On the other hand, upon altering the pH to more extreme conditions, the micro-
organisms spend greater amount of energy to maintain the pH and ionic strength gradients
across the cytoplasmic membrane, eventually leading to cell lysis (Miller, 1969) or a
disruption of the cellular membrane causing cytoplasmic leakage (Kabara and Orth, 1997).
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Figure 6.2. Preservative efficacy of captopril formulations at pH 3.4 on Gram-negative and Gram-
positive bacteria, after 28 days incubation under 25 oC (75 % humidity) conditions. (A) Captopril
with 0.1 % (w/v) EDTA, and (B) Captopril with 0.1 % (w/v) EDTA and HPβCD. Both formulations
exhibited a log reduction of 5 after 7 days, with further inhibition after 28 days inoculation. (n=3)
(A)
(B)
1.0x101 CFU.mL-1 2.7x101 CFU.mL-1 1.3x101 CFU.mL-
1
0.3x101 CFU.mL-1 1.0x101 CFU.mL-
1
1.0x101 CFU.mL-1
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The pH of the captopril self-preserving formulations containing EDTA and EDTA-HPβCD was
3.4. Figure 6.2 highlights the effectiveness of these preservative-free formulations against
both Gram-negative (E. Coli and P. aeruginosa) and Gram-positive bacteria (S. aureus).
After 7 days incubation, the number of colony forming units (CFU.mL-1) was observed to
have declined by a log10 reduction of 5. According to BP guidelines, a log10 reduction of 3
must be achieved for the formulations to pass the preservative efficacy test. After 28 days
incubation no further increase in bacterial colony re-growth was observed. These
observations were observed to be consistent for both formulations 1 and 2, both of which
were acidic in nature and contained EDTA (chelating agent) (Figure 6.2).
6.3.1.2.2. Preservative efficacy using chelating agents on Gram-negative
bacteria.
The acidity of the captopril formulations possibly provided optimum conditions for the
preservative efficacy of EDTA. Under acidic pH conditions (< pH 3), EDTA is fully ionised and
is able to complex with and inactivate metal ions present in the medium (Kristensen et al,
2008).The chelating agents are anionic in nature, and thus are able to act by binding to
cationic alkaline earth and heavy metal ions, such as copper, manganese and phosphate
(Kabara and Orth, 1997). Gram-negative bacteria contain divalent cations (Figure 6.3a) on
the outer cell wall, thus have greater sensitivity towards chelating agents than Gram-positive
bacteria.
EDTA is a chelating agent that has been GRAS listed, is inexpensive and is effective in small
quantities. Most importantly it was reported to have preservative efficacy against Gram-
negative bacteria in 1958 by Mac Gregor and Elliker. The chelating agent acts by having a
lysis affect on the outer cell wall of the Gram-negative bacteria, thereby increasing the
permeability (permeabiliser) of the outer membrane. As seen from figure 6.3a the outer
membrane of Gram-negative is maintained by a number of structural bodies, such as
hydrophobic lipopolysaccharide (LPS)-LPS and LPS-protein interactions and divalent cations
(Mg2+) which stabilise the strong anionic charges of the oligosaccharide chain of the LPS
molecule. In the presence of EDTA, the chelating agent is able to bind to these cations
(Figure 6.3b), destabilising the outer membrane by releasing the LPS molecules and
exposing the non-polar phospholipids attached to the inner membrane below (Figure 6.3c).
The phospholipids are composed of two parts; hydrophilic heads and hydrophobic tails. Upon
their exposure, the phospholipids are forced to quickly realign themselves to form a
hydrophobic core, resulting in the cell wall folding upon itself causing partial solubility and
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permeability of the cell wall, exposing the cytoplasmic contents beneath. This partial
permeability of the cell wall allows for the movement of intracellular solutes out of the cell
(Figure 6.3d), ultimately causing cell lysis. It can therefore be hypothesized that EDTA acts
as a preservative agent by increasing cell permeability.
6.3.1.2.3. Conclusion.
The preservative-free captopril formulations 1 and 2 inhibited the growth of Gram-negative
and Gram-positive bacteria cells eventually leading to cell lysis. The Gram-negative bacteria
were attacked using a synergistic effect of chelating agent with acidic medium, whereas the
Gram-positive bacteria were predominantly affected by the acidic pH of the medium in the
formulations. Although EDTA was able to act as an antimicrobial, it can also act in synergy
with other commonly used pharmaceutical preservatives (such as potassium sorbate)
enhancing their preservative action.
6.3.1.3. Synergistic effect of EDTA with potassium sorbate
EDTA was used as an antioxidant and as an enhancer of the antimicrobial properties of
potassium sorbate in the melatonin formulation (Section 5.2.2.3.). The formulation was
prepared at pH 4.5 to maximise the antibacterial and antifungal properties of potassium
sorbate, as the preservative had minimal antimicrobial properties above pH 6 (Rowe et al,
2006). At pH 4.5 potassium sorbate, although mainly in the undissociated form (pKa = 4.74),
was expected to remain effective in inhibiting bacterial growth (Beales, 2004).
The effect of potassium sorbate on the inhibition of Gram-negative and Gram-positive
bacteria is presented in figure 6.4 and table 6.3. After 7 days incubation with S. aureus,
P. aeruginosa and E. coli, melatonin formulation exhibited strong antibacterial properties with
the number of viable microorganisms being reduced by a log10 reduction of 5. After 28 days
S. aureus and E. coli growth was completely inhibited. The inhibition of the Gram-negative
and Gram-positive bacteria was possibly associated with the synergistic effect of EDTA,
potassium sorbate and acidic pH. EDTA possibly influenced the permeability of the cell wall
of gram-negative bacteria (as described in Figure 6.3), allowing for the movement of
potassium sorbate into the bacterial cell to initiate bactericidal properties. The Gram-positive
bacterium (S. aureus) was inhibited by the synergistic effect of acidic pH of the medium
(pH 4.5) acting on the cell wall, modification of internal pH of the cell as potassium sorbate
transgressed through the cell wall into the cytoplasm (Figure 6.5).
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Figure 6.3. Schematic representation of the affect of EDTA on a Gram-negative bacteria cell
wall. (A) Gram-negative bacteria cell wall, (B) EDTA removes the divalent cations binding the
LPS to the cell wall, (C) LPS are detached from the cell wall exposing the phospholipid layer,
(D) Partial permeability of the cell wall causes cytoplasmic contents to leak out of the cell,
resulting in cell lysis.
(A)
(B)
(C)
(D)
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Figure 6.4. Preservative efficacy of potassium sorbate in the melatonin formulation against Gram-
positive (S. aureus) and Gram-negative (P. aeruginosa and E. coli) bacteria. After 28 days there was
complete inhibition of S. aureus and E. coli. The number of viable P. aeruginosa colonies observed a
log10 reduction of 5. (n=3)
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Bacteria Day 7 Day 14 Day 28
S. aureus
P. aeruginosa
E. coli
Table 6.3. Tryptone soya agar plates cultured with bacteria after inoculation with potassium
sorbate in the melatonin pharmaceutical preparation. Samples were cultured on days 7, 14 and 28.
The preservative was found to be effective in inhibiting Gram-positive and Gram-negative bacteria
growth in the oral liquid formulation. (n=3)
2x101 CFU.mL-1 0.3x101 CFU.mL-1
Complete
1.0x101 CFU.mL-1 0.3x101 CFU.mL-1 1.0x101 CFU.mL-1
1.3x101 CFU.mL-1 0.3x101 CFU.mL-1 0.7x101 CFU.mL-1
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Figure 6.5. A schematic representation of the antimicrobial mechanism of potassium sorbate
(C6H9O2K) in the presence of EDTA on a Gram-negative cell. (A) The reaction is initiated by EDTA
removing the divalent cations binding the LPS to the cell wall. (B) The exposed LPS layer enables
potassium to migrate through the outer membrane, into the periplasm and peptidoglycan, and
through the inner membrane into the cytoplasm. The neutral pH of the cytoplasm dissociates
potassium sorbate into sorbic acid and K+. As the concentration of sorbic acid increases in the
cytoplasm, the internal pH of the cell decreases until cellular activity is inhibited (modified from
Beales, 2004).
Cytoplasm
Cell Wall
Surrounding
formulation
medium
pH 4.5
(A)
(B)
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6.3.1.4. Preservative affects of sodium benzoate
Sodium benzoate was used as a preservative agent in the L-arginine formulation that was
prepared at pH 4 with 40 % (w/v) sorbitol (Section 4.2.2.3). Figure 6.6 and table 6.4
highlights the preservative efficacy of sodium benzoate against Gram-negative and Gram-
positive bacteria. It was observed that after 7 days inocculation with the microorganisms, the
number of viable cells of E. coli was 102 CFU.mL-1 thereby exhibitng a log10 reduction of 4,
with S. aureus and P. aeruginosa exhibiting a log10 reduction of 5. After 28 days no further
growth of bacterium was observed, with sodium benzoate achieving complete inhibition of
S.aureus.
Figure 6.6. Preservative efficacy of sodium benzoate in the L-arginine formulation against Gram-
positive (S. aureus) and Gram-negative (P. aeruginosa and E. coli) bacteria. A gradual inhibition of
E. coli was observed, with a microbial concentration of 2x102 CFU.mL-1 present after 7 days
inoculation, decreasing to 1x101 CFU.mL-1 after 28 days inoculation. P. aeruginosa was observed
to have 101 CFU.mL-1 remaining, with there being complete inhibition of S. aureus after 28 days
inoculation. (n=3)
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Bacteria Day 7 Day 14 Day 28
S. aureus
P. aeruginosa
E. coli
Table 6.4. Tryptone soya agar plates cultured with bacteria after inoculation with sodium benzoate in
the L-arginine pharmaceutical preparation. Samples were cultured on days 7, 14 and 28. The
preservative was found to be effective in inhibiting Gram-positive and Gram-negative bacteria growth
in the oral liquid formulation. (n=3)
6.0x101 CFU.mL-1 1.3x101 CFU.mL-1
Complete inhibition
2.0x101 CFU.mL-1 0.7x101 CFU.mL-1 1.3x101 CFU.mL-1
4.73x102 CFU.mL-1 1.3x101 CFU.mL-1 1.0x101 CFU.mL-1
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Figure 6.7. demonstrates the bactericidal actions of sodium benzoate on the bacterial cell.
Under acidic conditions (pH 2-5), sodium benzoate remains mainly in the undissociated form
with high lipid solubility (Rowe et al, 2006). This lipophillic nature of sodium benzoate
enables it to accumulate on the surface of the bacterial cell and is transported across the
phospholipid layer of the cell wall (Chen et al, 1996). Once the preservative enters the
cytoplasm of the bacterial cell (pH 7), the change in pH causes sodium benzoate to
dissociate into benzoic acid and its sodium proton. As the concentration of benzoic acid
increases within the cytoplasm of the cell, the intracellular pH increases in acidity causing
inhibition of bacterial cellular activity (Krebs et al, 1983).
Figure 6.7. A schematic representation of the antimicrobial mechanism of sodium benzoate on the
Gram-negative cell. The accumulation of sodium benzoate on the surface of the bacterial cell wall
causes an influx of the preservative into the cell (modified from Chen et al, 1996).
Cytoplasm
Cell wall
External
medium
Sodium benzoate
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6.3.1.5. Preservative affects of parabens
In Chapter 3, two protocols were established in solubilising Gliclazide in water. The first
method was based on using L-arginine (Section 3.2.4.1) and the second included Pluronic
F127 and 15 % (v/v) ethanol (Section 3.2.4.2). Both formulations displayed alkaline pH
profiles of pH 8 and pH 9 respectively, which were ideal conditions for propyl- and butyl-
parabens to exert their antibacterial effects. Parabens are alkyl esters of p-hydroxybenzoic
acid with broad antimicrobial properties, particularly against yeast and moulds, and are
relatively stable over the pH range (Nguyen et al, 2005).
Figure 6.8 highlights the preservative efficacy of the parabens against Gram-positive and
Gram-negative bacteria. After 7 days of inoculation with the microorganisms, the number of
viable bacterial cells was reduced to 1.0x101, 6.3x101, and 1.7x101 CFU.mL-1, for E. coli,
S. aureus, and P. aeruginosa respectively. After 28 days inoculation, E. coli and S. aureus
exhibited further reduced growth with the number of viable bacterial cells being reduced to
0.7x101 and 0.3x101 CFU.mL-1 respectively. No further inhibition of P. aeruginosa was
observed after 28 days inoculation (Table 6.5).
Figure 6.8. Preservative efficacy of propyl- and butyl- paraben in the Gliclazide formulation
containing L-arginine against Gram-positive (S. aureus) and Gram-negative (P. aeruginosa and
E. coli) bacteria. After 7 days inoculation the number of viable cells was reduced by a log of 5,
which was maintained or further reduced by day 28. (n=3)
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Bacteria Day 7 Day 14 Day 28
S. aureus
P. aeruginosa
E. coli
Table 6.5. Tryptone soya agar plates cultured with bacteria after inoculation with parabens in the
Gliclazide-L-arginine pharmaceutical preparation. Samples were cultured on days 7, 14 and 28. The
preservative was found to be effective in inhibiting Gram-positive and Gram-negative bacteria growth
in the oral liquid formulation. (n=3)
6.3x101 CFU.mL-1 2.7x101 CFU.mL-1 0.3x101 CFU.mL-1
1.7x101 CFU.mL-1 0.7x101 CFU.mL-1 2.3x101 CFU.mL-1
1.0x101 CFU.mL-1 1.7x101 CFU.mL-1 0.7x101 CFU.mL-1
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Figure 6.9 and table 6.6 show similar preservative efficacy of the parabens against Gram-
positive and Gram-negative bacteria when prepared in the Gliclazide formulation containing
pluronic F127 and 15 % (v/v) Ethanol. After 7 days inoculation with the microorganisms, the
number of viable bacterial cells was reduced to 0.7x101, 0.7x101, and 1.7x101 CFU.mL-1, for
E. coli, S. aureus, and P. aeruginosa respectively. After 28 days, no further growth of
inhibition of E. coli and P. aeruginosa was observed, whereas S. aureus exhibited complete
inhibition.
The bactericidal actions of the Gliclazide formulations were initiated by parabens which work
in synergy to cause damage to the cytoplasmic membrane and thus inducing intracellular
leakage through the cell wall (Furr and Russell, 1972; Soni et al, 2001; Nguyen et al 2005).
Although the main antibacterial properties of the parabens involves their inhibitory effect on
oxygen consumption and most oxidative enzymes, the exact mechanism by which this
occurs remains relatively unknown (Soni et al, 2001).
Figure 6.9. Preservative efficacy of propyl- and butyl- paraben in the Gliclazide formulation
containing Pluronic F127 and ethanol (15 % v/v) against Gram-positive (S. aureus) and Gram-
negative (P. aeruginosa and E. coli) bacteria. Complete inhibition of S. aureus was achieved after
28 days, with the number of viable Gram-negative cells being reduced by a log10 of 5. (n=3)
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Bacteria Day 7 Day 14 Day 28
S. aureus
P. aeruginosa
E. coli
Table 6.6. Tryptone soya agar plates cultured with bacteria after inoculation with parabens in the
gliclazide-ethanol (15 % v/v) pharmaceutical preparation. Samples were cultured on days 7, 14 and
28. The preservative was found to be effective in inhibiting Gram-positive and Gram-negative
bacteria growth in the oral liquid formulation. (n=3)
0.7x101 CFU.mL-1 0.3x101 CFU.mL-1
1.7x101 CFU.mL-1 0.3x101 CFU.mL-1
0.7x101 CFU.mL-10.7x101 CFU.mL-1 0.7x101 CFU.mL-1
1.7x101 CFU.mL-1
Complete
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6.3.2. Preservative activity against Fungi
6.3.2.1. Fungi structure and classification
In contrast to bacterial cells (prokaryotic), fungi cells are eukaryotic in structure containing
complex structures such as; mitochondria, golgi apparatus, microtubules and a nucleus
enclosing the cellular DNA (Murray et al, 2002). Their cell wall is structurally different from
the bacterial cell wall and comprises of an outer layer of mannoproteins forming a matrix with
β-glucan and chitin, and an inner phospholipid membrane containing trans-membrane
proteins (plasmalemma) (Figure 6.10). It is this outer cell wall that further differentiates fungal
cell from mammalian cells (also eukaryotic cells).
Fungi are classified into three types based on their morphology; (1) threadlike tubular
filaments (hypha), (2) group of hyphae (mycelium), and (3) single cell units reproducing by
budding (yeast). However the morphology of fungi cannot be fixed as some fungal species
(e.g. C. albicans) are dimorphic and opportunistic, and thus are able to exist in mycelium or
yeast morphology depending on the growth conditions (Rose and Barron, 1983; Murray et al,
2002).
Figure 6.10. A schematic representation of a eukaryotic cell wall. The outer cell wall provides
adhesion molecules and is composed of mannoproteins stabilised by β-glucan and chitin, with the
inner cell wall composed of a phospholipid membrane regulating the transport of substances into the
cell through transport proteins. (Modified from Grubb et al, 2008)
Cell wall
mannoproteins
β-glucan
Chitin
Phospholipid
cell membrane
Transport
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6.3.2.2. Preservative efficacy against C. albicans
C .albicans is an opportunistic fungi found on human mucosal surfaces, existing in the yeast
form when placed in acidic-to-neutral conditions. (Grubb et al, 2008 and Bamford et al,
2009). Therefore oral pharmaceutical formulations stored in multi-dose containers must have
sufficient antifungal properties to prevent proliferation.
Figure 6.11 highlights the antifungal efficacy of preservative-free captopril formulations
(Section 2.2.3.3) against C. albicans. In the absence of a preservative, after 7 days the
number of viable microbes was reduced to 104 CFU.mL-1, achieving a log10 reduction of 2.
After 28 days no increases or reduction in the number of C. albicans was observed for either
of the captopril formulations (Table 6.7). In contrast to bacterial cells, the growth of
C. albicans decreases with increasing environmental pH conditions, with optimum microbial
growth occurring at pH 6 (Faergemann et al, 2000). The initial decrease in microbial growth
seen in figure 6.11 was attributed to the microbe being more sensitive to environmental
change at the beginning of its growth. Thus as the yeast cells attempt to replicate by
budding, the newly formed cells consequently lyse (Aboellil and Al-Tuwaijri, 2010).
Figure 6.11. Preservative efficacy of captopril formulations containing EDTA (formulation 1) and
EDTA with HPβCD (formulation 2) against C. albicans. After 7 days, the growth of the yeast has
been reduced by a 102 CFU.mL-1, with no further reduction of increase in the number of viable
microbes being observed after 28 days. (n=3)
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The preservative affect of potassium sorbate, sodium benzoate and parabens on the
microbial growth of C. albicans is illustrated in figure 6.12 and table 6.8. After 7 days
inoculation with the yeast, the number of viable microbial cells was reduced to
1x104 CFU.mL-1 by potassium sorbate and sodium benzoate. After 28 days, the number of
viable microbial cells was further reduced to 1.3x101 CFU.mL-1 (potassium sorbate) and
6.33x102 CFU.mL-1 (sodium benzoate), thus achieving a preservative efficacy by a log10
reduction of 5 and 4 respectively. The inhibition of yeast was associated to the ability of the
preservatives to transgress through C. albicans cell wall and into the cytoplasm. The neutral
pH of the cytoplasmic fluid initiates the reaction of the undissociated form of the
preservatives into their respective dissociated forms, thereby increasing toxicity and inhibiting
cell growth (Beales, 2004).
Captopril
formulation
Day 14 Day 28
EDTA
EDTA-HPβCD
Table 6.7. Sabroud dextrose agar plates cultured with C. albicans after inoculation with preservative-
free captopril formulations. Samples were cultured on days 7, 14 and 28. The formulations were found
to be ineffective in inhibiting the yeast despite the acidic pH of the pharmaceutical preparations. (n=3)
6.3x104 CFU.mL-1 4.5x104 CFU.mL-1
7.5x104 CFU.mL-1 4.0x104 CFU.mL-1
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Figure 6.12 and table 6.8 displays the biocidal properties of gliclazide formulations against
C. albicans, with the parabens working in synergy with the alkaline pH of the formulations
(pH 8-9). Within 7 days of inoculation, the parabens (gliclazide-ethanol formulation, pH 9)
had completely destroyed the yeast cells, with no re-growth occurring within the 28 day test
period. In the absence of ethanol (gliclazide-L-arginine formulation, pH 8), parabens possibly
had an inhibitory affect on the oxidative enzymes within the cytoplasm (Soni et al, 2001)
thereby causing cell death and a reduction in the number of viable cells by 105 CFU.mL-1 at
day 7, with almost complete inhibition occurring by day 28 (0.3x101 CFU.mL-1). The latter
formulation exhibited slightly slower biocidal affects which was attributed to the lowered
alkaline environment in comparison to the former formulation. It was known that inhibition of
C. albicans increased with increasing pH above 6 (Faergemann et al, 2000).
Figure 6.12. Preservative efficacy of; potassium sorbate (melatonin formulation), sodium
benzoate (L-arginine formulation), parabens (gliclazide-L-arginine formulation) and
parabens with ethanol (gliclazide-ethanol formulation) against C. albicans. After 7 days
inoculation, potassium sorbate and sodium benzoate achieve a microbial reduction of
102 CFU.mL-1, with the number of viable cell decreasing to 101 and 102 CFU.mL-1 by day
28. The parabens exhibited excellent biocidal properties against C. albicans with
complete inhibition by day 14. (n=3)
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Preservatives Day 7 Day 14 Day 28
Potassium sorbate 1.3x101 CFU.mL-1
Sodium benzoate 6.33x102 CFU.mL-1
Parabens
Parabens in the
presence of ethanol
(15 % v/v)
Table 6.8. Sabroud dextrose agar plates cultured with C. albicans after inoculation with formulations
containing; potassium sorbate, sodium benzoate, parabens, or parabens in the presence of ethanol
(15 % v/v). Samples were cultured on days 7, 14 and 28. The formulations were found to be effective
in inhibiting yeast cells. (n=3)
1.0x104 CFU.mL-1 1.0x10
4 CFU.mL-1
2.16x104 CFU.mL-11.0x104 CFU.mL-1
1.7x101 CFU.mL-1 0.3x101 CFU.mL-1 0.3x101 CFU.mL-1
Complete Complete Complete
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6.3.2.3. Preservative efficacy against A.niger
A. niger is classified as a filamentous fungi with hyphe morphology. Its structure enables
production of club-shaped cell (ascomycete) spores. These cells are rich in supply of a range
of hydrolytic and oxidative enzymes that are susceptible to attack by antimicrobial agents
(Baker, 2006). In the presence of antimicrobial preservatives, almost complete inhibition of
A. niger was achieved within 7 days of inoculation (Figure 6.13 and Table 6.9). After 28 days
inoculation, the parabens had effectively eliminated majority of the fungal cells, with the
microbial cell count in the presence of potassium sorbate and sodium benzoate being
reduced to 0.3x101 and 0.7x101 CFU.mL-1 respectively, achieving a log10 reduction of 5. The
eradication of the microbial cells was possibly associated with the increase of β-glucan
sensitivity to alkaline conditions (pH> 5) (Shenoy et al, 1984), thereby being more
susceptible to attack in the early stage of microbial growth. The parabens exhibited biocidal
actions by inhibiting the oxidative enzymes and causes cell starvation and death (Soni et al,
2001).
Figure 6.13. Inhibition of A. niger by preservative-containing formulations within 28 days of
inoculation. The rich oxidative enzymes within the microbial cell allowed for the complete inhibition
of A. niger within 7 days of inoculation. After 28 days, formulations containing parabens had
eradicated the fungi, with the microbial cell count being reduced to 0.3x101 and 0.7x101 CFU.mL-1
by potassium sorbate and sodium benzoate respectively. (n=3)
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Preservative Day 7 Day 14 Day 28
Potassium sorbate
Sodium benzoate
Parabens
Parabens in the
presence of
ethanol (15 % v/v)
Table 6.9. Sabroud dextrose agar plates cultured with A. niger after inoculation with formulations
containing; potassium sorbate, sodium benzoate, parabens, or parabens in the presence of ethanol
(15 % v/v). Samples were cultured on days 7, 14 and 28. The formulations were found to be effective
in inhibiting fungi cells. (n=3)
1.3x101 CFU.mL-1 0.3x101 CFU.mL-11.3x10
1 F . L-1 72.0x10
1 CFU.mL-1
Complete CompleteComplete l t
8.7x101 CFU. L-10.3 1 .m -1
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6.4. Conclusion
The preservative efficacy test was aimed to challenge the efficacy of the antimicrobials when
placed in a pharmaceutical preparation containing active constituents. This was essential
with preparations being stored in multi-dose containers that were susceptible to microbial
contamination. According to the BP (2009), the criteria of acceptance for oral preparations
was a log10 reduction of 3 and 1 for bacteria and fungi respectively, with no further increase
in growth within 28 days of incubation. The study has shown that all the different formulations
had sufficient preservative activity against both bacterial as well as fungal microbes.
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CHAPTER 7
Solubilisation of a proton pump inhibitor (lansoprazole)
using nano-particulate delivery
7.1. Introduction
7.1.1. Therapeutic effect of proton pump inhibitors (PPI’s)
Proton pump inhibitors (PPI’s) are a specialised class of anti-secretory drugs used to treat
peptic ulcer, gastroeosophageal reflux, dyspepsia, gastrinomas, Barett’s oesophagus and
laryngopharyngeal reflux. They act by preventing the secretion of H+ ions into the gastric
lumen and lowering acid production by blocking the gastric proton pump of the parietal cells
(terminal stage in gastric secretion).
7.1.1.1. Structure, mechanism of action and metabolism of lansoprazole
Lansoprazole (PPI) is a substituted benzimidazole, [[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-
pyridyl] methyl] sulfinyl] benzimidazole (Figure 7.1), with a molecular weight of 369.37 and
pKa 17.3. The molecule is relatively lipophillic with a water solubility profile of 0.97 mg.L-1.
This enables the molecule to readily cross the cell membranes into acidic intracellular
compartments, resulting in protonation of the drug into its active form and allowing it to
covalently and irreversibly bind to the gastric pump resulting in its deactivation.
Lansoprazole ultimately blocks the final step in acid production. This is carried out by
suppressing the gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme
system at the secretory surface of the gastric parietal cell (Wallmark et al, 1983). The extent
of acid inhibition can be dose related and leads to inhibition of the basal and the stimulated
gastric acid secretion, regardless of the stimulus.
Lansoprazole can be metabolised in two ways. The first is by S-mephenytoin 4¢-hydroxylase
(CYP2C19) which converts lansoprazole to hydroxylansoprazole (Shirai et al, 2002). The
second method involves partial conversion to lansoprazole sulphone by CYP3A4 followed by
full metabolism to hydroxylansoprazole sulphone by CYP2C19 (Pearce et al, 1996). Both
metabolised products are then excreted in the urine.
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7.1.1.2. Current dosage forms
Currently lansoprazole is only marketed as a solid dosage form: Zoton® (FasTab®) and
Lansoprazole (capsules), supplied as 15 and 30 mg doses. In the US however, lansoprazole
is available as a delayed release capsule (Prevacid) and a delayed release orally
disintegrating tablet (Solutab). However, aqueous preparations (liquid dosage forms) have as
yet to be developed for the pharmaceutical market due to two major obstacles: (1) insolubility
in water and (2) degradation rate increasing with decreasing pH.
7.1.2. Polymeric nanoparticle delivery
In order to overcome obstacles of poor water solubility and degradation in acidic media,
polymeric particles provide a practical approach as their matrix provides a hydrophobic
environment within which the drug molecule is protected from the harsh acidic conditions in
the stomach. Therefore for the current study, polymeric nanoparticles were prepared using
the solvent displacement technique, chosen for its simple manufacturing process and its
success with high entrapment of poorly soluble drugs (Fessi et al, 1989; Quintanar-Guerroro,
1998; Barichello et al, 1999; Hans and Lowman, 2002). However the efficiency of entrapment
was found to be dependent upon the compatibility between the drug and the polymer.
Polycaprolactone (PCL) and Polylactide-coglycolide (PLGA) (Figure 7.1) are hydrophobic
biodegradable polymers that are approved by the FDA for human use (Faraji and Wipf,
2009). PCL has a semi-crystalline structure with its crystallinity decreasing with increasing
molecular weight (Woodruff and Hutmacher, 2010). It was initially synthesised in the early
1930s (Van Natta et al, 1934). The polymer’s numerous advantages have propelled its use
within the biomedical field which include: good solubility, low melting point of 59-64 oC and a
glass transition temperature of –60 oC enabling ease of preparation at relatively low
temperatures, tailorable degradation kinetics and mechanical properties capable of providing
controlled release of the drug load from its matrix (Chandra and Rustgi, 1998; Okada, 2002;
Nair and Laurencin, 2007). PLGA (a poly-lactide (50:50)) has an amorphous structure with a
glass transition temperature of 55-50 oC.
Both polymers were chosen for their dual action purpose; (1) protection of lansoprazole
against acid degradation and (2) regulation of the release rate of lansoprazole.
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7.1.2.1. Special consideration for nanoparticulates during formulation
After administration, the main parameters controlling the drug distribution, absorption and
biological activity include: mean particle size, surface charge, and hydrophobicity of the
biodegradable polymer (Gibaud et al, 1996). These nanoparticle characteristics are key
determinates of nanoparticle interaction with the intestinal cell membrane and their
penetration across the physiological drug barriers (Norris et al, 1998; Kumari et al, 2010).
This was particularly important with regard to the hydrophobicity and particle size of the
nanoparticles, as by reducing the hydrophobicity of the particle with the adsorption of
poloxamines, the uptake of particles into the cells of the immune systems was also reduced,
and thus enabling the nanoparticles to avoid elimination (Moghimi et al, 1994; Florence et al,
1995; Hillery and Florence, 1996; Davis and Illum, 1998). Similarly, a reduction in particle
size results in an increase in the absorption of particles across the cell wall barrier and thus
more particles are distributed more easily to distant sites and remain undetected by
macrophages for a longer period of time.
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Figure 7.1. Chemical structures of: (A) lansoprazole and the monomer units of (B) PLGA
(C) PCL, (D) Trehalose and (E) Pluronic F127.
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With regard to oral delivery of nanoparticles, the composition of the particle must enable it to
navigate pH gradients, have a protective membrane, pass through hydrophilic and
hydrophobic domains, pass through opposing solubility and absorption regimes and survive
various metabolic and transport proteins (Arayne et al, 2007).
7.1.3. Aim
Previous studies indicated that a variation in the polymer-drug ratio, molecular weight and
composition of the polymer can modify the extent of release of the drug (Prabha and
Labhasetwar, 2004b). The choice of polymer also influences the mechanism of
internalisation and intracellular localisation (Murakami et al, 1999). Therefore the polymer
chosen to form the colloidal matrix was extremely important not only for polymer-drug
compatibility to ensure maximum loading but also to ensure maximum in-vivo effects at the
targeted site of action. Therefore PCL and PLGA were chosen for their biodegradable and
hydrophobic nature.
The overall aim of the study was to establish a validated calibration protocol for the extraction
and quantification of lansoprazole using UV spectrophotometry and formulate nanoparticles
loaded with a minimum dose of 1 mg.mL-1 that could potentially be effective in-vivo.
The objectives included:
 Preparation and characterisation of PCL and PLGA nanoparticles at varying polymer-
drug ratios (5:1, 6:1 and 7:1) using the solvent displacement technique
 Comparison of the solvent displacement technique against emulsion diffusion
technique using PCL nanoparticles at a varying polymer-drug ratios (5:1, 6:1 and 7:1)
 Influence of milled polymers on the characterisation of the nanoparticles
 Physical implications of milling on PCL and PLGA
 Physicochemical implications on the nanoparticles formed
 Drug release studies and the implication of milling the polymer on the drug release
rate
Chapter 7: Solubilisation of a proton pump inhibitor (lansoprazole) using nano-particulate delivery
212
7.2. Methods and Materials
7.2.1. Materials
Lansoprazole (assay >98%), polycaprolactone (PCL, Mw 115,000), poly (DL-lactide-co-
glycolide) (PLGA, 50:50, Mw 5,000-15,000), phosphate buffered saline (PBS), pluronic F127.
Trehalose, monobasic sodium phosphate, sodium hydroxide and sodium dodecylsulphate
and HCl were all purchased from Sigma (U.K.). Tetrahydrofuran and acetone were
purchased from Fisher Scientific (UK). Deuterated Dimethyl sulfoxide (DMSO-D6) was
purchased from Goss Scientific Instrument Ltd (Cheshire, UK).
7.2.2. Methods
7.2.2.1. Development of a calibration method for lansoprazole
Calibration was carried out using a JENWAY 6105 U.V/Vis spectrophotometer at a
wavelength of 285 nm. 6 mg of lansoprazole was dissolved in 350 mL PBS to obtain a stock
concentration of 17 μg.mL-1. Serial dilutions were then carried out to obtain further
concentrations (3, 6, 9, 11, 13 and 15 μg.mL-1). Once the UV spectrophotometer had been
set to zero using PBS, 2.5 mL of each lansoprazole concentration was analysed in
disposable cuvettes.
7.2.2.2.1. Calibration validation protocol
Linearity
Linear regression was calculated by the least square regression method, with the standard
curves being prepared on three different days. The calibration curves were obtained using
six concentrations of reference standard solution for the spectrophotometric method (3, 6, 9,
11, 13, and 15 g.mL-1).
Precision
The precision of the protocol was determined by immediate precision of the calibration
protocol (intra-day), which was evaluated by assaying samples of set sample concentrations
on the same day, and repeatability (inter-day), which was analysed by comparing the assays
on three different days.
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Accuracy
The accuracy was determined by assaying three known concentrations in triplicate. For the
spectrophotometric method these concentrations were 5, 10 and 14 g.mL-1.
Limit of detection (LOD)
The LOD was calculated on the SD of the response and slope. The equation used is as
follows:
3.3 x Mean SD of blank determination
LOD =
Slope of standard curve
Limit of quantification (LOQ)
The LOQ was calculated based on the SD of the response and slope using three calibration
curves. The equation is as follows:
10 x Mean SD of blank determination
LOQ =
Slope of standard curve
7.2.2.2. Nanoparticle preparation using the solvent displacement
technique
The polymer (PLGA or PCL) was dissolved in 10 mL of acetone, with slight heating, to which
10 mg of lansoprazole was added and left to stir until lansoprazole had fully dissolved. The
amount of polymer added was varied to produce the following polymer-to-drug ratios: 5:1, 6:1
and 7:1. The organic solution formed was added drop-wise slowly into 0.25 % (w/v) Pluronic
F127 solution in PBS, under magnetic stirring. The volume of nanosphere dispersion was
then concentrated to 10 mL under reduced pressure. The final solution was then centrifuged
at 3200 for 30 minutes or 20000 rpm for 1 hour (PLGA and PCL nanoparticles respectively),
to allow for the separation of the non-encapsulated lansoprazole from the encapsulated
nanoparticles. The supernatant formed was separated for lansoprazole analysis via UV and
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the pellets were re-dispersed in distilled water to produce a final concentration of 1 mg.mL-1
of lansoprazole.
7.2.2.3. Nanoparticle preparation using the emulsion diffusion technique
PCL was dissolved in 5 mL of acetone, with slight heating, to which 10 mg of lansoprazole
was added and left to stir until lansoprazole had fully dissolved. The amount of polymer
added was varied to produce the following polymer-to-drug ratios: 5:1, 6:1 and 7:1. The
organic solution formed was added drop-wise slowly into 0.25 % (w/v) Pluronic F127 solution
in PBS under magnetic stirring. The nanoparticle solution was magnetically stirred for
3 minutes before being emulsified for 7 minutes with a high-speed homogeniser, after which
25 mL of water was added under moderate magnetic stirring for 3 minutes. This nanosphere
solution was then centrifuged at 4,500 rpm for 1 hour to allow for the separation of the non-
encapsulated lansoprazole. The supernatant formed was separated and the pellets were re-
dispersed in 5 mL of distilled water to produce a final concentration of 1 mg.mL-1 of
lansoprazole.
7.2.2.5. pH
The pH of each sample was analysed using a Hydrus 500 (Fisherbrand, UK), calibrated at
pH 4, 7 and 10.
7.2.2.6. Particle sizing
Particle size of the nanoparticulate suspension was analysed using a Zetasizer (Brookhaven,
U.K). 50 μL of sample was diluted in 2 mL of distilled water in a cuvette. Values reported are
the mean + SD of 3 different batches of each formulation. For particle size analysis the
polydispersity index was also measured. This is a measure of the width of distribution
calculated from the SD of the distribution divided by the mean value.
7.2.2.7. Planetary-ball milling
PCL was initially mechanically milled by pestle and mortar as the sample must be less than
0.5 mm in diameter prior to planetary micromilling. Into each of the planetary mill chambers
were placed 18 agate balls, to which 3 g of the polymer was placed on top. The lid was
secured in place ensuring the white rim was also in place to help seal the lid down. The
chambers were then screwed securely in place. PLGA and PCL polymers were milled using
a planetary micromill (Pulveristte 7, Fritsch, Germany) for 1 hour at 200 rpm and 400 rpm.
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7.2.2.8. Scanning electron microscopy (SEM)
SEM was performed on the milled and non-milled polymers and on PCL nanospheres. The
samples were mounted onto standard specimen stubs using a double-sided adhesive tape
and left to air dry for 24 hours. The stubs were then in turn loaded and fastened to a
universal specimen holder and subjected to low-vacuum gold splutter before being subjected
to SEM.
7.2.2.9. Micro-viscosity testing of PCL nanoparticles
Non-milled PCL lansoprazole-loaded nanoparticles prepared using the emulsion diffusion
techniques were measured for their viscosity before and after homogenisation. This was
carried out using the automated micro-viscometer (Anton-Paar, AMVn, Graz, Austria), which
measures the viscosity of a sample by measuring the rolling ball time between a fixed
distance along the 1.8 mm glass capillary tube. Temperature within the capillary tube was
controlled to 25 oC.
7.2.2.10. Molecular weight analysis of milled polymers using gel
permeation chromatography (GPC)
Using a PL-GPC 50 machine (A Varian, Inc. Company, by polymer laboratories), 3 mg of the
milled polymer was dissolved in 1 mL of tetrahydrofuran, which was then injected into the
GPC machine. Samples were analysed using the GPC/SEC software.
7.2.2.11. Wettability profiling
Contact angle measurements were made using the Wilhelmy-plate method in order to
determine the wetting interaction between the polymer surface and distilled water. This was
carried out using the QCT-100 programme in which the glass coverslip was coated with
double-sided tape and dipped into the polymer ensuring both sides of the coverslip was
thoroughly coated. Excess particles were dabbed off into a plastic tray. The coverslip was
then hung on a balance and slowly lowered into a beaker containing distilled water at a rate
of 0.2 mm.s-1. The advancing, receding and hysterisis contact angles of the particles was
then calculated using the QCT-100 software provided.
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7.2.2.13. Freeze-drying preparation of nanoparticles
Nanoparticles were prepared using the solvent displacement technique. After re-hydration in
distilled water, 1 % (w/v) trehalose was added to provide structural integrity and support
during the freeze-drying process. The freeze-drying process involves primary drying for 48
hours at a shelf temperature of -40 ºC followed by secondary drying for 10 hours at a shelf
temperature of 20 ºC. Both drying stages were carried out at a vacuum pressure of 50 mTorr.
7.2.2.14. Differential scanning calorimetry (DSC)
DSC (Perkin-Elmer, Wellesley, USA) was used to study the Tg and melting points.
Approximately 5 mg of sample was placed in a Perkin-Elmer aluminium pan. The sample
was cooled to 10 oC using the attached intra-cooler (2P Perkin-Elmer, Wellesley, USA)
followed by heating to 240 oC at a rate of 10 oC.min-1, with a nitrogen purge of 20 mL.min-1.
The samples consisted of lansoprazole, PCL and PLGA in their original states, and after
planetary-ball milling at 200 rpm for 1 hour, and various nanoparticle formulations after being
freeze-dried. An empty aluminium pan was used as a reference.
The Tg and Tm were then analysed using the Pyris Manager software. All of the
measurements were carried out in triplicate with fresh samples being prepared for each DSC
run. The DSC was calibrated for temperature and heat flow, prior to the samples being tested
using standard samples of indium (Tm 156.6 oC) and zinc.
7.2.2.15. Thermogravimetric Analysis (TGA)
Thermal degradation of lansoprazole was performed using a TGA which determines the
dependence of the weight loss of a sample as a function of temperature. The system
consisted of a Pyris 1 Thermogravimetric Analyzer (Perkin Elmer). The sample masses
ranged from 2-5 mg and were heated from 25-300 oC at a rate of 10 oC.min-1 in a dry
nitrogen atmosphere. The instrument regulated the heating rate automatically in order to
maintain a constant temperature during a given thermal event.
7.2.2.16. Fourier Transform Infrared Spectroscopy (FTIR)
FTIR spectra of samples (lansoprazole, PLGA, milled PLGA, PCL, milled PCL, pluronic
F127, and nanoparticle formulations) were obtained on an IR spectrophotometer (UK). The
sample and freeze-dried nanoparticles (7.2.2.13.) were added to potassium bromide at a
ratio of 1:5 (sample : potassium bromide) and thoroughly mixed which was then compacted
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by a mechanical press for 5 minutes to form the translucent pellet used to determine the
transmittance of each excipient.
7.2.2.17. Proton Nuclear Magnetic Resonance Spectroscopy (H1-NMR)
Lansoprazole-loaded nanoparticles (PCL/PLGA), physical mixture of PCL/PLGA and
lansoprazole were dissolved in DMSO-D6 solution at room temperature in 5 mm glass tubes.
Approximately 2 mg of sample dissolved in 600 μL of DMSO-D6. All NMR measurements
were done with standard Bruker pulse sequences.
7.2.2.18. In Vitro Release Studies
The release of lansoprazole from the nanoparticles was studied in the fasted state in
accordance with the USP 31-standard, and non-fasted states in accordance with the BP
standard. All dissolution vessels have been wrapped in foil to prevent photodegradation of
lansoprazole as it was being released from the nanoparticles into the medium.
In vitro release was carried out in dissolution baths at 37 oC in various buffers according to
the fasted and non-fasted state protocols.
7.2.2.18.1. Nanoparticle preparation
PCL and PLGA loaded nanoparticles were prepared according to the above protocol
(7.2.2.2) at 20,000 rpm for 1 hour.
2.2.2.18.2. Fasted State
The buffer consisted of an acid stage containing 500 mL 0.1 M HCl at pH 3. The
nanoparticles were placed in rotating baskets at 75 rpm for 1 hour in the acid solution. After
which samples were placed into a 900 mL phosphate buffer at pH 6.8. The buffer consisted
of monobasic sodium phosphate, sodium hydroxide (NaOH) and sodium dodecylsulphate
(16.35 g, 7.05 g and 3 g respectively in 1 L of distilled water). The buffer was adjusted to
pH 6.8 using 10 M NaOH. At set time points (5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360,
1440 and 2880 minutes) 5 mL samples of the release medium was withdrawn, following this
5 mL of fresh phosphate buffer was added to the dissolution baths in order to maintain sink
conditions. The 5 mL samples of release medium were then assayed at 285 nm for drug
recovery using the UV spectrophotometer. The drug release experiments were carried out in
triplicate.
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7.2.2.18.3. Non-Fasted State
The buffer consisted of an acid stage containing 500 mL phosphate buffer at pH 4.5,
composed of 10 M sodium hydroxide and 0.05 M phosphate buffer (1:99 ml respectively).
The nanoparticles were placed in rotating baskets at 75 rpm for 1 hour in the acid solution.
After which samples were placed into a 900 mL phosphate buffer at pH 6.8. The buffer
consisted of monobasic sodium phosphate, sodium hydroxide and sodium dodecylsulphate
(16.35 g, 7.05 g and 3 g respectively in 1 L of distilled water). The buffer is adjusted to pH 7
using 10 M NaOH. At set time points (5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 1440 and
2880 minutes) 5 mL of the release medium is withdrawn and immediately replaced with fresh
5 mL phosphate buffer in order to maintain sink conditions. The samples taken from the
release medium was then assayed at 285 nm for drug recovery using the UV
spectrophotometer. The drug release experiments were carried out in triplicate.
7.2.2.19. Statistical analysis
Statistical analysis was carried out by analysis of variance (ANOVA) and the unpaired t-test,
with the significant differences being judged as P<0.05.
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7.3. Results
7.3.1. Calibration Validation
A UV spectrophotometer calibration was used to produce a validated calibration protocol for
the in-direct determination of lansoprazole loaded within the nanoparticles. At a detection
wavelength of 285 nm, the supernatant of the nanoparticles was dissolved in PBS to quantify
the amount of lansoprazole un-bounded to the nanoparticles.
7.3.1.1 Linearity
The linearity of the UV method was evaluated by preparing the standard curve for
lansoprazole on 3 consecutive days. The absorbance was plotted against the lansoprazole
concentration and the calibration response was assessed for variances. The results show
that the data complied with the Beer Lambert’s law in the concentration range investigated
(3-17 μg.mL-1), with the linear plot producing a regression equation of y=0.0319x (R2=0.9955)
(Figure 7.2).
7.3.1.2 Precision
In order to assess the reproducibility of the calibration protocol, the calibration method was
carried out in triplicate over a period of 3 days for interday precision, and in triplicate on the
Figure 7.2. Graph of lansoprazole calibration highlighting the linearity of the validation protocol.
(n=3)
Chapter 7: Solubilisation of a proton pump inhibitor (lansoprazole) using nano-particulate delivery
220
same day for intraday precision. It was concluded that the calibration method was
reproducible, with inter-day precision of 110.3 %, and the intra-day precision of 109.1 %.
Statistical data was compared using ANOVA statistical test, with the resulting inter-day and
intra-day precision being calculated to have a variance of P>0.05 (Table 7.1).
7.3.1.3. Accuracy
The accuracy of the developed method was determined from three concentrations of
lansoprazole in PBS, representing the low, medium and high portions of the standard curve
(5, 10 and 14 μg.mL-1). Accuracy of the three concentrations was in the range of 98.1-99.3 %
(Table 7.1).
7.3.1.4 Limit of detection (LOD) and limit of quantification (LOQ)
The limit of detection of an individual analytical procedure is the lowest amount of analyte in
a sample which can be detected but not necessarily quantifiable as an exact value (EMEA,
1995). From the calibration range the LOD was calculated as 0.321 μg.mL-1.
The limit of quantification of an individual analytical procedure is the lowest amount of
analyte in a sample which can be quantitatively determined with accuracy and precision.
From the calibration range the LOQ was calculated as 0.972 μg.mL-1.
Criteria Validation
Y = 0.0319 x
R2 0.9955
Intra-day Precision 109.1%
Inter-day Precision 110.3%
Accuracy (±SD): 5 μg.mL-1 99.2% (±0.96%)
Accuracy (±SD): 10 μg.mL-1 99.3% (± 0.18%)
Accuracy (±SD): 14 μg.mL-1 98.1% (±0.59%)
LOD μg.mL-1 0.321
LOQ μg.mL-1 0.972
Table 7.1. Calibration validation of lansoprazole using a UV spectrophotometer
Chapter 7: Solubilisation of a proton pump inhibitor (lansoprazole) using nano-particulate delivery
221
7.3.2. Influence of PCL and PLGA polymer ratio on nanoparticle
preparation and characterisation using the solvent displacement
technique
The influence of PCL concentration on nanoparticle characteristics is presented in table 7.2.
In the absence of lansoprazole, the nanoparticle size was observed to increase as the
polymer concentration increased (448.4 + 16.6 to 538.5 + 47.8 nm). These results were
significantly larger in comparison to the lansoprazole-loaded nanoparticles (P<0.05), which
also displayed a similar trend (increasing particle size with increasing polymer
concentration). This increase in particle size was attributed to the lowered viscosity of the
inner organic phase, preventing formation of polymer chain aggregates and ultimately
forming smaller particles (Khandal et al, 2010). Both of these formulations (drug loaded and
unloaded) were seen to exert anionic properties, which increased in strength with increasing
polymer concentration. Interestingly, although an increase in PCL concentration resulted in
larger particles being formed, the drug-loading efficiency of the particles decreased. As the
polymer-drug ratio increased from 5:1 to 7:1, the drug entrapment efficiency decreased from
85.57 + 1.80 to 76.21 + 1.54 % respectively (P<0.05).
Polymer to
drug ratio
Particle size
(nm) PI
Zeta potential
(mV) pH
Drug loading
(%)
5:0 448.4±16.6 0.01±0.00 -16.19±7.32 7.01±0.04 -
6:0 478.3±29.7 0.01±0.00 -24.55±3.08 7.07±0.05 -
7:0 538.5±47.83 0.14±0.06 -30.10±1.92 7.11±0.02 -
5:1 271.8±4.75 0.11±0.01 -15.78±4.00 7.09±0.01 85.57±1.80
6:1 285.1±13.37 0.05±0.01 -16.41±0.20 7.11±0.01 80.38±0.66
7:1 301.2±13.64 0.27±0.01 -24.73±5.35 7.53±0.03 76.21±1.54
Table 7.2. Characterisation of PCL nanoparticles before and after lansoprazole loading. It was
observed that an increase in polymer concentration resulted in larger nanoparticles being formed
ranging in size from 448-538 nm in the absence of drug and 271-301 nm in the presence of
lansoprazole. The polymer exerted anionic properties, which increased in strength with increasing
PCL concentration. (n=3)
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The choice of polymer used to form the nanoparticle matrix had a drastic impact on the
characteristics and drug-loading capabilities of the nanoparticles formed. This was clearly
observed when the influence of PLGA on nanoparticle formation was investigated
(Table 7.3). It was observed that in the absence of lansoprazole, the particles formed were
above the nano-metric range, which increased significantly from 1146.3 + 480.2 to
1508.4 + 44.1 nm as the polymer concentration increased (5:0 to 7:0 polymer-drug ratio
respectively) (P<0.05). However once the particles had been loaded with lansoprazole, the
particle size was significantly reduced into the nano-metric range, ranging from 259.8 + 17.41
to 292.5 + 21.0 nm (5:1 to 7:1 polymer-drug ratio respectively). A slight increase in particle
size was observed as the polymer concentration was increased (P=0.044). Interestingly the
loading of polymer concentration had no impact on the entrapment efficiency of lansoprazole,
which remained consistent at 80 %.
The characterisation differences observed between the PCL and PLGA nanoparticles can be
explained by the structural folding nature of the polymers when in an aqueous environment.
The flexibility of a polymer chain can be related to the length of its monomer backbone. PCL
has a longer monomer backbone (-CH2- groups) than PLGA (Figure 7.1), which hinders its
ability to form a tight nanosphere construct, and hence resulting in PLGA nanoparticles being
relatively smaller in size than PCL nanoparticles (Leroueil-Le Verger et al, 1998). The extent
Polymer to
drug ratio
Particle size
(nm) PI
Zeta potential
(mV) pH
Drug loading
(%)
5:0 1146.3±480.2 0.27±0.01 -37.64±3.25 7.21±0.12 -
6:0 1286.5±93.4 0.25±0.04 -38.73±1.15 7.21±0.02 -
7:0 1508.4±44.1 0.30±0.15 -39.60±2.88 7.29±0.05 -
5:1 259.8±17.41 0.13±0.05 -25.89±3.22 6.10±0.25 80.55±0.64
6:1 272.0±1.56 0.12±0.04 -37.31±6.44 6.76±0.12 80.01±0.65
7:1 292.5±21.0 0.06±0.03 -37.64±4.65 7.11±0.05 80.49±0.54
Table 7.3. Characterisation of PLGA nanoparticles with and without lansoprazole loading. It was
observed that an increase in polymer concentration resulted in significantly larger nanoparticles
being formed ranging in size from 1146-1508 nm in the absence of drug, in comparison to
nanoparticles prepared in the presence of lansoprazole (259-292 nm). The polymer exerted
strong anionic properties, which increased in strength with increasing PLGA concentration. (n=3)
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of anionic charge exhibited by the nanoparticles was attributed to two factors: (1) the type of
polymer used to form the particle and (2) the number of terminal carboxylic groups on the
polymer being forced to protrude out of the particle matrix (Leroueil-Le Verger et al, 1998). It
has been generally perceived that a higher energy barrier associated with a bigger particle
charge forms a more stable suspension (Benita and Levy, 1993). For example a particle
charge of –25 mV has greater electronegative properties enabling the particles to repel each
other when in suspension, preventing aggregation upon ageing and thereby ensuring particle
stability (Muller, 1991). From the results however (Table 7.2 and Table 7.3) it was observed
that drug-loading caused a reduction in the extent of anionic charge exerted. This can be
attributed to the rearrangement of the polymer chains in the particle matrix in order to
accommodate for the drug into its hydrophobic core and possible surface adsorption of the
drug.
Figure 7.3 and 7.4 show images of nanoparticles when in suspension (light microscope) and
when exposed to SEM respectively. The former demonstrates that the nanoparticles were
free of aggregation when still in aqueous suspension. However, when the particles were
treated with trehalose for the freeze-drying protocol partial aggregation was observed. This
Figure 7.3. Light microscopy of PCL nanoparticles in suspension and viewed on a glass slide
and coverslip at 100 x objection. The largest visible nanoparticle was observed to be ~1.77 μm.
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affect was attributed to the influence of stabilising agent trehalose, a non-reducing
disaccharide that had been extensively used in the freeze-drying process of nanospheres,
microspheres, solid- lipid nanoparticles (SLN) and liposomes (Saez et al, 2000; Abdelwahed
et al, 2006; Lee et al, 2007). It was found that trehalose was able to bind to the surface of a
liposomal particle through hydrogen bonding resulting in a significant increase in the size of
the particle without distorting its structure (Christensen et al, 2007).
The type of polymer also had an influence on the efficiency of drug entrapment, which was
attributed to two factors: (1) pH of the colloidal system and (2) chemical structure and
flexibility of the polymer chains (Li and Zhao, 2003). Previous studies have shown that the
pH of the colloidal suspension influences the extent of drug incorporation, with increased
entrapment occurring when the pH of the colloidal system was below the pKa of the drug
(Govender et al, 1999). The pKa of lansoprazole is 7.3 with the pH of the colloidal system
being ~pH 7.Thus it can be concluded that the extent of drug loading was less influenced by
pH and mostly influenced by the composition and flexibility of the polymer.
Figure 7.4. SEM profiling of PCL-coated nanoparticles after freeze-drying. The addition of
trehalose caused a significant rise in the size of the particles, resulting in microparticles (1- 4 μm).
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7.3.3. Influence of the mode of preparation of PCL nanoparticles:
solvent displacement versus emulsion diffusion method
The solvent displacement technique resulted in a reduction in the loading efficiency of PCL
nanoparticles. Therefore an alternative method was utilised to investigate the influence of
nanoparticle preparation technique against drug loading, with the ultimate aim to increase the
drug loading capabilities of PCL nanoparticles. The emulsion diffusion was chosen for its
viscosity enhancing properties, which would aid the rate of diffusion of lansoprazole into the
nanoparticle matrix.
7.3.3.1. Characterisation of lansoprazole loaded PCL nanoparticles
Table 7.4 demonstrates the influence of nanoparticle preparation techniques (solvent
displacement vs. emulsion diffusion) on the characterisation of the lansoprazole loaded PCL
nanoparticles. In the previous study with nanoparticles prepared using the solvent
displacement technique, it was concluded that an increase in polymer load resulted in an
increase in particle size and charge (Section 7.3.2). Nanoparticles prepared using the
emulsion diffusion technique remained fairly consistent, with the polymer load having no
influence over the particle characteristics (Table 7.4). Statistically no variation in particle size
and particle charge was observed as the polymer-drug ratio was increased (P>0.05). At the
5:1, 6:1 and 7:1 polymer-drug ratios the nanoparticles measured 299.27 + 2.46,
293.53 + 14.05 and 298.90 + 13.90 nm respectively, and exerted strong anionic properties
(-21.29 + 4.06, -24.10 + 3.82 and -23.10 + 4.55 mV respectively). Interestingly, by altering
the method of nanoparticle preparation to the emulsion diffusion technique the drug loading
efficiency increase significantly (P<0.05). Particles prepared at the 5:1 polymer-drug ratio
had 91.06 + 0.13 % entrapment efficiency. As the polymer load was increased to 6:1
(polymer-drug ratio) the entrapment efficiency was reduced to 88.46 + 0.66 %, which
remained consistent as the polymer load was increased further. This increase in drug-loading
efficiency using the emulsion diffusion technique can be explained by the viscosity of the
suspensions.
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7.3.3.2.1. Influence of viscosity
The characterisation of the nanoparticles has ascertained that the homogenisation of the
organic solution during the formation of the nanoparticles not only ensures homogeneity of
particle size but also increases the drug-loading efficiency. These findings can be attributed
to the shear force of the homogeniser and to the viscosity of the nanoparticle solution
formed.
The size of the nanoparticle formed was attributed to the macromolecular coiling capabilities
of the polymer: by increasing the speed of rotation through homogenisation, the amount of
time the polymer had to rearrange its hydrophobic chain into a protected shell
(colloid/nanoparticle) was considerably reduced (Kwon et al, 2001). Therefore the shear
force of the homogeniser effectively hindered large nanoparticle growth. This however had a
marked affect on the viscosity of the organic solution. Figure 7.5 highlights the viscosity of
the suspension being lowered after homogenisation. The greatest difference in viscosity was
observed with the 5:1 polymer-drug ratio (P<0.05). Before homogenisation the particles had
particle size of 271.8 + 4.75 nm with a drug entrapment efficiency of 85.57 + 1.80 %. This
Nanoparticle
preparation
technique
Polymer
to drug
ratio
Particle size
(nm) PI
Zeta
potential
(mV)
pH
Drug
loading
(%)
5:1 271.8±4.75 0.11±0.01 -15.78±4.00 7.09±0.01 85.57±1.80
6:1 285.1±13.37 0.05±0.01 -16.41±0.20 7.11±0.01 80.38±0.66Solventdisplacement
7:1 301.2±13.64 0.27±0.01 -24.73±5.35 7.53±0.03 76.21±1.54
5:1 299.3±2.46 0.10±0.08 -21.29±4.06 6.88±0.35 91.06±0.13
6:1 293.5±14.05 0.18±0.05 -24.10±3.82 6.84±0.36 88.46±0.66Emulsiondiffusion
7:1 298.9±13.90 0.10±0.06 -23.10±4.55 7.19±0.06 88.15±1.03
Table 7.4. Comparison of lansoprazole loaded PCL nanoparticles preparation techniques: solvent
displacement vs. emulsion diffusion. The former method exhibited an increase in particle size and
charge, and a reduction in drug loading, with increasing polymer concentration. The latter
technique exhibited no significant change in particle size or charge as the polymer concentration
increased. However, a higher drug loading was achieved in comparison to the solvent diffusion
method, with the 5:1 polymer-drug ratio achieving 91.06 + 0.13 % drug loading, this was reduced
to 88.46 + 0.66 % with a 6:1 polymer-drug ratio, with no significant increase with the 7:1 polymer-
drug ratio. (n=3)
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was significantly improved on by lowering the viscosity of the suspension to
1.0907 + 0.01 mPa.s-1 (299 + 2.46 nm with 91.06 + 0.13 % entrapment efficiency). In a
suspension with less viscosity, the interfacial tension/resistance between two components
(such as organic solution and nanoparticles) becomes weaker, thereby making it easier for
the drug molecule to diffuse across the polymer outer shell into its hydrophobic core (from a
high to a low concentration), and ultimately increasing the drug-loading efficiency of the PCL
nanoparticle. These results therefore enforce viscosity to be a major factor in efficient drug
loading.
7.3.3.2.1. Conclusion
In order to increase the drug load of a nanoparticle, the viscosity of the organic solution had
to be reduced. This can normally be achieved by applying shear force in the method of
nanoparticle preparation. However, this can result in the generation of heat which could
cause degradation to heat-sensitive compounds. Since the aim of the study was to produce a
simple nanoparticle protocol which ultimately would result in high loading efficiency with
relatively small nanoparticles, an alternative method of preparation was to be investigated,
such as planetary ball milling.
Figure 7.5. Viscosity measurements of PCL nanospheres before and after homogenisation. The
homogenisation process significantly reduced the viscosity of the nanoparticle solution, with the
greatest reduction being observed with 5:1 polymer-drug ratio. (n=3)
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7.3.4. Planetary ball milling
Various studies have been reported where the loading and sizing on nanoparticles has been
recorded using pre-formed polymers, however limited research has highlighted the
implications of modifying the surface properties of the polymer prior to nanoparticle
formation, and analysing its implications on its physical characteristics, drug loading and
release profile. The major advantage of dry milling the polymer prior to nanoparticle
formation involved the modification of polymer surface characteristics without the need for
any chemical modification. Planetary ball milling can be used to reduce particle size and in
turn alter the surface properties of materials by increasing the surface area, porosity and
shape. Therefore the aim of the following study was to ascertain the implications of milling on
the physical properties of the polymer and when prepared as a colloidal suspension.
7.3.4.1. Implications on physical properties of PCL and PLGA
7.3.4.1.1. Impact on molecular weight
The molecular weight of PCL and PLGA before and after milling was analysed using a
GPC/SEC software, in order to ascertain the influence of milling on the physical properties of
the polymers (Table 7.5). It was observed that the repeated mechanical impaction of the
Polymer Rotation speed(rpm)
Duration
(mins)
Molecular weight
(Mw)
PLGA - - 8260
Milled PLGA 200 60 8356
PCL - - 14000
Milled PCL 200 60 60054
Milled PCL 400 15 35263
Milled PCL 400 30 30388
Milled PCL 400 45 37070
Milled PCL 400 60 29067
Table 7.5. Influence of milling on the molecular weight of PCL and PLGA. Both polymers showed a
significant increase in molecular weight after milling, with PCL displaying variation and inconsistency
as the milling time was increased from 15 to 60 mins at 400 rpm. This was associated with the
robustness of the polymer surface.
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agate balls on the polymer surface caused a significant increase in the polymers molecular
weight, particularly with regard to the milled PCL polymer. This can be associated with the
scissoring, mass transfer and cross linking events in the polymer chain (Smith et al, 2001).
The extent of which was dependent upon the surface structure of the polymer, as PCL had a
tough surface which required greater energy to grind than the glassy structure of PLGA.
Therefore although the molecular weight of PCL increased after milling, it displayed a
variation and inconsistency as the milling time was increased from 15 to 60 minutes at
400 rpm.
7.3.4.1.2. Wettability studies: Impact on polymer hydrophobicity
Wettability is used to assess the hydrophobic and hydrophilic properties of materials. The
compositions of the milled and non-milled polymers were analysed using Camtel QCT-100
tensiometer. This calculates the advancing and receding angle of the hydrophobicity of the
polymer, with the difference between the two angles being used to calculate the hysterisis
angle, the results of which are displayed in table 7.6. The contact angle is a quantitative
Polymer Rotation speed/ rpm(duration/ mins)
Advancing angle
(±SD)
Receding angle
(±SD) Hysterisis
0 60.25±14.93 90.00±0.00 29.75
200 (60 mins) 59.57±10.58 90.00±0.00 30.43
400 (15 mins) 59.03±11.36 90.00±0.00 30.97
400 (30 mins) 63.77±1.65 90.00±0.00 26.23
400 (45 mins) 57.99±4.82 90.00±0.00 32.01
PCL
400 (60 mins) 58.99±11.91 90.00±0.00 31.01
0 67.17±0.43 90.00±0.00 22.83
PLGA
200 (60 mins) 51.71±10.97 - 38.29
Table 7.6. Wettability profiling of PCL and PLGA before and after milling. Prior to planetary ball
milling, both polymers exhibited hydrophobic properties with receding contact angles of
90.00 + 0.00o. After planetary ball milling, PCL retained its hydrophobicity (receding contact angle of
90.00 + 0.00o), however the receding angle for milled PLGA was not measurable, indicating
incomplete wetting. (n=3)
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measure of the wetting of a solid by a liquid, with the contact angle of less than 90 o
indicating that the liquid wets the solid spontaneously (lower the contact angle greater the
wetting of the solid). An angle of greater than 90 o indicates that the solid has not wetted at
all, and that it is hydrophobic in nature. Currently there are three methods to measure the
wettability of a solid sample: Washburn method, Goniometry, and Tensiometry. For the
purpose of this study, the latter method was employed using the Wilhelmy method, which
allowed for fast and accurate measurements to be taken and was able to calculate the
hysterisis of the two contact angles, an advantage over the Goniometry method.
Table 7.6 highlights the wetting profiles of PCL and PLGA and their relative milled versions.
PCL was a hydrophobic polymer, as indicated by table 7.6 and figure 7.6a in which after
complete immersion in distilled water, the advancing contact angle was 60.25 + 14.93 o, and
the receding angle was 90.00 + 0.00 o. These results indicated that the polymer had not
‘wetted’ and was therefore hydrophobic. After the polymer had been milled for 1 hour at
200 rpm, the advancing contact angle was 59.57 + 10.58 o, and the receding angle was
90.00 + 0.00 o. As the rotational speed of the mill was increased to 400 rpm, the physical
appearance of the polymer showed no significant change (Figure 7.6b), with the receding
angle remaining consistent at 90.00 + 0.00 o.
The SEM profiling of PCL highlighted in figure 7.6 showed that the milling process did not
alter the physical appearance of the polymer; it only reduced the size of the polymer particles
which retained their sheet-like appearance. This was attributed to the robustness of the
polymer and its ability to withstand the heat generated in the planetary mill. Therefore it can
be concluded that the hydrophobicity of the PCL was not influenced by the milling process.
Similarly, PLGA was a hydrophobic polymer, as shown by results in table 7.6 and figure 7.7a
in which after complete immersion in distilled water, the advancing contact angle was
67.17 + 0.43 o, and the receding angle was 90.00 + 0.00 o. Interestingly however, after the
polymer had been milled at 200 rpm for 1 hour, the advancing angle was 51.71 + 0.91 o with
incomplete wetting during the receding angle (no angle was measurable), indicating the
hydrophobicity of the polymer had been altered. This was further supported by the physical
alteration of the PLGA polymer after milling (Figure 7.7). Prior to milling PLGA had a large
smooth glassy appearance, however the milling process caused physical changes in the
PLGA polymer. This resulted in the formation of smaller particles aggregated together to
form a bigger globular structure, containing nano-pores/tubules.
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Figure 7.6. Wettability and SEM profiling of PCL (A) before and (B) after milling for 1 hour at
200 rpm. Prior to milling PCL had an advancing contact angle of 60.25 + 14.93 o, and the receding
angle was 90.00 + 0.00 o, with SEM showing a smooth sheet-like structure. After milling, the
physical appearance of the polymer did not change, the advancing contact angle was
59.57 + 10.58 o, and the receding angle was 90.00 + 0.00 o. Thus the milling process had no
influence on the hydrophobicity of PCL. (n=3)
(A)
(B)
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Figure 7.7. Wettability and SEM profiling of PLGA (A) before and (B) after milling for 1 hour at
200 rpm. Prior to milling PLGA has an advancing contact angle 67.17 + 0.43 o, and the receding
angle was 90.00 + 0.00 o, with SEM showing a smooth glassy structure. The heat of generated
during the milling process resulted in the polymer forming a multi-globular nano-porous structure.
These nano-pores caused the hydrophobicity of PLGA to be reduced (advancing angle was
51.71 + 0.91 o, with incomplete wetting during the receding angle (no angle was measurable). (n=3)
(A)
(B)
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In the field of material science, research has shown that the application of milling results in
the formation of amorphous phase and nano-porous structures within the surface, which
further results in increased surface area (Oberlain, 1989; Chen et al, 1999). The formation of
the nano-porous surface was attributed to the high energy impact that occurred when the
surface of the material came into direct contact with the rotating balls in the planetary mill,
thus resulting in the formation of the nano-pores due to the heat generated between the two
surfaces. Therefore it can be concluded that the reduced hydrophobicity of milled PLGA
displayed by the wettability studies was a direct result of water penetration into these nano-
pores.
7.3.4.1.3. Thermal analysis
DSC was carried out in order to establish the thermodynamics of the non-milled and milled
PCL and PLGA polymers. The DSC technique involved measuring the effect of change in
temperature on the heat flow in or out of the known sample compared with an inert reference
pan. The heat flow can be defined as a function of the change in temperature and of the
absolute temperature. Data was represented in the form of a thermal analysis curve, which
depicts the change in heat flow against temperature, from which three main transitions can
be detected: a Tm, crystallisation (solid to crystal transition), and a Tg. Tg occurs at the
temperature at which the heat capacity reaches halfway between that of the liquid and glassy
states.
Figure 7.8 shows the influence on milling PCL and PLGA on their relative Tm, which were
seen to decrease significantly (P<0.05). Pure PCL has a Tm of 62 + 0.05 oC which was
reduced to 57 + 0.07 oC once the polymer had been milled for 1 hour at 200 rpm. Similarly a
reduction in Tm was observed for pure PLGA after being milled under the same conditions,
from 33 + 0.03 oC to 29 + 0.06 oC respectively. This was attributed to the milling process
weakening the polymer chain bonds through repetitive impaction, and ultimately resulting in
less energy to break the polymer chains.
A parallel study was carried out looking at the milling process of the candidate drug alone
(lansoprazole), in order to ascertain its stability and robustness under stress conditions.
Figure 7.8 and 7.9 show that pure lansoprazole has a Tm of 180 + 0.04 oC which was
instantly followed by a sharp exothermic reaction (degradation) (Zhang et al, 2008).
Surprisingly following planetary ball milling lansoprazole for 1 hour at 200 rpm, two
thermodynamic responses occurred; the first was the expected reduction in Tm (reduced to
177 + 0.03 oC), however the second was the unexpected formation of a Tg at 87 + 0.06 oC.
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Tg was indicative of the alteration of heat capacity as the drug matrix changed from a glass
state to a rubber state (2nd order endothermic reaction). The Tg can be attributed to the
repeating mechanical impaction on the structural properties of lansoprazole, with the degrees
of Tg shift being influenced greatly by the duration and frequency of milling (Chieng et al,
2009; Corrigan and Li, 2009).
Therefore, planetary ball milling caused weakening of the chemical composition of the PCL
and PLGA, resulting in a reduced Tm with no indication of any instability. In contrast, the
mechanical impaction on lansoprazole caused a shift in its chemical state, in the form of a
Figure 7.8. DSC thermographs of; (A) PLGA, (B) milled PLGA, (C) PCL, (D) milled PCL, (E)
lansoprazole and (F) milled lansoprazole. The planetary ball milling of the pure components resulted in
a reduction of their relative Tm. Pure PLGA and PCL have a Tm of 33 + 0.03 oC and 62 + 0.05 oC
respectively, which were reduced after milling for 1 hour at 200 rpm (29 + 0.06 oC and 57 + 0.07 oC
respectively). Pure lansoprazole has a Tm at 180 + 0.04 oC with instant degradation occurring,
interestingly the milled lansoprazole displayed a reduction in its Tm (177 + 0.03 oC) and an additional
Tg (87 + 0.06 oC). (n=3)
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Figure 7.9. TGA and DSC thermographs of lansoprazole: (A) un-milled and (B) milled. Pure
lansoprazole displays a Tm at 180 + 0.04 oC followed by immediate degradation, supported by the
TGA significant weight loss at180 oC. Similarly the milled lansoprazole displays a similar profile at a
reduced temperature (177 + 0.03 oC), with its Tg (87 + 0.06 oC) being displayed clearly. (n=3)
(A)
(B)
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Tg. The aim of the study was to prepare a nanoparticle system for the safe delivery of
lansoprazole to the patient; however these findings have highlighted that by milling the drug,
lansoprazole would no longer be in its true thermodynamic form. Therefore the following
study will concentrate on lansoprazole loaded nanoparticles being prepared from pre-milled
polymers (200 rpm for 1 hour).
7.3.4.2. Influence of milled polymers on nanoparticle formation
Numerous studies have been carried out on milling of polymers in solution (wet milling) in
order to reduce the particle drug size and control its release profile in vitro (Gubskaya et al,
1995; Annapragada et al 1996; and Villiers, 1996). However, no study has yet to look at the
effects of milling on the polymer prior to drug encapsulation. Thus the aim of the study was to
assess if milling the polymer prior to nanoparticle formation would result in a reduction in
particle size and thus an increase in the polymer surface area and drug-loading efficiency.
Lansoprazole loaded nanoparticles were therefore prepared with pre-milled PCL and PLGA
polymers (200 rpm for 1 hour) using the solvent displacement technique and characterised
for particle size, particle charge, and drug loading.
7.3.4.2.1. Milled PCL nanoparticles
The characterisation of lansoprazole loaded nanoparticles prepared using milled PCL is
displayed in table 7.7. It was observed that the 5:1, 6:1 and 7:1 polymer-drug ratios formed
286.1 + 7.92, 275.9 + 0.78 and 292.3 + 7.71 nm nanoparticles respectively, which exhibited a
Polymer
ratio
Particle size
(nm) PI
Zeta Potential
(mV) PH
LSP retention
(%)
5:1 286.1±7.92 0.06±0.05 -16.11±1.37 6.84±0.13 79.97±5.88
6:1 275.9±0.78 0.05±0.03 -15.94±0.24 6.77±0.24 90.70±2.14
7:1 292.3±7.71 0.06±0.00 -16.61±2.13 7.16±0.03 91.87±0.43
Table 7.7. Characterisation of nanoparticles prepared using milled PCL (200 rpm, 1 hour). As the
polymer-drug ratio increased from 6:1 to 7:1, a significant increased in particle size was observed
(P<0.05). Interestingly a significant rise in drug loading was observed as the polymer-drug ratio
was increased from 5:1 to 6:1(P<0.05), which remained stable when the polymer concentration
was further increased to 7:1 (P>0.05). (n=3)
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stable anionic charge (-16.11 + 1.37, -15.94 + 0.24 and -16.61 + 2.13 mV respectively).
These findings were found to be significantly different to nanoparticles prepared from pure
PCL (P<0.05), which were characterised to be greater in size and anionic charge (Table 7.2).
In contrast to the nanoparticles prepared with non-milled PCL (Table 7.2) it was observed
that an increase in polymer concentration resulted in an increase in drug loading, with
nanoparticles prepared using the 6:1 polymer-drug ratio achieving a loading efficiency of
90.70 + 2.14 %. Statistically this was a significant improvement on the non-milled PCL
nanoparticles which previously achieved a maximum drug load of 85.57 ± 1.80 % (5:1
polymer-drug ratio).
7.3.4.2.2. Milled PLGA nanoparticles
The characterisation of lansoprazole loaded nanoparticles prepared using milled PLGA is
presented in table 7.8. As the polymer-drug ratio increased from 5:1 to 7:1, a significant
increase in the nanoparticle size (237.7 + 7.44 to 267.6 + 10.05 nm respectively) and particle
charge was observed (-14.78 + 4.53 to -30.60 + 2.63 mV) (P<0.05). Interestingly, the rise in
polymer-drug ratio from 6:1 to 7:1 resulted in no significant change in either of these particle
characterisations (P<0.05), which was further reflected with their drug loading efficiency.
However, a significant increase in drug loading was observed as the polymer drug ratio
increased from 5:1 to 6:1 (92.37 + 1.31 and 96.30 + 0.93 % respectively) (P<0.05), with no
further improvement in lansoprazole entrapment as the polymer-drug ratio was further
increased to 7:1 (P>0.05). Statistically these results showed a significant improvement on the
non-milled PLGA nanoparticles which ranged in size from 259-292 nm and achieved a
maximum drug-loading efficiency of 80 % (P<0.05) (Table 7.3).
Polymer
ratio
Particle size
(nm) PI
Zeta Potential
(mV) PH
LSP retention
(%)
5:1 237.7±7.44 0.07±0.06 -14.78±4.53 7.21±0.06 92.37±1.31
6:1 257.6±8.40 0.10±0.01 -30.56±4.27 6.85±0.10 96.30±0.93
7:1 267.6±10.05 0.14±0.09 -30.60±2.63 7.16±0.05 95.38±3.23
Table 7.8. Characterisation of nanoparticles prepared using milled PLGA (200 rpm, 1 hour). As the
polymer-drug ratio increased from 5:1 to 6:1, a significant increased in particle size, particle charge
and drug loading was observed (P<0.05), with no significant change as the polymer-drug ratio was
further increased to 7:1 (P>0.05).
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The milling of polymers prior to nanoparticle formation resulted in both PLGA and PCL
exhibiting smaller nanoparticles with higher drug loading. This was attributed to the repeated
mechanical impaction weakening the rigidity of the polymer chains (as seen with reduced Tm
in the DSC study). The reduction in structural rigidity enabled the polymer to form tighter coils
and therefore form smaller nanoparticles. This reduction in particle size was a direct result of
the planetary mill causing a shortening of the polymer chains, thereby once the polymer was
dissolved in acetone during the nanoparticle formation, shorter chain lengths were formed
and ultimately forming smaller nanospheres once exposed to the surfactant solution. In
contrast the non-milled polymers have a longer chain length due to their molecular weight,
whereby the milling process bridges new bonds (weak) between the polymer chains and thus
ultimately increasing their molecular weight.
The reduction in particle charge exhibited by milled polymers can be attributed to the partial
masking of the polymer charge, even though pluronic F127 is a non-ionic surfactant. This
has been supported by the work carried out by Mosqueira and co-workers (2000), who
determined that the particle charge was influenced by the surfactant, oil and polymer
molecular weight. With the latter it was expected that the higher the molecular weight of the
polymer, the smaller the influence on particle charge for the same weight of the polymer.
This was due to the fact that a smaller number of end groups are present in the larger
polymer molecular weight. However in the present study, there was a decrease in the zeta
potential, the reverse of what was expected, and thus concluded that the surfactant was
acting as a masking agent of the end carboxyl groups. An alternate reasoning for the milled
polymers exhibiting greater drug-loading efficiency was increased adsorption of lansoprazole
molecules on the nanoparticle surface, which may attribute to the masking of the particle
charge and thereby decreasing the extent of anionic charge exerted.
Milling has previously been used to study the effect of ball milling on the surface area of
certain compounds, such as carbon. A study carried out by Chen and co-workers (1999) was
one such study, where the effect of ball milling (wet and dry) was assessed with regard to the
nano-porous structure and the changes in internal and external surface areas. By using a
vertical planetary ball mill and a vibrating frame grinder (Pulverisette 0, Fritsch, Germany) it
was found that approximately 50 % of the internal surface area was a result of the formation
of nanosized pores. It was found that an initial increase in the surface area during the first
stage of milling was a result of “particle fracturing induced by ball impaction”, after which the
surface area began to decrease due to agglomeration of the particles. This can be related to
the present study and can be clearly observed with the PLGA particles (Figure 7.7), where
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the SEM photomicrographs clearly show the initial external surface area of PLGA to be flat
and large, however after planetary milling at 200 rpm for 1 hour, the particles are seen to
agglomerate together, thereby decreasing the external particle size. With regard to the
internal surface area, both Chen and co-workers (1999) and Oberlain (1989) agreed that the
nano-porous structure increased with extended milling times. It was deemed by both authors
that the formation of these nano-porous structures was most likely to be linked to the
formation of an amorphous phase, micro-pores formed during agglomeration of very fine
particles during wielding under the ball impacts. Thus in the current study it can be said that
the increase in the internal particle size resulting from the hydrophobic nano-porous structure
of PLGA formed after milling, resulted in increased areas of hydrophobic pockets within
which the hydrophobic lansoprazole was able to bind to. This then results in increased drug
loading efficiency from 80 % to approximately 95 %.
PCL-milled nanoparticles displayed a smaller increase in drug loading compared with PLGA-
milled nanoparticles, with there being no significant difference between the 6:1 and 7:1 ratios
(Table 7.7). This was possibly as a result of the particle fracturing being in balance with the
formation of agglomerates, and thus the external surface area remained constant with no
additional nano-porous structures being produced (Chen et al, 1999). The SEM (Figure 7.6)
confirmed this, where no significant difference was observed between the milled and non-
milled PCL.
7.3.4.3. Physiochemical analysis of milled PCL and milled PLGA
nanoparticles
7.3.4.3.1. H1-NMR
H1-NMR was carried out in order to establish structural changes within the polymer chain
according to the number of protons present. To some extent the scope and limitation of
analysis of polymer composites using H1-NMR spectroscopy depends upon the appearance
of the non-superimposed signals of the components in the spectra. Therefore the first stage
was to highlight the spectra of the pure components.
With F127 a sharp singlet peak was obtained at 3.50 ppm which had a broad base (Figure
7.10). The integration calculation indicates 12 H-ions to be present within this peak, thus the
singlet corresponds to the main body of the F127 chain including the methyl side chain. At
1 ppm a doublet peak was observed which corresponds to the OH- groups present at the
end of the chains. The NMR spectrum for lansoprazole shows; a single peak at 13.58 ppm
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corresponding to the N-H chain on the cyclic amide group, a set of 6 peaks at 4.82 ppm
corresponding to the cyclic chain of lansoprazole and a triplet peak at 7.70 ppm
corresponding to the CH3- methyl side group on the amide cyclic chain (Figure 7.11). The
H1-NMR spectrum for PCL shows a triplet at 3.95 ppm, a doublet at 2.25 ppm, a quartet at
1.56 ppm and a triplet at 1.29 ppm corresponding to its various carbonyl groups (Petrova et
al, 2008), in total 1 polymer chain potentially holds 10 H-ions (Figure 7.12). The H1-NMR
spectrum for PLGA shows a large peak at 1.48 ppm corresponding to 37 H-ions, a large
single peak at 3.36 ppm corresponding to approximately 14 H-ions and a doublet peak at
4.93 ppm corresponding to 23 H-ions and a further broad peak at 5.23 ppm indicating 12 H-
ions are present, in total 1 polymer chain potentially holds 86 H-ions (Figure 7.13).
Figure 7.10. H1-NMR spectrum (DMSO-D6) of pure pluronic F127.
Figure 7.11. H1-NMR spectrum (DMSO-D6) of pure lansoprazole.
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Figure 7.12. H1-NMR spectrum (DMSO-D6) of pure PCL.
Figure 7.13. H1-NMR spectrum (DMSO-D6) of pure PLGA.
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PCL nanoparticles
By eliminating the known spectral peaks of the individual components of the nanoparticle,
any interaction occurring in the physical mixture or the nanoparticle itself can be determined.
The H1-NMR spectrum for the physical mixture of non-milled and milled PCL with
lansoprazole showed similar profiles, with all of the protons being present (Figure 7.14 and
7.15). Therefore the results confirm that the process of milling does not cause any chemical
change in the chemical chain but only aids in changing the chain length of the polymer and
thus its molecular weight.
The NMR scans for PCL nanoparticles loaded with lansoprazole displayed the absence of
the lansoprazole fingerprint (13.58, 1.48 and 2.18 ppm peaks are missing) (Figure 7.16).
Therefore indicating lansoprazole to be fully incorporated into the core and not adsorbed
onto the surface of the particle.
Figure 7.14. H1-NMR spectrum (DMSO-D6) of physical mixture of PCL and lansoprazole.
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Figure 7.15. H1-NMR spectrum (DMSO-D6) of physical mixture of milled PCL and lansoprazole.
Figure 7.16. H1-NMR spectrum (DMSO-D6) of PCL-coated lansoprazole-loaded nanoparticles.
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PLGA nanoparticles
The H1-NMR spectrums for the physical mixture of non-milled and milled PLGA with
lansoprazole were distinctly different. The non-milled PLGA displayed a small single peak at
13.58 ppm that represents the -N-H group from the lansoprazole structure. Also at 8.29 ppm
a small doublet peak was observed with further 2 smaller single peaks at 7.33 and 7.12 ppm.
Multiple peaks are seen at 4.93 and 5.20 ppm equalling to 14 and 6 H-ions respectively. A
new peak was observed at 2.18 ppm representing 2 H-ions, with the peak 1.47 ppm
representing 20 H-ions, previously 37 H-ions with regard to the pure compound
(Figure 7.17).
When the physical mixture of milled PLGA and lansoprazole was analysed (Figure 7.18), it
could be observed that despite the peak specific to –N-H being present at 13.58 ppm,
several other peaks were either not present or had a lower number of H-ions assigned to it.
One particular example was the 20 H-ion large peak at 1.47 ppm, which was now
representative of 1 H-ion. The NMR scans demonstrate significant differences between the
physical mixture of milled and non-milled PLGA with lansoprazole.
The NMR scans for PLGA nanoparticles loaded with lansoprazole displayed the absence of
the lansoprazole fingerprint (13.58, 1.48 and 2.18 ppm peaks are missing) (Figure 7.19).
Thus indicating that lansoprazole had been fully incorporated into the core and not adsorbed
onto the particle surface.
Figure 7.17. H1-NMR spectrum (DMSO-D6) of physical mixture of PLGA and lansoprazole.
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Figure 7.19. H1-NMR spectrum (DMSO-D6) of PLGA-coated lansoprazole-loaded nanoparticles.
Figure 7.18. H1-NMR spectrum (DMSO-D6) of physical mixture of milled PLGA and lansoprazole.
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Therefore the NMR results establish the loading of lansoprazole to be within the core of the
nanoparticles, and not adhered to the outside, with no interaction occurring between the
polymers and the drug.
7.3.4.3.2. FTIR
FTIR was carried out in order to assess the bond integrity of the non-milled and milled
polymers and respective nanoparticles. The scope and limitation of FTIR analysis depends
upon the appearance of the non-superimposed transmittance spectrum, thus the first stage
was to highlight the spectra of the pure components. The structural composition of pluronic
F127, lansoprazole, PCL, PLGA and trehalose have been displayed in figure 7.1.
Figure 7.20 demonstrates the transmittance spectrum of trehalose, pluronic F127, PCL and
lansoprazole. Trehalose showed a distinct broad peak at 3367 cm-1 corresponding to an –OH
group, with pluronic F127 having two distinct transmittance peaks at 2890 and 1112 cm-1,
corresponding to a –C-H stretch and a –C-O bond respectively. Lansoprazole displayed
transmittance peaks at 3222, 2983, 1580, 1282 and 1117 cm-1, which denoted to the
stretching vibrations of –NH, -CH2-, the aromatic ring, C-N on the pyridyl ring and the ether
bond respectively (Zhang et al, 2008). Further multiple transmittance peaks for lansoprazole
were detected at 2930, 1127, 800 and 577 cm-1, which correspond to its –C-H alkane, a
–C=N alkyl halide, a –C-H, and a –C-S bonds.
PCL nanoparticles
PCL displayed a transmittance peak at 2994, 1726, 1243 and 1365cm-1 which corresponded
to the –C-H stretch, -C=O, -C-O, and the –C-H (rock) respectively. The milled polymer
displayed similar transmittance data with very slight deviation. When the PCL and milled PCL
nanoparticles were analysed with FT-IR, they both displayed a similar transmittance profile
(Table 7.9 and Figure 7.21). Both nanoparticle formulations demonstrated new transmittance
peaks at 990 and 841 cm-1, corresponding to a =C-H and an alkyl halide bond. This was
indicative of a weak interaction (weak transmittance peak) occurring between the halide of
lansoprazole and the double bonded carbon of PCL.
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Table 7.9. Analysis of excipient interaction and chemical bond donation with PCL nanoparticles,
prepared at a 5:1 polymer-drug ratio. A new bond formation was observed at 990 and 841 cm-1
corresponding to a =C-H and an alkyl halide bond.
Peak No. Wavelength/cm-1 Donated from Bond
1 3350 Trehalose O-H
2 2938 PCL, F127, LSP C-H alkanes
3 1728 PCL C=O
4 1365 PCL C-H rock
5 1241 PCL C-O
6 1150 LSP C-N /alkyl halides –CH2X
7 1107 LSP C-O / C-N
8 990 =C-H
9 841 alkyl halide
10 803 LSP C-H aomatic
11 575 LSP C-Br stretch
Trehalose
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%T
Pluronic F127 17.05.10
20
%T
PCL
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%T
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%T
LSP-PCL freeze-dried
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500100015002000250030003500
Wavenumbers (cm-1)
Figure 7.20. Comparison of FTIR spectrum for trehalose, pluronic F127, lansoprazole (LSP),
standard PLGA and PLGA nanoparticles prepared at a 5:1 polymer drug ratio.
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PLGA nanoparticles
PLGA displayed a transmittance peak at 2999, 3527, 1759, 1456 and 1182 cm-1 which
correspond to –O-H, -O-H (alcohol), -C=O (ester), -CH3, and –C-O-C- (ester) bonds
respectively (Figure 7.22). The milled polymer displayed similar transmittance data with very
slight deviation. When non milled PLGA and milled PLGA nanoparticles were analysed with
FTIR, they both displayed a similar transmittance profile (Table 7.10 and Figure 7.23). Both
nanoparticle formulations demonstrated new transmittance peaks at 991 and 843 cm-1,
corresponding to a =C-H and an alkyl halide bond (similar to the PCL nanoparticles). This
was indicative of a weak interaction (weak transmittance peak) occurring between the halide
(lansoprazole) and a double bonded carbon (PLGA).
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Figure 7.21. FTIR spectra of PCL nanoparticles prepared at a 5:1 polymer-drug ratio. No significant
difference was observed in the transmittance peaks of (A) milled PCL and (B) non-milled PCL
nanoparticles.
(A)
(B)
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Figure 7.22. Comparison of FTIR spectrum for trehalose, pluronic F127, lansoprazole (LSP),
standard PLGA and PLGA nanoparticles prepared at a 5:1 polymer drug ratio.
Table 7.10. Analysis of excipient interaction and chemical bond donation with PLGA nanoparticles,
prepared at a 5:1 polymer-drug ratio. A new bond formation was observed at 991 and 843 cm-1
corresponding to a =C-H and an alkyl halide bond.
Peak No. Wavelength/cm-1 Donated from Bond
1 3392 PLGA/mPLGA/trehalose O-H
2 2936 PLGA/mPLGA CH3
3 1760 PLGA/mPLGA C=O
4 1643 LSP N-H bending
5 1428 PLGA/mPLGA C-O-H bending
6 1149 LSP C-N/alkyl halide –CH2X
7 1103 LSP C-O/C-N
8 1078 F127 C-O
9 1031 F127 C-O
10 991 =C-H
11 942 LSP =C-H
12 843 Alkyl halide
13 803 LSP C-H aromatic
14 576 LSP C-BR stretch
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7.3.4.3.3. DSC
DSC was carried out to ascertain the thermodynamics of the nanoparticles and to confirm the
absorption of lansoprazole into its hydrophobic core. The study was carried out using freeze-
dried nanoparticles prepared with trehalose, which acts as a cryoprotectant (Cerimedo et al,
2008).
Milled PCL nanoparticles versus non-milled PCL nanoparticles
It was known that PCL and lansoprazole had on-set Tm of 62 and 180 oC respectively
(Figure 7.8). Interestingly however the thermographs of non-milled and milled PCL
nanoparticles at 5:1, 6:1 and 7:1 polymer-drug ratios (Figure 7.24 and 7.25) all display a
single onset melting endotherm at 49 + 3 oC with no enthalpic peak being observed for
lansoprazole at 180 oC, therefore confirming the incorporation of lansoprazole into the
hydrophobic core of the nanoparticle.
Figure 7.23. Comparison of FTIR spectrum for trehalose, pluronic F127, lansoprazole (LSP), milled
PLGA and milled PLGA nanoparticles prepared at a 5:1 polymer drug ratio.
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Figure 7.24. DSC thermogram of PCL lansoprazole nanoparticles at varying ratios, at a scan rate of
150 oC.min-1. At all three ratios a melt is observed at 59 oC, and a subsequent crystallisation at
117 oC.
Figure 7.25. DSC thermogram of milled PCL lansoprazole nanoparticles at varying ratios, at a scan
rate of 150 oC.min-1. At all three ratios a melt is observed at 56 oC, and a subsequent crystallisation
at 120 oC. Contrary to the non-milled PCL nanoparticles, immediately after the crystallisation a melt is
observed at 129 oC.
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Milled PLGA nanoparticles versus non-milled PLGA nanoparticles
It was known from previous studies that PLGA had on-set Tm of 33 oC which was observed
as a small endothermic peak (Figure 7.8). However the DSC thermograms of the polymer in
the milled and non-milled PLGA nanoparticles were masked by the presence of trehalose,
which has a polymorphic crystalline pattern (Figure 7.26 and 7.27). Importantly however, the
lansoprazole Tm was absent on both thermographs (at 180 oC), therefore confirming the
drug to be fully incorporated into the hydrophobic matrix of the milled and non-milled PLGA
nanoparticles.
Figure 7.26. DSC thermogram for the milled PLGA nanoparticles at varying ratios, at a scan rate of
150 oC.min-1. For the 5:1 ratio, a melting peak is observed at 73 oC with an addition melt occurring at
128 oC.
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Figure 7.27. DSC thermogram for PLGA nanoparticles at varying polymer-drug concentrations, at a
scan rate of 150 oC.min-1. (A) The Tm of lansoprazole at 180 oC was absent indicating complete
absorption into the polymeric matrix. (B) Polymorphic crystallinity of trehalose detected at the 5:1 ratio.
(C) Polymorphic crystallinity of trehalose detected at the 6:1 ratio. (D) Polymorphic crystallinity of
trehalose detected at the 7:1 ratio.
(B) (C)
(D)
(A)
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7.3.5. In Vitro release study
The release study for the lansoprazole-loaded nanoparticles was carried out in two stages;
the first stage was in 0.1 M HCL or pH 4.5 aimed at mimicking the acid in the stomach in the
fasted and fed state respectively. The second phase was in the buffer at pH 6.8, aimed at
mimicking the conditions within the small intestine.
7.3.5.1. Implications of the fasted state conditions (0.1 M HCL) on non-
milled and milled polymeric nanoparticles
Figure 7.28 displays the release profile of lansoprazole from non-milled and milled PCL
nanoparticles prepared at a polymer-drug ratio of 5:1. In the acid phase ~51 % of
lansoprazole was released from the PCL nanoparticles, with the milled PCL nanoparticles
displaying a relatively lower release profile (19-30 %). In the buffer stage, the drug was
released from the nanoparticles at a steady rate, after an initial burst release of ~22 %.
However, the release rate from the non-milled PCL nanoparticles was significantly higher
than the release obtained from the milled PCL nanoparticles. At the 4 hour mark in the buffer
Figure 7.28. Release profile of milled and non-milled PCL nanoparticles (5:1 polymer-drug ratio) in
the buffer phase when under fasting conditions. Milled PCL nanoparticles displayed a quicker
release profile than non-milled PCL nanoparticles. At the 4 hour phase hour mark in the buffer
phase, 37.70 + 8.48 and 53.34 + 28.59 % of lansoprazole from PCL and milled PCL nanoparticles
had been released respectively. (n=3)
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phase, 37.70 + 8.48 and 53.34 + 28.59 % of lansoprazole from PCL and milled PCL
nanoparticles had been released respectively. At the 48 hour mark, lansoprazole increased
to 49.27 + 3.91 and 69.89 + 29.88 % respectively. It was concluded that approximately
100 % had been released in total from the PCL nano-suspension, and 81-100 % from the
milled PCL nano-suspension.
Figure 7.29 displays the release profile of lansoprazole from non-milled and milled PLGA
nanoparticles prepared at a polymer-drug ratio of 5:1. In the acid phase 25-35 % of
lansoprazole was released from the PLGA nanoparticles, with a greater proportion of
lansoprazole being released from the milled PLGA nanoparticles (34-44 %). In the buffer
stage, this trend continued in which the release rate of lansoprazole from milled PLGA
nanoparticles was significantly higher than the release obtained from non-milled PLGA
nanoparticles. Within the first 5 minutes a burst affect was observed, with non-milled PLGA
releasing 6.28 + 5.64 %, in comparison with milled PLGA nanoparticle releasing
26.49 +17.53 % lansoprazole. The burst affect was attributed to the adsorption of
lansoprazole near the outer layers of the nanoparticle matrix (Magenheim et al, 1993; Singh
Figure 7.29. Release profile of milled and non-milled PLGA nanoparticles (5:1 polymer-drug ratio) in
the buffer phase when under fasting conditions. Milled PLGA nanoparticles displayed a quicker
release profile than non-milled PLGA nanoparticles. At the 4 hour phase hour mark in the buffer
phase, 15.87 + 9.05 and 40.34 + 18.08 % of lansoprazole from PLGA and milled PLGA nanoparticles
had been released respectively. (n=3)
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and Lillard, 2009). After the burst affect, both nanoparticles released the drug at a steady
increase. At the 4 hour mark in the buffer phase, 15.87 + 9.05 % of lansoprazole from PLGA
nanoparticles was released, increasing to 27.56 + 14.05 % after 48 hours. In contrast, milled
PLGA nanoparticles released 40.50 + 18.08 % of lansoprazole within 4 hours, with no further
release by the 48 hour mark. It was concluded that approximately 33-52 % had been
released in total from the PLGA nano-suspension, and 69-100 % from the milled PLGA
nano-suspension.
7.3.5.2. Implications of the fed state conditions (pH 4.5) on milled and
non-milled polymeric nanoparticles
Figure 7.30 displays the release profile of lansoprazole nanoparticles prepared from standard
PCL and PLGA at a polymer-drug ratio of 5:1. In the acid phase (pH 4.5) 24.27+ 2.52 % of
lansoprazole was released from the PCL nanoparticles, with PLGA nanoparticles exhibiting a
lowered release profile (11.28 + 2.42 %). In the buffer stage, the drug was released from the
nanoparticles at a slow steady rate, with no burst affect being observed. At the 48 hour mark
in the buffer phase, 61.36 + 6.53 and 42.74 + 8.57 % of lansoprazole from PCL and PLGA
nanoparticles had been released respectively. It was thus concluded that approximately
85 % had been released in total from the PCL colloidal system, and approximately 53 % from
the milled PCL matrix system.
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Figure 7.30. Release profile of PCL and PLGA nanoparticles (5:1 polymer-drug ratio) in the buffer
phase, when under fed condition. Both polymers displayed a fairly similar release profile; slow and
steady. At the 48 hour phase hour mark in the buffer phase, 61.36 + 6.53 and 42.74 + 8.57 % of
lansoprazole from PCL and PLGA nanoparticles had been released respectively. (n=3)
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7.3.5.3. Fasting versus Fed conditions
The conditions of the stomach greatly influenced the release rate of lansoprazole from the
nanoparticles. A greater proportion of the lansoprazole was released from the nanoparticles
(standard and milled polymers) under fasted conditions (0.1 M HCL) than under fed
conditions (pH 4.5). These variances can be attributed to the acidic environment degrading
the outer layers of the polymer coat, and thus resulting in increased dispersion of
lansoprazole into the acid environment. Therefore, these results highlight the importance of
pre-drug delivery conditions, and can be recommended that for polymeric nanoparticle
delivery the patient is medicated after food intake in order to reduce the degradative
properties of the stomach environment.
In the second phase of the release study the nanoparticles were placed in buffer conditions
(pH 6.8) for 48 hours, representing nanoparticles in the small intestine. The PCL and PLGA
nanoparticles showed no significant difference in the initial rate of release, neither of which
exhibited a burst affect, however after 48 hours the greatest lansoprazole release was
exerted by the PCL matrix system. In contrast, under fasting conditions, milled and non-
milled polymer nanoparticles exhibited a burst release of lansoprazole, which was associated
with increased polymer degradation in the acid phase. This initial degradation of the polymer
coat resulted in a smaller distance for the drug had to diffuse across, and thus causing the
initial burst release affect.
Nanoparticles release their drug load either by diffusion or matrix erosion, with the method of
release depending on the rate of matrix erosion. In the present study, lansoprazole was
found to be diffusing through the matrix at a faster rate than the polymer was degrading, and
therefore the rate of release in this system was concluded to be controlled by a diffusion
process. Interestingly the rate of release was also controlled by a second factor: particle size
of the colloidal system. The milled polymers produced smaller nanoparticles, thereby
increasing their surface area-to-volume ratio. Hence the majority of the drug load was
located nearer to the polymeric nanoparticle surface resulting in a faster drug release profile.
The non-milled polymer nanoparticles displayed a significantly larger particle size, and
therefore had a larger matrix system allowing a greater amount of drug to be encapsulated
within a single nanoparticle. In a larger polymeric nanoparticle, longer time was required to
degrade the polymer in order to release all of its drug contents, resulting in a slower release
profile (Redhead et al, 2001; Singh and Lillard, 2009). The rate of release of lansoprazole
can therefore be directly related to particle size and the rate of drug diffusion.
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7.4. Conclusion
The current study showed that the solvent displacement and the emulsion diffusion
techniques successfully produced polymeric nanoparticles; however the drug load was
greatly influenced by the composition of the polymer and the polymer concentration. It was
found that PCL nanoparticles decreased in drug loading with increasing polymer
concentration, whereas PLGA nanoparticles remained relatively unaffected by the polymer-
drug ratio. A third factor governing the loading efficiency of the nanoparticles was mechanical
milling of the polymers prior to nanoparticle preparation. The process of milling altered the
molecular weight of the polymers, and also changed the physical aspects of the PLGA
polymer, making its less glassy in structure and more globular. Also the repeated mechanical
impaction of the mill caused a weakening of the polymer chain, enabling increased flexibility
of the polymer to coil into a more condensed particle. This in turn resulted in smaller particles
with higher drug loading efficiency. Preparative polymer variables (molecular weight and
concentration) are important factors for the formation of polymeric nanoparticles. The release
kinetics of the drug was governed by the initial drug loading, higher the initial drug loading
resulted in a faster drug release profile. The process of milling resulted in milled polymers
nanoparticles having a greater drug loading efficiency and thus had a faster release profile
than the non-milled polymer.
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General Conclusions
8.1. Summary of research findings
The thesis highlights the systematic approaches towards development of oral liquid
formulation and overcoming barriers associated with poorly soluble drugs and drugs which
are unstable in aqueous environments, in order to improve patient compliance along with
providing alternative pharmaceutical preparations to potentially increase patent-life. By
investigating the drug formulation criteria, the formulation parameters could be assessed and
an oral liquid solution or suspension prepared. The investigation revealed that the
stabilisation of poorly soluble drugs was attributed to reduced polarity and increasing
potential hydrophobic binding constants, such as cyclodextrins and nanoparticles.
Accordingly, research was carried out to explore and optimise simple approaches towards
specific hydrophobic drug solubilisation and hydrophilic drug stabilisation, which could be
easily scaled up for industrial manufacturing. As a result of this research, various excipients
commonly used in the pharmaceutical industry were studied.
8.1.1. Formulation development and physicochemical investigation
of a stable aqueous preparation of captopril
Hydrophilic drugs can hinder the development of aqueous preparations, particularly when
challenged with instability and self-dimerisation issues. Captopril is one such drug that
despite it hydrophilicity (160 mg.mL-1) remains unstable in solution. The degradation of
captopril is initiated by the ionisation of the carboxylic group, which in turn ionises the thiol
group yielding the major degradation product captopril disulphide (oxygen-facilitated, first
order, free radical oxidation).
EDTA and HP-β-CD were introduced into a solution of 1 mg.mL-1 and 5 mg.mL-1 captopril, in
an attempt to stabilise the drug and to prevent the initiation of its degradation pathway. EDTA
acts by a chelation mechanism: its protonated carboxyl group binds to the ionised thiol group
of captopril preventing captopril dimerisation. The aromatic side chain and a carboxylic acid
side group of captopril was found to be reversibly bound to the core of HP-β-CD, thereby
forming a rigid structure. This steric hindrance resulted in a reduction in the sulphuric-like
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odour normally associated with captopril. 1 mg.mL-1 and 5 mg.mL-1 captopril formulations
comprising of EDTA and EDTA-HP-β-C-D were found to be stable for 12 months both
chemically and organoleptically, when stored under 5 oC, 25 oC and 40 oC conditions (drug
retention above 95 %).
8.1.2. Solubilisation and physicochemical analysis of gliclazide
Poorly soluble drugs display particular challenges when formulating an alternate dosage form
to tablets, such as aqueous solutions/suspensions. Gliclazide has very poor water solubility
(55 mg.L-1) and is currently only available as a tablet. Enhancement of drug solubilisation can
be carried out by adjusting the polarity of the medium (using a co-solvent system) or by
adjustment of pH (using amino acids).
Gliclazide was solubilised (8 mg.mL-1 dosage) using L-arginine, which was found to be stable
chemically and organoleptically for 12 months when stored under 5 oC, 25 oC and 40 oC
conditions (drug retention above 95 %). The stability was assessed by DSC, FTIR and
H1-NMR, and was found to be attributed to the intermolecular bonding (hydrogen bonding)
between the 1:1 stereochemistry of L-arginine and gliclazide.
A second aqueous preparation of gliclazide (16 mg.mL-1) was prepared using dual action of a
co-solvent and a surfactant (CMC = 5 % w/v). This method of preparation was dependent
upon two factors: (1) the dielectric constant (polarity) of the medium, and (2) the pH of the
system (gliclazide concentration increased with increasing pH). The formulation was found
to be stable, analytically and organoleptically, for 12 months when stored under 5 oC, 25 oC
and 40 oC conditions (drug retention above 95 %).
8.1.3. Solubilisation and formulation of melatonin as a liquid oral
dosage form
Photosensitive drugs, such as melatonin, hinder the development of new dosage forms by
limiting the type of dosage forms available to patients. The rate of degradation increases
exponentially when the drug compound has been solubilised in solution, exposing its
chemical structure to the harmful UV rays. By temporarily binding melatonin to HP-β-CD, the
cyclodextrin was able to successfully mask the affects of UV, thereby stabilising and
preventing degradation in an aqueous environment.
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The results showed that melatonin was solubilised in water to achieve a drug dosage
concentration of 1 mg.mL-1, by reducing the polarity of the aqueous medium using sorbitol
and heat. Samples stored at 5 oC were stable for up to 6 months (93.63 + 1.12 %), with
samples stored at 25 oC achieving a 12 month stability profile of 91.52 + 0.77 %. However,
aqueous preparations of 1 mg.mL-1 melatonin were only stable for 3 months at 40 oC
(91.80 + 1.73 %). This degradation was associated with: (1) the scavenging of hydroxide
radicals (●OH), (2) the formation of hydronium ions from tartaric acid, and (3) Le Chatelier’s
Principle.
8.1.4. Optimisation of an extraction protocol and development of an
oral liquid formulation for L-arginine
In the developmental stages of drug formulation, the organoleptic properties are crucial in
determining the acceptability of the drug formulation for the patient. For oral liquid
preparations these properties include; pleasant smell, smooth consistency, and most
importantly a palatable taste (not too sour or too sweet). A common organoleptic property
associated with basic amino acids, particularly L-arginine, is extreme bitterness when in
solution, which can affect the compliance issues associated with formulation and dosing.
The bitterness of L-arginine intensified as the concentration of the drug was increased, which
was attributed to an increase in concentration of its guanidinium groups further increasing the
alkalinicity of the solution (100 mg.mL-1: L-arginine in water = pH 11). The addition of
4 % (w/v) tartaric acid resulted in neutralising this bitterness and subsequently enabling a
dosage of 100 mg.mL-1 to be prepared.
Extensive investigation of the analytical method resulted in the development of ninhydrin
assay which was simple, reproducible and validated method for assessing the concentration
of L arginine. Utilising this protocol, L-arginine was found to be stable in solution when
stored for 12 months at 5 oC, 25 oC and 40 oC (L-arginine retention was 95.86 + 4.91,
93.15 + 2.82, and 92.05 + 3.72 % respectively). However the organoleptic property (smell) of
the formulation stored under accelerated conditions (40 oC, 75 % humidity) decreased over
time, which was attributed to the excipients in the formulation and not the amino acid.
8.1.5. Preservative Efficacy Test (PET)
Investigation of microbial contamination of pharmaceutical products is vital to the
pharmaceutical industry and the World Health Organisation, as it can become a major cause
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of product and economic losses, as well as deterioration in the patients’ health or related side
effects. Pharmaceutical preservatives that have been listed as GRAS are used to reduce the
likelihood of microbial growth in aqueous systems. This is essential with preparations being
stored in multi-dose containers that are susceptible to microbial contamination. Ideal
preservative characteristics include broad spectrum of activity, active within the formulation
at low concentration and effective within the pH range of the formulation.
A PET was carried out in accordance with the USP and BP guidelines, in order to evaluate
the effectiveness of the preservative within the pharmaceutical preparation. Five specific
microbes (S.aureus, E.coli, P.aerginosa, A.niger and C.albicans) were used to challenge
captopril (with (1) EDTA and (2) EDTA-HPβ-CD), gliclazide (with (1) ethanol-F127 and
(2) L-arginine), melatonin and L-arginine formulations. According to the BP (2009), the
criteria of acceptance for oral preparations were a log10 reduction of 3 and 1 for bacteria and
fungi respectively, with no further increase in growth after 28 days incubation. The results
revealed all of the formulations to have sufficient preservative activity against both bacterial
as well as fungal microbes.
8.1.6. Solubilisation of a proton pump inhibitor (Lansoprazole)
using nano-particulate delivery
Acid labile drugs are particularly difficult to formulate as suspension or solutions, as the
exposure of the drug through the GIT has to be carefully considered during the formulation
process. Lansoprazole has two major obstacles when formulating an oral suspension: (1) it
is very poorly soluble (0.97 mg.L-1), and (2) it undergoes degradation when exposed to acidic
environments. Therefore the formulation strategy involved preparing a 1 mg.mL-1 suspension
using nano-particulate delivery, with the aim that the nanoparticle protects the drug as it
enters the stomach.
It was found that the composition of the polymer had an influence on the drug loading and
the release rates, with PCL achieving a maximum of 85.57 + 1.80 % (5:1 polymer drug ratio)
and PLGA achieving a maximum of 80 % (polymer ratio had no influence on drug loading).
By milling the polymer prior to nanoparticle preparation, the drug loading increased to
91.87 + 0.43 (7:1 polymer:drug ratio) and 96.30 + 0.93 (6:1 polymer:drug ratio) for PCL and
PLGA respectively. The increase in drug loading was attributed to the repeated mechanical
impaction of the mill causing a weakening of the polymer chain and altering the molecular
weight of the polymers. This resulted in increased flexibility of the polymers to coil into a
Chapter 8 – General Conclusions
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more condensed particle, thereby forming a higher concentration of smaller particles within
solution and ultimately increasing the nanoparticle surface area available for drug loading.
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